CRP11	Only single nucleotide polymorphisms (SNPs) in BHMT were significantly associated in the overall data set; this significance was strongest when mothers took  bbbbb1 folate eeeee1  bbbbb2 BHMT eeeee2  were significantly associated in the overall data set; this significance was strongest when mothers took folate-containing nutritional supplements before conception
CRP11	Only single  bbbbb1 nucleotide eeeee1  polymorphisms (SNPs) in  bbbbb2 BHMT eeeee2  were significantly associated in the overall data set; this significance was strongest when mothers took folate-containing nutritional supplements before conception
CRP11	 bbbbb1 Lysine eeeee1  48-linked polyubiquitination of organic anion transporter-1 is essential for its  bbbbb2 protein kinase C eeeee2 -regulated endocytosis
CRP11	 bbbbb1 Lysine eeeee1  48-linked polyubiquitination of  bbbbb2 organic anion transporter-1 eeeee2  is essential for its protein kinase C-regulated endocytosis
CRP11	Mass spectroscopy has revealed that ubiquitination of OAT1 consists of polyubiquitin chains, primarily through  bbbbb1 lysine eeeee1  bbbbb2 OAT1 eeeee2  consists of polyubiquitin chains, primarily through lysine 48 linkage
CRP11	Transfection of cells with the dominant negative mutant of  bbbbb1 ubi eeeee1 quitin Ub-K48R, which prevents the formation o bbbbb2 f L eeeee2 ys48-linked polyubiquitin chains, abolishes PKC-stimulated OAT1 ubiquitination and internalization
CRP11	Transfection of cells with the dominant negative mutant of  bbbbb1 ubi eeeee1 quitin Ub-K48R, which prevents the formation of Lys48-linked bbbbb2  pol eeeee2 yubiquitin chains, abolishes PKC-stimulated OAT1 ubiquitination and internalization
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1  bbbbb2 LDL eeeee2 - and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1 ,  bbbbb2 glutathione peroxidase eeeee2 , malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1 , glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum  bbbbb2 C-reactive protein eeeee2 , orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1 , glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid,  bbbbb2 IL-2 eeeee2  and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1 , glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and  bbbbb2 IL-6 eeeee2 
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1  bbbbb2 transthyretin eeeee2 ; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1  bbbbb2 serum albumin eeeee2  and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1  bbbbb2 lipoprotein (a) eeeee2 ; oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1  bbbbb2 HDL eeeee2 -cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1 , glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein,  bbbbb2 orosomucoid eeeee2 , IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol,  bbbbb1 selenium eeeee1  bbbbb2 apo A-I, A-II, B, C-II, C-III, E eeeee2  and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1  bbbbb2 LDL eeeee2 - and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1 , phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb2 glutathione peroxidase eeeee2 , malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1 , phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum  bbbbb2 C-reactive protein eeeee2 , orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1 , phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid,  bbbbb2 IL-2 eeeee2  and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1 , phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and  bbbbb2 IL-6 eeeee2 
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1  bbbbb2 transthyretin eeeee2 ; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1  bbbbb2 serum albumin eeeee2  and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1 , phospholipids, apo A-I, A-II, B, C-II, C-III, E and  bbbbb2 lipoprotein (a) eeeee2 ; oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1  bbbbb2 HDL eeeee2 -cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1 , phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein,  bbbbb2 orosomucoid eeeee2 , IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol,  bbbbb1 triacylglycerols eeeee1 , phospholipids,  bbbbb2 apo A-I, A-II, B, C-II, C-III, E eeeee2  and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1  bbbbb2 LDL eeeee2 - and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1 , selenium,  bbbbb2 glutathione peroxidase eeeee2 , malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1 , selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum  bbbbb2 C-reactive protein eeeee2 , orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1 , selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid,  bbbbb2 IL-2 eeeee2  and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1 , selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and  bbbbb2 IL-6 eeeee2 
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1  bbbbb2 transthyretin eeeee2 ; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1  bbbbb2 serum albumin eeeee2  and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1  bbbbb2 lipoprotein (a) eeeee2 ; oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1  bbbbb2 HDL eeeee2 -cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1 , selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein,  bbbbb2 orosomucoid eeeee2 , IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol,  bbbbb1 retinol eeeee1  bbbbb2 apo A-I, A-II, B, C-II, C-III, E eeeee2  and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 LDL eeeee2 - and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1 , retinol, selenium,  bbbbb2 glutathione peroxidase eeeee2 , malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1 , retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum  bbbbb2 C-reactive protein eeeee2 , orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1 , retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid,  bbbbb2 IL-2 eeeee2  and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1 , retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and  bbbbb2 IL-6 eeeee2 
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 transthyretin eeeee2 ; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 serum albumin eeeee2  and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 lipoprotein (a) eeeee2 ; oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 HDL eeeee2 -cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1 , retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein,  bbbbb2 orosomucoid eeeee2 , IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 apo A-I, A-II, B, C-II, C-III, E eeeee2  and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  bbbbb2 LDL eeeee2 - and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  bbbbb2 glutathione peroxidase eeeee2 , malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  and advanced oxidized protein products; inflammatory status by serum  bbbbb2 C-reactive protein eeeee2 , orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid,  bbbbb2 IL-2 eeeee2  and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and  bbbbb2 IL-6 eeeee2 
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  bbbbb2 transthyretin eeeee2 ; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  bbbbb2 serum albumin eeeee2  and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  bbbbb2 lipoprotein (a) eeeee2 ; oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  bbbbb2 HDL eeeee2 -cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  and advanced oxidized protein products; inflammatory status by serum C-reactive protein,  bbbbb2 orosomucoid eeeee2 , IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase,  bbbbb1 malondialdehyde eeeee1  bbbbb2 apo A-I, A-II, B, C-II, C-III, E eeeee2  and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 , serum albumin and transthyretin; lipid metabolism by plasma  bbbbb2 LDL eeeee2 - and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 , serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb2 glutathione peroxidase eeeee2 , malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 , serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum  bbbbb2 C-reactive protein eeeee2 , orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 , serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid,  bbbbb2 IL-2 eeeee2  and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 , serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and  bbbbb2 IL-6 eeeee2 
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 , serum albumin and  bbbbb2 transthyretin eeeee2 ; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 ,  bbbbb2 serum albumin eeeee2  and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 , serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and  bbbbb2 lipoprotein (a) eeeee2 ; oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 , serum albumin and transthyretin; lipid metabolism by plasma LDL- and  bbbbb2 HDL eeeee2 -cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 , serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein,  bbbbb2 orosomucoid eeeee2 , IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic  bbbbb1 creatinine eeeee1 , serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids,  bbbbb2 apo A-I, A-II, B, C-II, C-III, E eeeee2  and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  bbbbb2 LDL eeeee2 - and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2 , malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum  bbbbb2 C-reactive protein eeeee2 , orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid,  bbbbb2 IL-2 eeeee2  and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and  bbbbb2 IL-6 eeeee2 
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  bbbbb2 transthyretin eeeee2 ; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  bbbbb2 serum albumin eeeee2  and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  bbbbb2 lipoprotein (a) eeeee2 ; oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  bbbbb2 HDL eeeee2 -cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein,  bbbbb2 orosomucoid eeeee2 , IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb1 glutathione eeeee1  bbbbb2 apo A-I, A-II, B, C-II, C-III, E eeeee2  and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1  bbbbb2 LDL eeeee2 - and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1 , triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium,  bbbbb2 glutathione peroxidase eeeee2 , malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1 , triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum  bbbbb2 C-reactive protein eeeee2 , orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1 , triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid,  bbbbb2 IL-2 eeeee2  and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1 , triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and  bbbbb2 IL-6 eeeee2 
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1  bbbbb2 transthyretin eeeee2 ; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1  bbbbb2 serum albumin eeeee2  and transthyretin; lipid metabolism by plasma LDL- and HDL-cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1 , triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and  bbbbb2 lipoprotein (a) eeeee2 ; oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1  bbbbb2 HDL eeeee2 -cholesterol, triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1 , triacylglycerols, phospholipids, apo A-I, A-II, B, C-II, C-III, E and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein,  bbbbb2 orosomucoid eeeee2 , IL-2 and IL-6
CRP11	On days 0 and 35, patients' nutritional status was assessed by BMI, normalized protein catabolic rate, predialytic creatinine, serum albumin and transthyretin; lipid metabolism by plasma LDL- and HDL- bbbbb1 cholesterol eeeee1 , triacylglycerols, phospholipids,  bbbbb2 apo A-I, A-II, B, C-II, C-III, E eeeee2  and lipoprotein (a); oxidative status by alpha-tocopherol, retinol, selenium, glutathione peroxidase, malondialdehyde and advanced oxidized protein products; inflammatory status by serum C-reactive protein, orosomucoid, IL-2 and IL-6
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and  bbbbb1 creatinine eeeee1  in SO); LDL-cholesterol,  bbbbb2 apo B, C-II, C-III eeeee2  and apo A-I/A-II ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and  bbbbb1 creatinine eeeee1  bbbbb2 transthyretin eeeee2  and creatinine in SO); LDL-cholesterol, apo B, C-II, C-III and apo A-I/A-II ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and  bbbbb1 creatinine eeeee1  in SO); LDL-cholesterol, apo B, C-II, C-III and  bbbbb2 apo A-I/A-II eeeee2  ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and  bbbbb1 creatinine eeeee1  bbbbb2 albumin eeeee2  in OO; albumin, transthyretin and creatinine in SO); LDL-cholesterol, apo B, C-II, C-III and apo A-I/A-II ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and  bbbbb1 creatinine eeeee1  bbbbb2 albumin eeeee2 , transthyretin and creatinine in SO); LDL-cholesterol, apo B, C-II, C-III and apo A-I/A-II ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and  bbbbb1 creatinine eeeee1  in SO);  bbbbb2 LDL eeeee2 -cholesterol, apo B, C-II, C-III and apo A-I/A-II ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and creatinine in SO); LDL- bbbbb1 cholesterol eeeee1 ,  bbbbb2 apo B, C-II, C-III eeeee2  and apo A-I/A-II ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and creatinine in SO); LDL- bbbbb1 cholesterol eeeee1  bbbbb2 transthyretin eeeee2  and creatinine in SO); LDL-cholesterol, apo B, C-II, C-III and apo A-I/A-II ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and creatinine in SO); LDL- bbbbb1 cholesterol eeeee1 , apo B, C-II, C-III and  bbbbb2 apo A-I/A-II eeeee2  ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and creatinine in SO); LDL- bbbbb1 cholesterol eeeee1  bbbbb2 albumin eeeee2  in OO; albumin, transthyretin and creatinine in SO); LDL-cholesterol, apo B, C-II, C-III and apo A-I/A-II ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and creatinine in SO); LDL- bbbbb1 cholesterol eeeee1  bbbbb2 albumin eeeee2 , transthyretin and creatinine in SO); LDL-cholesterol, apo B, C-II, C-III and apo A-I/A-II ratio increased in both groups
CRP11	Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved (albumin in OO; albumin, transthyretin and creatinine in SO); LDL- bbbbb1 cholesterol eeeee1  bbbbb2 LDL eeeee2 -cholesterol, apo B, C-II, C-III and apo A-I/A-II ratio increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/ bbbbb1 cholesterol eeeee1  bbbbb2 lipoprotein (a) eeeee2  decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/ bbbbb1 cholesterol eeeee1  bbbbb2 HDL eeeee2 -cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/ bbbbb1 cholesterol eeeee1  bbbbb2 apo E eeeee2  increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/ bbbbb1 cholesterol eeeee1  ratio increased in OO; malondialdehyde decreased in both groups;  bbbbb2 IL-2 eeeee2  increased in both groups
CRP11	HDL- bbbbb1 cholesterol eeeee1  decreased in OO; apo E increased and  bbbbb2 lipoprotein (a) eeeee2  decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL- bbbbb1 cholesterol eeeee1  bbbbb2 HDL eeeee2 -cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL- bbbbb1 cholesterol eeeee1  decreased in OO;  bbbbb2 apo E eeeee2  increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL- bbbbb1 cholesterol eeeee1  decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups;  bbbbb2 IL-2 eeeee2  increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO;  bbbbb1 malondialdehyde eeeee1  bbbbb2 lipoprotein (a) eeeee2  decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO;  bbbbb1 malondialdehyde eeeee1  bbbbb2 HDL eeeee2 -cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO;  bbbbb1 malondialdehyde eeeee1  bbbbb2 apo E eeeee2  increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO;  bbbbb1 malondialdehyde eeeee1  decreased in both groups;  bbbbb2 IL-2 eeeee2  increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO;  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 lipoprotein (a) eeeee2  decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO;  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 HDL eeeee2 -cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO;  bbbbb1 alpha-tocopherol eeeee1  bbbbb2 apo E eeeee2  increased and lipoprotein (a) decreased in SO; alpha-tocopherol/cholesterol ratio increased in OO; malondialdehyde decreased in both groups; IL-2 increased in both groups
CRP11	HDL-cholesterol decreased in OO; apo E increased and lipoprotein (a) decreased in SO;  bbbbb1 alpha-tocopherol eeeee1 /cholesterol ratio increased in OO; malondialdehyde decreased in both groups;  bbbbb2 IL-2 eeeee2  increased in both groups
CRP11	The other mutation results in acceleration of the recovery of the  bbbbb1 sodium eeeee1  bbbbb2 sodium channel eeeee2  from inactivation
CRP11	Two mutations result in total loss of function of the  bbbbb1 sodium eeeee1  bbbbb2 sodium channel eeeee2 
CRP11	All three mutations affect the structure and the function of the  bbbbb1 sodium eeeee1  channel  bbbbb2 SCN5A eeeee2 
CRP11	All three mutations affect the structure and the function of the  bbbbb1 sodium eeeee1  bbbbb2 sodium channel eeeee2  SCN5A
CRP11	With respect to the type of neurotransmitter control underlying  bbbbb1 the chan eeeee1  bbbbb2 the changes produced eeeee2  by various neuroleptics, it is quite obvious from the comparisons with the respective drug effects that dopamine-D1-receptor controlled transmission is not responsible for this action
CRP11	Sixty-four female mice (ICR) were injected with  bbbbb1 ketorolac eeeee1  (0, 7.5, 15 and 30 µg/d) for 3 d starting from the day of  bbbbb2 eCG eeeee2  treatment
CRP11	Glutathione  bbbbb1 S eeeee1  bbbbb2 Glutathione S-transferase M1 and P1 eeeee2  polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women
CRP11	 bbbbb1 Glutathione eeeee1  bbbbb2 Glutathione S-transferase M1 and P1 eeeee2  polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women
CRP11	Enzymes encoded by the glutathione  bbbbb1 S eeeee1  bbbbb2 glutathione S-tranferase mu 1 eeeee2  (GSTM1) and pi 1 (GSTP1) genes, which are expressed in breast tissue, catalyze the detoxification of endogenous and exogenous electrophiles
CRP11	Enzymes encoded by the glutathione  bbbbb1 S eeeee1 -tranferase mu 1 (GSTM1) and  bbbbb2 pi 1 eeeee2  (GSTP1) genes, which are expressed in breast tissue, catalyze the detoxification of endogenous and exogenous electrophiles
CRP11	Enzymes encoded by the glutathione  bbbbb1 S eeeee1 -tranferase mu 1 (GSTM1) and pi 1 ( bbbbb2 GSTP1 eeeee2 ) genes, which are expressed in breast tissue, catalyze the detoxification of endogenous and exogenous electrophiles
CRP11	Enzymes encoded by the glutathione  bbbbb1 S eeeee1 -tranferase mu 1 ( bbbbb2 GSTM1 eeeee2 ) and pi 1 (GSTP1) genes, which are expressed in breast tissue, catalyze the detoxification of endogenous and exogenous electrophiles
CRP11	Enzymes encoded by the  bbbbb1 glutathione eeeee1  bbbbb2 glutathione S-tranferase mu 1 eeeee2  (GSTM1) and pi 1 (GSTP1) genes, which are expressed in breast tissue, catalyze the detoxification of endogenous and exogenous electrophiles
CRP11	Enzymes encoded by the  bbbbb1 glutathione eeeee1  S-tranferase mu 1 (GSTM1) and  bbbbb2 pi 1 eeeee2  (GSTP1) genes, which are expressed in breast tissue, catalyze the detoxification of endogenous and exogenous electrophiles
CRP11	Enzymes encoded by the  bbbbb1 glutathione eeeee1  S-tranferase mu 1 (GSTM1) and pi 1 ( bbbbb2 GSTP1 eeeee2 ) genes, which are expressed in breast tissue, catalyze the detoxification of endogenous and exogenous electrophiles
CRP11	Enzymes encoded by the  bbbbb1 glutathione eeeee1  S-tranferase mu 1 ( bbbbb2 GSTM1 eeeee2 ) and pi 1 (GSTP1) genes, which are expressed in breast tissue, catalyze the detoxification of endogenous and exogenous electrophiles
CRP11	In contrast, mutation c.1244T>C results in an  bbbbb1 amino acid eeeee1  bbbbb2 c.1244T>C eeeee2  results in an amino acid substitution (Ile415Thr), which abolishes signal transduction due to structural changes
CRP11	In contrast, mutation c.1244T>C results in an  bbbbb1 amino acid eeeee1  substitution ( bbbbb2 Ile415Thr eeeee2 ), which abolishes signal transduction due to structural changes
CRP11	Some of the most commonly affected assays were CYPs (CYP2C9, CYP2C19), transporters (mitochondrial TSPO,  bbbbb1 norepinephrine eeeee1  bbbbb2 CYP2C19 eeeee2 ), transporters (mitochondrial TSPO, norepinephrine, dopaminergic), and GPCRs (aminergic)
CRP11	Some of the most commonly affected assays were CYPs (CYP2C9, CYP2C19), transporters (mitochondrial TSPO,  bbbbb1 norepinephrine eeeee1 , dopaminergic), and  bbbbb2 GPCRs eeeee2  (aminergic)
CRP11	Some of the most commonly affected assays were CYPs (CYP2C9, CYP2C19), transporters (mitochondrial TSPO,  bbbbb1 norepinephrine eeeee1  bbbbb2 CYP2C9 eeeee2 , CYP2C19), transporters (mitochondrial TSPO, norepinephrine, dopaminergic), and GPCRs (aminergic)
CRP11	Some of the most commonly affected assays were CYPs (CYP2C9, CYP2C19), transporters (mitochondrial TSPO,  bbbbb1 norepinephrine eeeee1  bbbbb2 CYPs eeeee2  (CYP2C9, CYP2C19), transporters (mitochondrial TSPO, norepinephrine, dopaminergic), and GPCRs (aminergic)
CRP11	Heavy metals, surfactants, and  bbbbb1 dithiocarbamate eeeee1  fungicides showed promiscuous, but distinctly different patterns of activity whereas many of the pharma compounds showed promiscuous activity across  bbbbb2 GPCRs eeeee2 
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT),  bbbbb1 superoxide eeeee1  dismutase (SOD), and  bbbbb2 glutathione peroxidase eeeee2  (GPX) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT),  bbbbb1 superoxide eeeee1  bbbbb2 CAT eeeee2 ), superoxide dismutase (SOD), and glutathione peroxidase (GPX) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT),  bbbbb1 superoxide eeeee1  dismutase (SOD), and glutathione peroxidase ( bbbbb2 GPX eeeee2 ) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT),  bbbbb1 superoxide eeeee1  bbbbb2 catalase eeeee2  (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPX) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT),  bbbbb1 superoxide eeeee1  dismutase ( bbbbb2 SOD eeeee2 ), and glutathione peroxidase (GPX) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT),  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), and glutathione peroxidase (GPX) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT), superoxide dismutase (SOD), and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GPX) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT), superoxide dismutase (SOD), and  bbbbb1 glutathione eeeee1  bbbbb2 CAT eeeee2 ), superoxide dismutase (SOD), and glutathione peroxidase (GPX) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT), superoxide dismutase (SOD), and  bbbbb1 glutathione eeeee1  peroxidase ( bbbbb2 GPX eeeee2 ) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT), superoxide dismutase (SOD), and  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2  (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPX) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT), superoxide dismutase (SOD), and  bbbbb1 glutathione eeeee1  bbbbb2 SOD eeeee2 ), and glutathione peroxidase (GPX) in vivo
CRP11	Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities, including catalase (CAT), superoxide dismutase (SOD), and  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD), and glutathione peroxidase (GPX) in vivo
CRP11	The anti-inflammatory effects of WOE were closely attributed to decreased levels of tissue  bbbbb1 NO eeeee1  and tumor necrosis factor-α ( bbbbb2 TNF-α eeeee2 )
CRP11	The anti-inflammatory effects of WOE were closely attributed to decreased levels of tissue  bbbbb1 NO eeeee1  and  bbbbb2 tumor necrosis factor-α eeeee2  (TNF-α)
CRP11	In light microscopy, several glutamate decarboxylase- or  bbbbb1 GABA eeeee1  bbbbb2 GABA-transaminase eeeee2 -immunoreactive principal nerve cells were detected in the superior cervical ganglion and coeliac-superior mesenteric ganglion complex
CRP11	In light microscopy, several glutamate decarboxylase- or  bbbbb1 GABA eeeee1  bbbbb2 glutamate decarboxylase eeeee2 - or GABA-transaminase-immunoreactive principal nerve cells were detected in the superior cervical ganglion and coeliac-superior mesenteric ganglion complex
CRP11	In light microscopy, several  bbbbb1 glutamate eeeee1  decarboxylase- or  bbbbb2 GABA-transaminase eeeee2 -immunoreactive principal nerve cells were detected in the superior cervical ganglion and coeliac-superior mesenteric ganglion complex
CRP11	In light microscopy, several  bbbbb1 glutamate eeeee1  bbbbb2 glutamate decarboxylase eeeee2 - or GABA-transaminase-immunoreactive principal nerve cells were detected in the superior cervical ganglion and coeliac-superior mesenteric ganglion complex
CRP11	In consecutive sections, the small glutamate decarboxylase-immunoreactive cell clusters also showed immunoreactivity to tyrosine hydroxylase, suggesting that these cells contain the enzymes for both GABA and  bbbbb1 catecholamine eeeee1  bbbbb2 tyrosine hydroxylase eeeee2 , suggesting that these cells contain the enzymes for both GABA and catecholamine synthesis
CRP11	In consecutive sections, the small glutamate decarboxylase-immunoreactive cell clusters also showed immunoreactivity to tyrosine hydroxylase, suggesting that these cells contain the enzymes for both GABA and  bbbbb1 catecholamine eeeee1  bbbbb2 glutamate decarboxylase eeeee2 -immunoreactive cell clusters also showed immunoreactivity to tyrosine hydroxylase, suggesting that these cells contain the enzymes for both GABA and catecholamine synthesis
CRP11	In consecutive sections, the small  bbbbb1 glutamate eeeee1  decarboxylase-immunoreactive cell clusters also showed immunoreactivity to  bbbbb2 tyrosine hydroxylase eeeee2 , suggesting that these cells contain the enzymes for both GABA and catecholamine synthesis
CRP11	In consecutive sections, the small  bbbbb1 glutamate eeeee1  bbbbb2 glutamate decarboxylase eeeee2 -immunoreactive cell clusters also showed immunoreactivity to tyrosine hydroxylase, suggesting that these cells contain the enzymes for both GABA and catecholamine synthesis
CRP11	In consecutive sections, the small glutamate decarboxylase-immunoreactive cell clusters also showed immunoreactivity to  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine hydroxylase eeeee2 , suggesting that these cells contain the enzymes for both GABA and catecholamine synthesis
CRP11	In consecutive sections, the small glutamate decarboxylase-immunoreactive cell clusters also showed immunoreactivity to  bbbbb1 tyrosine eeeee1  bbbbb2 glutamate decarboxylase eeeee2 -immunoreactive cell clusters also showed immunoreactivity to tyrosine hydroxylase, suggesting that these cells contain the enzymes for both GABA and catecholamine synthesis
CRP11	In consecutive sections, the small glutamate decarboxylase-immunoreactive cell clusters also showed immunoreactivity to tyrosine hydroxylase, suggesting that these cells contain the enzymes for both  bbbbb1 GABA eeeee1  bbbbb2 tyrosine hydroxylase eeeee2 , suggesting that these cells contain the enzymes for both GABA and catecholamine synthesis
CRP11	In consecutive sections, the small glutamate decarboxylase-immunoreactive cell clusters also showed immunoreactivity to tyrosine hydroxylase, suggesting that these cells contain the enzymes for both  bbbbb1 GABA eeeee1  bbbbb2 glutamate decarboxylase eeeee2 -immunoreactive cell clusters also showed immunoreactivity to tyrosine hydroxylase, suggesting that these cells contain the enzymes for both GABA and catecholamine synthesis
CRP11	Furthermore,  bbbbb1 GABA eeeee1  bbbbb2 GABA-transaminase eeeee2  immunoreactivity was observed in fibre-like structures close to the capsule of the ganglia
CRP11	In addition, numerous small cells in both the superior cervical ganglion and coeliac-superior mesenteric ganglion complex showed intense immunoreactivity to  bbbbb1 glutamate eeeee1  bbbbb2 glutamate decarboxylase eeeee2  or GABA-transaminase
CRP11	In addition, numerous small cells in both the superior cervical ganglion and coeliac-superior mesenteric ganglion complex showed intense immunoreactivity to  bbbbb1 glutamate eeeee1  decarboxylase or  bbbbb2 GABA-transaminase eeeee2 
CRP11	In addition, numerous small cells in both the superior cervical ganglion and coeliac-superior mesenteric ganglion complex showed intense immunoreactivity to glutamate decarboxylase or  bbbbb1 GABA eeeee1  bbbbb2 glutamate decarboxylase eeeee2  or GABA-transaminase
CRP11	In addition, numerous small cells in both the superior cervical ganglion and coeliac-superior mesenteric ganglion complex showed intense immunoreactivity to glutamate decarboxylase or  bbbbb1 GABA eeeee1  bbbbb2 GABA-transaminase eeeee2 
CRP11	Division of the preganglionic nerve trunk of the superior cervical ganglion caused no detectable change in  bbbbb1 GABA eeeee1  bbbbb2 GABA-transaminase eeeee2  immunoreactivity in the ganglion
CRP11	Localization of  bbbbb1 L-glutamate eeeee1  decarboxylase and  bbbbb2 GABA transaminase eeeee2  immunoreactivity in the sympathetic ganglia of the rat
CRP11	Localization of  bbbbb1 L-glutamate eeeee1  bbbbb2 L-glutamate decarboxylase eeeee2  and GABA transaminase immunoreactivity in the sympathetic ganglia of the rat
CRP11	Localization of L-glutamate decarboxylase and  bbbbb1 GABA eeeee1  bbbbb2 GABA transaminase eeeee2  immunoreactivity in the sympathetic ganglia of the rat
CRP11	Localization of L-glutamate decarboxylase and  bbbbb1 GABA eeeee1  bbbbb2 L-glutamate decarboxylase eeeee2  and GABA transaminase immunoreactivity in the sympathetic ganglia of the rat
CRP11	In the superior cervical ganglion and in the coeliac-superior mesenteric ganglion complex,  bbbbb1 GABA eeeee1  bbbbb2 GABA-transaminase eeeee2  immunoreactivity was also localized in fibre-like processes around and between the principal nerve cells, in nerve trunks traversing the ganglia, and around or in close contact with ganglionic blood vessels
CRP11	In immunoelectron microscopy of the superior cervical ganglion,  bbbbb1 GABA eeeee1  bbbbb2 GABA-transaminase eeeee2  immunoreactivity was localized in nerve fibres in association with neurotubules
CRP11	The location of L-glutamate decarboxylase and gamma-aminobutyrate ( bbbbb1 GABA eeeee1  bbbbb2 gamma-aminobutyrate (GABA)-transaminase eeeee2  immunoreactivity in the superior cervical ganglion and in the coeliac-superior mesenteric ganglion complex of the rat was studied by an indirect immunofluorescence method and by immunoelectron microscopy, with specific antisera raised in rabbits against the corresponding enzymes
CRP11	The location of L-glutamate decarboxylase and gamma-aminobutyrate ( bbbbb1 GABA eeeee1  bbbbb2 L-glutamate decarboxylase eeeee2  and gamma-aminobutyrate (GABA)-transaminase immunoreactivity in the superior cervical ganglion and in the coeliac-superior mesenteric ganglion complex of the rat was studied by an indirect immunofluorescence method and by immunoelectron microscopy, with specific antisera raised in rabbits against the corresponding enzymes
CRP11	The location of L-glutamate decarboxylase and  bbbbb1 gamma-aminobutyrate eeeee1  bbbbb2 gamma-aminobutyrate (GABA)-transaminase eeeee2  immunoreactivity in the superior cervical ganglion and in the coeliac-superior mesenteric ganglion complex of the rat was studied by an indirect immunofluorescence method and by immunoelectron microscopy, with specific antisera raised in rabbits against the corresponding enzymes
CRP11	The location of L-glutamate decarboxylase and  bbbbb1 gamma-aminobutyrate eeeee1  bbbbb2 L-glutamate decarboxylase eeeee2  and gamma-aminobutyrate (GABA)-transaminase immunoreactivity in the superior cervical ganglion and in the coeliac-superior mesenteric ganglion complex of the rat was studied by an indirect immunofluorescence method and by immunoelectron microscopy, with specific antisera raised in rabbits against the corresponding enzymes
CRP11	The location of  bbbbb1 L-glutamate eeeee1  decarboxylase and  bbbbb2 gamma-aminobutyrate (GABA)-transaminase eeeee2  immunoreactivity in the superior cervical ganglion and in the coeliac-superior mesenteric ganglion complex of the rat was studied by an indirect immunofluorescence method and by immunoelectron microscopy, with specific antisera raised in rabbits against the corresponding enzymes
CRP11	The location of  bbbbb1 L-glutamate eeeee1  bbbbb2 L-glutamate decarboxylase eeeee2  and gamma-aminobutyrate (GABA)-transaminase immunoreactivity in the superior cervical ganglion and in the coeliac-superior mesenteric ganglion complex of the rat was studied by an indirect immunofluorescence method and by immunoelectron microscopy, with specific antisera raised in rabbits against the corresponding enzymes
CRP11	Autoradiographs of PAGE-separated reactions containing either (125)I-labeled factor IX or  bbbbb1 (125)I eeeee1  bbbbb2 factor IX eeeee2  or (125)I-labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either (125)I-labeled factor IX or  bbbbb1 (125)I eeeee1 -labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of  bbbbb2 factor IX eeeee2  and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either (125)I-labeled factor IX or  bbbbb1 (125)I eeeee1 -labeled factor X showed that the increased  bbbbb2 factor X eeeee2  activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either (125)I-labeled factor IX or  bbbbb1 (125)I eeeee1 -labeled factor X showed that the increased factor X activation was not due to  bbbbb2 factor Xa eeeee2 -mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either (125)I-labeled factor IX or  bbbbb1 (125)I eeeee1 -labeled  bbbbb2 factor X eeeee2  showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either (125)I-labeled factor IX or  bbbbb1 (125)I eeeee1 -labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of  bbbbb2 factor X heavy chain eeeee2  in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either (125)I-labeled factor IX or  bbbbb1 (125)I eeeee1 -labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of  bbbbb2 factor IX eeeee2  in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either  bbbbb1 (125)I eeeee1 -labeled  bbbbb2 factor IX eeeee2  or (125)I-labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either  bbbbb1 (125)I eeeee1 -labeled factor IX or (125)I-labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of  bbbbb2 factor IX eeeee2  and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either  bbbbb1 (125)I eeeee1 -labeled factor IX or (125)I-labeled factor X showed that the increased  bbbbb2 factor X eeeee2  activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either  bbbbb1 (125)I eeeee1 -labeled factor IX or (125)I-labeled factor X showed that the increased factor X activation was not due to  bbbbb2 factor Xa eeeee2 -mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either  bbbbb1 (125)I eeeee1 -labeled factor IX or (125)I-labeled  bbbbb2 factor X eeeee2  showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either  bbbbb1 (125)I eeeee1 -labeled factor IX or (125)I-labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of  bbbbb2 factor X heavy chain eeeee2  in the presence of factor IX in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Autoradiographs of PAGE-separated reactions containing either  bbbbb1 (125)I eeeee1 -labeled factor IX or (125)I-labeled factor X showed that the increased factor X activation was not due to factor Xa-mediated feedback activation of factor IX and that there was increased cleavage of factor X heavy chain in the presence of  bbbbb2 factor IX eeeee2  in comparison with control reactions but only in the presence of both the enzyme and the surface
CRP11	Women who developed GDM had lower 1st-trimester adiponectin levels (9.67 ± 3.84 vs. 11.92 ± 4.59 µg/mL in women with normal  bbbbb1 glucose eeeee1  bbbbb2 adiponectin eeeee2  levels (9.67 ± 3.84 vs. 11.92 ± 4.59 µg/mL in women with normal glucose tolerance)
CRP11	Insulin was measured (ELISA; Luminex) to estimate homeostasis model assessment of insulin resistance (HOMA-IR), β-cell function (HOMA-B), insulin sensitivity (Matsuda index), insulin secretion (AUC(insulin/ bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  sensitivity (Matsuda index), insulin secretion (AUC(insulin/glucose)), and β-cell compensation (insulin secretion sensitivity index-2)
CRP11	Insulin was measured (ELISA; Luminex) to estimate homeostasis model assessment of insulin resistance (HOMA-IR), β-cell function (HOMA-B), insulin sensitivity (Matsuda index), insulin secretion (AUC(insulin/ bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  resistance (HOMA-IR), β-cell function (HOMA-B), insulin sensitivity (Matsuda index), insulin secretion (AUC(insulin/glucose)), and β-cell compensation (insulin secretion sensitivity index-2)
CRP11	Insulin was measured (ELISA; Luminex) to estimate homeostasis model assessment of insulin resistance (HOMA-IR), β-cell function (HOMA-B), insulin sensitivity (Matsuda index), insulin secretion (AUC(insulin/ bbbbb1 glucose eeeee1  bbbbb2 Insulin eeeee2  was measured (ELISA; Luminex) to estimate homeostasis model assessment of insulin resistance (HOMA-IR), β-cell function (HOMA-B), insulin sensitivity (Matsuda index), insulin secretion (AUC(insulin/glucose)), and β-cell compensation (insulin secretion sensitivity index-2)
CRP11	Insulin was measured (ELISA; Luminex) to estimate homeostasis model assessment of insulin resistance (HOMA-IR), β-cell function (HOMA-B), insulin sensitivity (Matsuda index), insulin secretion (AUC(insulin/ bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2 /glucose)), and β-cell compensation (insulin secretion sensitivity index-2)
CRP11	Insulin was measured (ELISA; Luminex) to estimate homeostasis model assessment of insulin resistance (HOMA-IR), β-cell function (HOMA-B), insulin sensitivity (Matsuda index), insulin secretion (AUC(insulin/ bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  secretion (AUC(insulin/glucose)), and β-cell compensation (insulin secretion sensitivity index-2)
CRP11	Insulin was measured (ELISA; Luminex) to estimate homeostasis model assessment of insulin resistance (HOMA-IR), β-cell function (HOMA-B), insulin sensitivity (Matsuda index), insulin secretion (AUC(insulin/ bbbbb1 glucose eeeee1 )), and β-cell compensation ( bbbbb2 insulin eeeee2  secretion sensitivity index-2)
CRP11	Adiponectin levels at 1st and 2nd trimesters were associated with HOMA-IR (both: r = -0.22, P < 0.0001) an bbbbb1 d Matsu eeeee1  bbbbb2 0001) a eeeee2 nd Matsuda index (r = 0.28, P < 0.0001, and r = 0.29, P < 0.0001)
CRP11	Adiponectin levels at 1st and 2nd trimesters were associated with HOMA-IR (both: r = -0.22, P < 0.0001) an bbbbb1 d Matsu eeeee1 da index (r = 0.28, P < 0.0001, and r = bbbbb2  0.29, P <  eeeee2 0.0001)
CRP11	Adiponectin levels at 1st and 2nd trimesters were associated with HOMA-IR (both: r = -0.22, P < 0.0001) an bbbbb1 d Matsu eeeee1 da index (r = 0.28, P < 0.0001, and r = 0.29, P < 0.0001) bbbbb2  eeeee2 
CRP11	Furthermore, immunohistochemistry studies showed that Rs-LPS inhibited the expression of interleukin 6 and matrix metalloproteinase-9 and reduced the content of monocytes and macrophages in a bbbbb1 therosclerot eeeee1  bbbbb2 ced  eeeee2 the content of monocytes and macrophages in atherosclerotic plaques
CRP11	Furthermore, immunohistochemistry studies showed that Rs-LPS inhibited the expression of interleukin 6 and matrix metalloproteinase-9 and reduced the content of monocytes and macrophages in a bbbbb1 therosclerot eeeee1  bbbbb2 ibit eeeee2 ed the expression of interleukin 6 and matrix metalloproteinase-9 and reduced the content of monocytes and macrophages in atherosclerotic plaques
CRP11	Furthermore, immunohistochemistry studies showed that Rs-LPS inhibited the expression of interleukin 6 and matrix metalloproteinase-9 and reduced the content of monocytes and macrophages in a bbbbb1 therosclerot eeeee1 ic plaques bbbbb2  eeeee2 
CRP11	Furthermore, immunohistochemistry studies showed that Rs-LPS inhibited the expression of interleukin 6 and matrix metalloproteinase-9 and reduced the content of monocytes and  bbbbb1 macrophages eeeee1  bbbbb2 ced  eeeee2 the content of monocytes and macrophages in atherosclerotic plaques
CRP11	Furthermore, immunohistochemistry studies showed that Rs-LPS inhibited the expression of interleukin 6 and matrix metalloproteinase-9 and reduced the content of monocytes and  bbbbb1 macrophages eeeee1  bbbbb2 ibit eeeee2 ed the expression of interleukin 6 and matrix metalloproteinase-9 and reduced the content of monocytes and macrophages in atherosclerotic plaques
CRP11	Furthermore, immunohistochemistry studies showed that Rs-LPS inhibited the expression of interleukin 6 and matrix metalloproteinase-9 and reduced the content of monocytes and  bbbbb1 macrophages eeeee1  in atherosclerotic plaques bbbbb2  eeeee2 
CRP11	In this study, we determined the effect of Rhodobacter sphaeroides lipopolysaccharide (Rs-LPS), an established TLR4 antagonist, on early-stage atherosclerosis in nondiabetic and  bbbbb1 streptozotocin eeeee1  bbbbb2 TLR4 eeeee2  antagonist, on early-stage atherosclerosis in nondiabetic and streptozotocin-induced diabetic apolipoprotein E-deficient (Apoe(-/-)) mice
CRP11	In this study, we determined the effect of Rhodobacter sphaeroides lipopolysaccharide (Rs-LPS), an established TLR4 antagonist, on early-stage atherosclerosis in nondiabetic and  bbbbb1 streptozotocin eeeee1 -induced diabetic  bbbbb2 apolipoprotein E eeeee2 -deficient (Apoe(-/-)) mice
CRP11	In this study, we determined the effect of Rhodobacter sphaeroides lipopolysaccharide (Rs-LPS), an established TLR4 antagonist, on early-stage atherosclerosis in nondiabetic and  bbbbb1 streptozotocin eeeee1 -induced diabetic apolipoprotein E-deficient ( bbbbb2 Apoe eeeee2 (-/-)) mice
CRP11	In situ hybridization data and a direct comparison of SN neurons expressing  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine hydroxylase eeeee2  (TH) and/or the beta-gal marker for EphB1 revealed that EphB1 is not expressed in TH+ neurons of pars compacta (SNc), but is restricted to neurons in pars reticulata (SNr)
CRP11	In situ hybridization data and a direct comparison of SN neurons expressing  bbbbb1 tyrosine eeeee1  hydroxylase ( bbbbb2 TH eeeee2 ) and/or the beta-gal marker for EphB1 revealed that EphB1 is not expressed in TH+ neurons of pars compacta (SNc), but is restricted to neurons in pars reticulata (SNr)
CRP11	In situ hybridization data and a direct comparison of SN neurons expressing  bbbbb1 tyrosine eeeee1  hydroxylase (TH) and/or the beta-gal marker for  bbbbb2 EphB1 eeeee2  revealed that EphB1 is not expressed in TH+ neurons of pars compacta (SNc), but is restricted to neurons in pars reticulata (SNr)
CRP11	In situ hybridization data and a direct comparison of SN neurons expressing  bbbbb1 tyrosine eeeee1  hydroxylase (TH) and/or the beta-gal marker for EphB1 revealed that  bbbbb2 EphB1 eeeee2  is not expressed in TH+ neurons of pars compacta (SNc), but is restricted to neurons in pars reticulata (SNr)
CRP11	In situ hybridization data and a direct comparison of SN neurons expressing  bbbbb1 tyrosine eeeee1  hydroxylase (TH) and/or the beta-gal marker for EphB1 revealed that EphB1 is not expressed in  bbbbb2 TH eeeee2 + neurons of pars compacta (SNc), but is restricted to neurons in pars reticulata (SNr)
CRP11	Consistent with this, we find that EphB1 null mice exhibit a significant decrease in the volume and number of neurons (40% decrease) in SNr, whereas the volume and number of TH+ neurons in SNc is not significantly affected nor are there changes in the distribution of nigrostriatal  bbbbb1 dopamine eeeee1  bbbbb2 TH eeeee2 + neurons in SNc is not significantly affected nor are there changes in the distribution of nigrostriatal dopamine neurons
CRP11	Consistent with this, we find that EphB1 null mice exhibit a significant decrease in the volume and number of neurons (40% decrease) in SNr, whereas the volume and number of TH+ neurons in SNc is not significantly affected nor are there changes in the distribution of nigrostriatal  bbbbb1 dopamine eeeee1  bbbbb2 EphB1 eeeee2  null mice exhibit a significant decrease in the volume and number of neurons (40% decrease) in SNr, whereas the volume and number of TH+ neurons in SNc is not significantly affected nor are there changes in the distribution of nigrostriatal dopamine neurons
CRP11	Eph receptor  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinases eeeee2  are potential participants in this process as they regulate development of other CNS regions and are expressed in basal ganglia nuclei, such as the substantia nigra (SN) and striatum
CRP11	Eph receptor  bbbbb1 tyrosine eeeee1  bbbbb2 Eph receptor eeeee2  tyrosine kinases are potential participants in this process as they regulate development of other CNS regions and are expressed in basal ganglia nuclei, such as the substantia nigra (SN) and striatum
CRP11	The  bbbbb1 PEG eeeee1  moiety of the  bbbbb2 Fab eeeee2  fragment, markedly increases the half-life of CZP and confers to the drug a unique structure that differs from the other anti-TNF-alpha agents tested for the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis, nonradiographic spondyloarthritis, PsO, and PsA
CRP11	The  bbbbb1 PEG eeeee1  moiety of the Fab fragment, markedly increases the half-life of CZP and confers to the drug a unique structure that differs from the other anti- bbbbb2 TNF-alpha eeeee2  agents tested for the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis, nonradiographic spondyloarthritis, PsO, and PsA
CRP11	In fact, while elimination of testicular androgens by castration alone has never been shown to prolong life in metastatic prostate cancer, combination of castration (surgical or medical with a gonadotropin-releasing hormone (GnRH) agonist) with a pure anti- bbbbb1 androgen eeeee1  bbbbb2 GnRH eeeee2 ) agonist) with a pure anti-androgen has been the first treatment shown to prolong life
CRP11	In fact, while elimination of testicular androgens by castration alone has never been shown to prolong life in metastatic prostate cancer, combination of castration (surgical or medical with a gonadotropin-releasing hormone (GnRH) agonist) with a pure anti- bbbbb1 androgen eeeee1  bbbbb2 gonadotropin-releasing hormone eeeee2  (GnRH) agonist) with a pure anti-androgen has been the first treatment shown to prolong life
CRP11	In fact, while elimination of testicular androgens by castration alone has never been shown to prolong life in metastatic prostate cancer, combination of castration (surgical or medical with a  bbbbb1 gonadotropin-releasing hormone eeeee1  ( bbbbb2 GnRH eeeee2 ) agonist) with a pure anti-androgen has been the first treatment shown to prolong life
CRP11	In fact, while elimination of testicular androgens by castration alone has never been shown to prolong life in metastatic prostate cancer, combination of castration (surgical or medical with a  bbbbb1 gonadotropin-releasing hormone eeeee1  bbbbb2 gonadotropin-releasing hormone eeeee2  (GnRH) agonist) with a pure anti-androgen has been the first treatment shown to prolong life
CRP11	In fact, while elimination of testicular androgens by castration alone has never been shown to prolong life in metastatic prostate cancer, combination of castration (surgical or medical with a gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 ) agonist) with a pure anti-androgen has been the first treatment shown to prolong life
CRP11	In fact, while elimination of testicular androgens by castration alone has never been shown to prolong life in metastatic prostate cancer, combination of castration (surgical or medical with a gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1  bbbbb2 gonadotropin-releasing hormone eeeee2  (GnRH) agonist) with a pure anti-androgen has been the first treatment shown to prolong life
CRP11	In fact, while elimination of testicular  bbbbb1 androgens eeeee1  by castration alone has never been shown to prolong life in metastatic prostate cancer, combination of castration (surgical or medical with a gonadotropin-releasing hormone ( bbbbb2 GnRH eeeee2 ) agonist) with a pure anti-androgen has been the first treatment shown to prolong life
CRP11	In fact, while elimination of testicular  bbbbb1 androgens eeeee1  by castration alone has never been shown to prolong life in metastatic prostate cancer, combination of castration (surgical or medical with a  bbbbb2 gonadotropin-releasing hormone eeeee2  (GnRH) agonist) with a pure anti-androgen has been the first treatment shown to prolong life
CRP11	Since the available anti- bbbbb1 androgens eeeee1  have low affinity for AR and cannot block androgen action completely, especially in the presence of increased  bbbbb2 AR eeeee2  levels, it becomes important to discover more potent and purely antagonistic blockers of AR
CRP11	Since the available anti- bbbbb1 androgens eeeee1  have low affinity for AR and cannot block androgen action completely, especially in the presence of increased AR levels, it becomes important to discover more potent and purely antagonistic blockers of  bbbbb2 AR eeeee2 
CRP11	Since the available anti- bbbbb1 androgens eeeee1  have low affinity for  bbbbb2 AR eeeee2  and cannot block androgen action completely, especially in the presence of increased AR levels, it becomes important to discover more potent and purely antagonistic blockers of AR
CRP11	Since the available anti-androgens have low affinity for AR and cannot block  bbbbb1 androgen eeeee1  action completely, especially in the presence of increased  bbbbb2 AR eeeee2  levels, it becomes important to discover more potent and purely antagonistic blockers of AR
CRP11	Since the available anti-androgens have low affinity for AR and cannot block  bbbbb1 androgen eeeee1  action completely, especially in the presence of increased AR levels, it becomes important to discover more potent and purely antagonistic blockers of  bbbbb2 AR eeeee2 
CRP11	Since the available anti-androgens have low affinity for AR and cannot block  bbbbb1 androgen eeeee1  bbbbb2 AR eeeee2  and cannot block androgen action completely, especially in the presence of increased AR levels, it becomes important to discover more potent and purely antagonistic blockers of AR
CRP11	While the role of androgens was believed to have become non-significant in cancer progressing under any form of androgen blockade, recent data have shown increased expression of the  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  (AR) in treatment-resistant disease with a benefit of further androgen blockade
CRP11	While the role of androgens was believed to have become non-significant in cancer progressing under any form of androgen blockade, recent data have shown increased expression of the  bbbbb1 androgen eeeee1  receptor ( bbbbb2 AR eeeee2 ) in treatment-resistant disease with a benefit of further androgen blockade
CRP11	While the role of androgens was believed to have become non-significant in cancer progressing under any form of  bbbbb1 androgen eeeee1  blockade, recent data have shown increased expression of the  bbbbb2 androgen receptor eeeee2  (AR) in treatment-resistant disease with a benefit of further androgen blockade
CRP11	While the role of androgens was believed to have become non-significant in cancer progressing under any form of  bbbbb1 androgen eeeee1  blockade, recent data have shown increased expression of the androgen receptor ( bbbbb2 AR eeeee2 ) in treatment-resistant disease with a benefit of further androgen blockade
CRP11	While the role of  bbbbb1 androgens eeeee1  was believed to have become non-significant in cancer progressing under any form of androgen blockade, recent data have shown increased expression of the  bbbbb2 androgen receptor eeeee2  (AR) in treatment-resistant disease with a benefit of further androgen blockade
CRP11	While the role of  bbbbb1 androgens eeeee1  was believed to have become non-significant in cancer progressing under any form of androgen blockade, recent data have shown increased expression of the androgen receptor ( bbbbb2 AR eeeee2 ) in treatment-resistant disease with a benefit of further androgen blockade
CRP11	While the role of androgens was believed to have become non-significant in cancer progressing under any form of androgen blockade, recent data have shown increased expression of the androgen receptor (AR) in treatment-resistant disease with a benefit of further  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  (AR) in treatment-resistant disease with a benefit of further androgen blockade
CRP11	While the role of androgens was believed to have become non-significant in cancer progressing under any form of androgen blockade, recent data have shown increased expression of the androgen receptor (AR) in treatment-resistant disease with a benefit of further  bbbbb1 androgen eeeee1  bbbbb2 AR eeeee2 ) in treatment-resistant disease with a benefit of further androgen blockade
CRP11	The four groups investigated included (i) a blank control (no GFs), (ii) GMP-loaded IGF-1 alone, (iii) GMP-loaded IGF-1 and gel-loaded TGF-β3, and (iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in  bbbbb1 OPF eeeee1  bbbbb2 TGF-β3 eeeee2  in OPF composite hydrogels
CRP11	The four groups investigated included (i) a blank control (no GFs), (ii) GMP-loaded IGF-1 alone, (iii) GMP-loaded IGF-1 and gel-loaded TGF-β3, and (iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in  bbbbb1 OPF eeeee1  bbbbb2 IGF-1 eeeee2  and GMP-loaded TGF-β3 in OPF composite hydrogels
CRP11	The four groups investigated included (i) a blank control (no GFs), (ii) GMP-loaded IGF-1 alone, (iii) GMP-loaded IGF-1 and gel-loaded TGF-β3, and (iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in  bbbbb1 OPF eeeee1  bbbbb2 IGF-1 eeeee2  and gel-loaded TGF-β3, and (iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in OPF composite hydrogels
CRP11	The four groups investigated included (i) a blank control (no GFs), (ii) GMP-loaded IGF-1 alone, (iii) GMP-loaded IGF-1 and gel-loaded TGF-β3, and (iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in  bbbbb1 OPF eeeee1  bbbbb2 TGF-β3 eeeee2 , and (iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in OPF composite hydrogels
CRP11	The four groups investigated included (i) a blank control (no GFs), (ii) GMP-loaded IGF-1 alone, (iii) GMP-loaded IGF-1 and gel-loaded TGF-β3, and (iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in  bbbbb1 OPF eeeee1  bbbbb2 IGF-1 eeeee2  alone, (iii) GMP-loaded IGF-1 and gel-loaded TGF-β3, and (iv) GMP-loaded IGF-1 and GMP-loaded TGF-β3 in OPF composite hydrogels
CRP11	In this study, a bilayered  bbbbb1 OPF eeeee1  composite hydrogel that mimics the distinctive hierarchical structure of native osteochondral tissue was utilized to investigate the effect of  bbbbb2 transforming growth factor-β3 eeeee2  (TGF-β3) with varying release kinetics and/or insulin-like growth factor-1 (IGF-1) on osteochondral tissue regeneration in a rabbit full-thickness osteochondral defect model
CRP11	In this study, a bilayered  bbbbb1 OPF eeeee1  composite hydrogel that mimics the distinctive hierarchical structure of native osteochondral tissue was utilized to investigate the effect of transforming growth factor-β3 ( bbbbb2 TGF-β3 eeeee2 ) with varying release kinetics and/or insulin-like growth factor-1 (IGF-1) on osteochondral tissue regeneration in a rabbit full-thickness osteochondral defect model
CRP11	In this study, a bilayered  bbbbb1 OPF eeeee1  composite hydrogel that mimics the distinctive hierarchical structure of native osteochondral tissue was utilized to investigate the effect of transforming growth factor-β3 (TGF-β3) with varying release kinetics and/or  bbbbb2 insulin-like growth factor-1 eeeee2  (IGF-1) on osteochondral tissue regeneration in a rabbit full-thickness osteochondral defect model
CRP11	In this study, a bilayered  bbbbb1 OPF eeeee1  composite hydrogel that mimics the distinctive hierarchical structure of native osteochondral tissue was utilized to investigate the effect of transforming growth factor-β3 (TGF-β3) with varying release kinetics and/or insulin-like growth factor-1 ( bbbbb2 IGF-1 eeeee2 ) on osteochondral tissue regeneration in a rabbit full-thickness osteochondral defect model
CRP11	Albiglutide has been studied as monotherapy and add-on therapy to  bbbbb1 metformin eeeee1 , sulfonylureas, thiazolidinediones,  bbbbb2 insulin eeeee2  glargine, and varying combinations of these agents
CRP11	Albiglutide has been studied as monotherapy and add-on therapy to metformin, sulfonylureas,  bbbbb1 thiazolidinediones eeeee1 ,  bbbbb2 insulin eeeee2  glargine, and varying combinations of these agents
CRP11	Albiglutide has been studied as monotherapy and add-on therapy to metformin,  bbbbb1 sulfonylureas eeeee1 , thiazolidinediones,  bbbbb2 insulin eeeee2  glargine, and varying combinations of these agents
CRP11	Clinical studies have shown albiglutide to be superior to placebo,  bbbbb1 sitagliptin eeeee1 , and glimepiride and noninferior to  bbbbb2 insulin eeeee2  glargine and insulin lispro at reducing A1C in T2D patients, with A1C changes from baseline ranging from -0.55% to -0.9%
CRP11	Clinical studies have shown albiglutide to be superior to placebo,  bbbbb1 sitagliptin eeeee1 , and glimepiride and noninferior to insulin glargine and insulin lispro at reducing  bbbbb2 A1C eeeee2  in T2D patients, with A1C changes from baseline ranging from -0.55% to -0.9%
CRP11	Clinical studies have shown albiglutide to be superior to placebo,  bbbbb1 sitagliptin eeeee1 , and glimepiride and noninferior to insulin glargine and  bbbbb2 insulin eeeee2  lispro at reducing A1C in T2D patients, with A1C changes from baseline ranging from -0.55% to -0.9%
CRP11	Clinical studies have shown albiglutide to be superior to placebo,  bbbbb1 sitagliptin eeeee1 , and glimepiride and noninferior to insulin glargine and insulin lispro at reducing A1C in T2D patients, with  bbbbb2 A1C eeeee2  changes from baseline ranging from -0.55% to -0.9%
CRP11	Clinical studies have shown albiglutide to be superior to placebo, sitagliptin, and  bbbbb1 glimepiride eeeee1  and noninferior to  bbbbb2 insulin eeeee2  glargine and insulin lispro at reducing A1C in T2D patients, with A1C changes from baseline ranging from -0.55% to -0.9%
CRP11	Clinical studies have shown albiglutide to be superior to placebo, sitagliptin, and  bbbbb1 glimepiride eeeee1  and noninferior to insulin glargine and insulin lispro at reducing  bbbbb2 A1C eeeee2  in T2D patients, with A1C changes from baseline ranging from -0.55% to -0.9%
CRP11	Clinical studies have shown albiglutide to be superior to placebo, sitagliptin, and  bbbbb1 glimepiride eeeee1  and noninferior to insulin glargine and  bbbbb2 insulin eeeee2  lispro at reducing A1C in T2D patients, with A1C changes from baseline ranging from -0.55% to -0.9%
CRP11	Clinical studies have shown albiglutide to be superior to placebo, sitagliptin, and  bbbbb1 glimepiride eeeee1  and noninferior to insulin glargine and insulin lispro at reducing A1C in T2D patients, with  bbbbb2 A1C eeeee2  changes from baseline ranging from -0.55% to -0.9%
CRP11	IS: Albiglutide is a long-acting GLP-1 RA that lowers glycosylated hemoglobin (A1C) and reduces weight by stimulating  bbbbb1 glucose eeeee1  bbbbb2 GLP-1 R eeeee2 A that lowers glycosylated hemoglobin (A1C) and reduces weight by stimulating glucose-dependent insulin secretion, suppressing glucagon secretion, delaying gastric emptying, and promoting satiety
CRP11	IS: Albiglutide is a long-acting GLP-1 RA that lowers glycosylated hemoglobin (A1C) and reduces weight by stimulating  bbbbb1 glucose eeeee1  bbbbb2 A1C eeeee2 ) and reduces weight by stimulating glucose-dependent insulin secretion, suppressing glucagon secretion, delaying gastric emptying, and promoting satiety
CRP11	IS: Albiglutide is a long-acting GLP-1 RA that lowers glycosylated hemoglobin (A1C) and reduces weight by stimulating  bbbbb1 glucose eeeee1  bbbbb2 glycosylated hemoglobin eeeee2  (A1C) and reduces weight by stimulating glucose-dependent insulin secretion, suppressing glucagon secretion, delaying gastric emptying, and promoting satiety
CRP11	IS: Albiglutide is a long-acting GLP-1 RA that lowers glycosylated hemoglobin (A1C) and reduces weight by stimulating  bbbbb1 glucose eeeee1 -dependent  bbbbb2 insulin eeeee2  secretion, suppressing glucagon secretion, delaying gastric emptying, and promoting satiety
CRP11	IS: Albiglutide is a long-acting GLP-1 RA that lowers glycosylated hemoglobin (A1C) and reduces weight by stimulating  bbbbb1 glucose eeeee1 -dependent insulin secretion, suppressing  bbbbb2 glucagon eeeee2  secretion, delaying gastric emptying, and promoting satiety
CRP11	In silico identification of  bbbbb1 poly(ADP-ribose) eeeee1  bbbbb2 poly(ADP-ribose)polymerase-1 eeeee2  inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells
CRP11	In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against  bbbbb1 cisplatin eeeee1  bbbbb2 poly(ADP-ribose)polymerase-1 eeeee2  inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells
CRP11	We then examined the chemosensitization of cisplatin by pre-treatm bbbbb1 ent of PARP-1 in eeeee1  bbbbb2 hemose eeeee2 nsitization of cisplatin by pre-treatment of PARP-1 inhibitors in cisplatin-resistant human gastric cancer cells
CRP11	We then examined the chemosensitization of cisplatin by pre-treatment of PARP-1 inhibitors in cisplatin-resistant h bbbbb1 uman gast eeeee1  bbbbb2 hemose eeeee2 nsitization of cisplatin by pre-treatment of PARP-1 inhibitors in cisplatin-resistant human gastric cancer cells
CRP11	 bbbbb1 Poly(ADP-ribose) eeeee1  bbbbb2 Poly(ADP-ribose)polymerase-1 eeeee2  (PARP-1) enzyme is involved in the repair of DNA damages made by certain anticancer agents
CRP11	 bbbbb1 Poly(ADP-ribose) eeeee1 polymerase-1 ( bbbbb2 PARP-1 eeeee2 ) enzyme is involved in the repair of DNA damages made by certain anticancer agents
CRP11	It is suggested that PARP-1 inhibitors potentiate the cytotoxic effects and circumvent the resistance of DNA-modifying anticancer agents such as  bbbbb1 cisplatin eeeee1  bbbbb2 PARP-1 eeeee2  inhibitors potentiate the cytotoxic effects and circumvent the resistance of DNA-modifying anticancer agents such as cisplatin
CRP11	The electrostatic potential of  bbbbb1 BH3 eeeee1  cleft of  bbbbb2 Bcl-2 eeeee2 /mutants and their heterodimerization with Bcl-2 associated X protein (Bax) were computationally evaluated
CRP11	The electrostatic potential of  bbbbb1 BH3 eeeee1  cleft of Bcl-2/mutants and their heterodimerization with  bbbbb2 Bcl-2 associated X protein eeeee2  (Bax) were computationally evaluated
CRP11	The electrostatic potential of  bbbbb1 BH3 eeeee1  bbbbb2 BH3 cleft eeeee2  of Bcl-2/mutants and their heterodimerization with Bcl-2 associated X protein (Bax) were computationally evaluated
CRP11	The electrostatic potential of  bbbbb1 BH3 eeeee1  cleft of Bcl-2/mutants and their heterodimerization with Bcl-2 associated X protein ( bbbbb2 Bax eeeee2 ) were computationally evaluated
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of  bbbbb1 malondialdehyde eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of  bbbbb1 malondialdehyde eeeee1  bbbbb2 GRx eeeee2 ) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of  bbbbb1 malondialdehyde eeeee1  bbbbb2 GPx eeeee2 ) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of  bbbbb1 malondialdehyde eeeee1  bbbbb2 glutathione reductase eeeee2  (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and  bbbbb1 glutathione eeeee1  reductase ( bbbbb2 GRx eeeee2 ) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and  bbbbb1 glutathione eeeee1  bbbbb2 GPx eeeee2 ) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione reductase eeeee2  (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and  bbbbb1 NO eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and  bbbbb1 NO eeeee1  bbbbb2 GRx eeeee2 ) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and  bbbbb1 NO eeeee1  bbbbb2 GPx eeeee2 ) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and  bbbbb1 NO eeeee1  bbbbb2 glutathione reductase eeeee2  (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of  bbbbb1 glutathione eeeee1  peroxidase (GPx) and glutathione reductase ( bbbbb2 GRx eeeee2 ) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of  bbbbb1 glutathione eeeee1  peroxidase ( bbbbb2 GPx eeeee2 ) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of  bbbbb1 glutathione eeeee1  peroxidase (GPx) and  bbbbb2 glutathione reductase eeeee2  (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 GRx eeeee2 ) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 GPx eeeee2 ) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	In order to investigate the anti-inflammatory mechanism of AGT, we have detected the activities of glutathione peroxidase (GPx) and glutathione reductase (GRx) in the liver and the levels of malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 glutathione reductase eeeee2  (GRx) in the liver and the levels of malondialdehyde (MDA) and NO in the edema paw
CRP11	These results suggested that AGT possessed analgesic and anti-inflammatory effects bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These results suggested that AGT possessed analgesic and anti-inflammatory effects bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These results suggested that AGT possessed analgesic and anti-inflammatory effects bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In the anti-inflammatory test, AGT (0.5 and 1.0 g/kg) decreased the paw edema at the third, fourth, fifth and sixth hour after lambda-carrageenan administration, and increased the activities of SOD, GPx and GRx in the liver tissue and decreased the  bbbbb1 MDA eeeee1  bbbbb2 GPx eeeee2  and GRx in the liver tissue and decreased the MDA level in the edema paw at the third hour after lambda-carrageenan injection
CRP11	In the anti-inflammatory test, AGT (0.5 and 1.0 g/kg) decreased the paw edema at the third, fourth, fifth and sixth hour after lambda-carrageenan administration, and increased the activities of SOD, GPx and GRx in the liver tissue and decreased the  bbbbb1 MDA eeeee1  bbbbb2 GRx eeeee2  in the liver tissue and decreased the MDA level in the edema paw at the third hour after lambda-carrageenan injection
CRP11	In the anti-inflammatory test, AGT (0.5 and 1.0 g/kg) decreased the paw edema at the third, fourth, fifth and sixth hour after lambda-carrageenan administration, and increased the activities of SOD, GPx and GRx in the liver tissue and decreased the  bbbbb1 MDA eeeee1  bbbbb2 SOD eeeee2 , GPx and GRx in the liver tissue and decreased the MDA level in the edema paw at the third hour after lambda-carrageenan injection
CRP11	After adjusting for age, sex, total cholesterol, HDL-cholesterol and  bbbbb1 triglyceride eeeee1 , max-IMT was significantly increased in the highest tertile of  bbbbb2 serum PCSK9 eeeee2  (0.969±0.033 vs 0.959±0.033 vs 1.077±0.033mm, respectively; P=0.026)
CRP11	After adjusting for age, sex, total cholesterol, HDL-cholesterol and  bbbbb1 triglyceride eeeee1  bbbbb2 HDL eeeee2 -cholesterol and triglyceride, max-IMT was significantly increased in the highest tertile of serum PCSK9 (0.969±0.033 vs 0.959±0.033 vs 1.077±0.033mm, respectively; P=0.026)
CRP11	After adjusting for age, sex, total  bbbbb1 cholesterol eeeee1 , HDL-cholesterol and triglyceride, max-IMT was significantly increased in the highest tertile of  bbbbb2 serum PCSK9 eeeee2  (0.969±0.033 vs 0.959±0.033 vs 1.077±0.033mm, respectively; P=0.026)
CRP11	After adjusting for age, sex, total  bbbbb1 cholesterol eeeee1 ,  bbbbb2 HDL eeeee2 -cholesterol and triglyceride, max-IMT was significantly increased in the highest tertile of serum PCSK9 (0.969±0.033 vs 0.959±0.033 vs 1.077±0.033mm, respectively; P=0.026)
CRP11	CA1 single nucleotide polymorphisms on high-density lipoprotein- bbbbb1 cholesterol eeeee1  bbbbb2 high-density lipoprotein eeeee2 -cholesterol and overweight: the D.E.S.I.R. study
CRP11	CA1 single  bbbbb1 nucleotide eeeee1  polymorphisms on  bbbbb2 high-density lipoprotein eeeee2 -cholesterol and overweight: the D.E.S.I.R. study
CRP11	Some ABCA1 gene polymorphisms have been associated with high-density lipoprotein- bbbbb1 cholesterol eeeee1  bbbbb2 high-density lipoprotein eeeee2 -cholesterol (HDL-C) concentrations
CRP11	Some ABCA1 gene polymorphisms have been associated with high-density lipoprotein- bbbbb1 cholesterol eeeee1  bbbbb2 ABCA1 eeeee2  gene polymorphisms have been associated with high-density lipoprotein-cholesterol (HDL-C) concentrations
CRP11	Some ABCA1 gene polymorphisms have been associated with high-density lipoprotein- bbbbb1 cholesterol eeeee1  ( bbbbb2 HDL eeeee2 -C) concentrations
CRP11	The adenosine triphosphate-binding cassette A1 (ABCA1) gene plays a key role in reverse  bbbbb1 cholesterol eeeee1  bbbbb2 adenosine triphosphate-binding cassette A1 eeeee2  (ABCA1) gene plays a key role in reverse cholesterol transport
CRP11	The adenosine triphosphate-binding cassette A1 (ABCA1) gene plays a key role in reverse  bbbbb1 cholesterol eeeee1  bbbbb2 ABCA1 eeeee2 ) gene plays a key role in reverse cholesterol transport
CRP11	The  bbbbb1 adenosine triphosphate eeeee1  bbbbb2 adenosine triphosphate-binding cassette A1 eeeee2  (ABCA1) gene plays a key role in reverse cholesterol transport
CRP11	The  bbbbb1 adenosine triphosphate eeeee1 -binding cassette A1 ( bbbbb2 ABCA1 eeeee2 ) gene plays a key role in reverse cholesterol transport
CRP11	This study investigated the effect of a structured self-monitoring of blood  bbbbb1 glucose eeeee1  (SMBG) protocol and the resulting improvements in glycemic control on changes in high-sensitivity C-reactive protein (hs-CRP) in insulin-naïve patients with type 2 diabetes.RESEARCH DESIGN AND METHODSThe Structured Testing Program (STeP) study was a prospective, cluster-randomized, multicenter trial in which 483 poorly controlled,  bbbbb2 insulin eeeee2 -naïve patients with type 2 diabetes were randomized to active control (ACG) or structured testing (STG) that included quarterly structured SMBG
CRP11	This study investigated the effect of a structured self-monitoring of blood  bbbbb1 glucose eeeee1  (SMBG) protocol and the resulting improvements in glycemic control on changes in high-sensitivity  bbbbb2 C-reactive protein eeeee2  (hs-CRP) in insulin-naïve patients with type 2 diabetes.RESEARCH DESIGN AND METHODSThe Structured Testing Program (STeP) study was a prospective, cluster-randomized, multicenter trial in which 483 poorly controlled, insulin-naïve patients with type 2 diabetes were randomized to active control (ACG) or structured testing (STG) that included quarterly structured SMBG
CRP11	This study investigated the effect of a structured self-monitoring of blood  bbbbb1 glucose eeeee1  (SMBG) protocol and the resulting improvements in glycemic control on changes in high-sensitivity C-reactive protein (hs-CRP) in  bbbbb2 insulin eeeee2 -naïve patients with type 2 diabetes.RESEARCH DESIGN AND METHODSThe Structured Testing Program (STeP) study was a prospective, cluster-randomized, multicenter trial in which 483 poorly controlled, insulin-naïve patients with type 2 diabetes were randomized to active control (ACG) or structured testing (STG) that included quarterly structured SMBG
CRP11	This study investigated the effect of a structured self-monitoring of blood  bbbbb1 glucose eeeee1  (SMBG) protocol and the resulting improvements in glycemic control on changes in high-sensitivity C-reactive protein ( bbbbb2 hs-CRP eeeee2 ) in insulin-naïve patients with type 2 diabetes.RESEARCH DESIGN AND METHODSThe Structured Testing Program (STeP) study was a prospective, cluster-randomized, multicenter trial in which 483 poorly controlled, insulin-naïve patients with type 2 diabetes were randomized to active control (ACG) or structured testing (STG) that included quarterly structured SMBG
CRP11	As the nucleus accumbens (Nac) is particularly involved in addictive behavior, we analyzed IEI-induced long-term neuroadaptations in the Nac using c-Fos immunohistochemistry and an array of neurotransmission-related genes bbbbb1  eeeee1  bbbbb2 immuno eeeee2 histochemistry and an array of neurotransmission-related genes
CRP11	As the nucleus accumbens (Nac) is particularly involved in addictive behavior, we analyzed IEI-induced long-term neuroadaptations in the Nac using c-Fos immunohistochemistry and an array of neurotransmission-related genes bbbbb1  eeeee1  bbbbb2 tive  eeeee2 behavior, we analyzed IEI-induced long-term neuroadaptations in the Nac using c-Fos immunohistochemistry and an array of neurotransmission-related genes
CRP11	As the nucleus accumbens (Nac) is particularly involved in addictive behavior, we analyzed IEI-induced long-term neuroadaptations in the Nac using c-Fos immunohistochemistry and an array of neurotransmission-related genes bbbbb1  eeeee1  bbbbb2 ng c eeeee2 -Fos immunohistochemistry and an array of neurotransmission-related genes
CRP11	As the nucleus accumbe bbbbb1 ns (Nac eeeee1 ) is particularly involved in addictive behavior, we analyzed IEI-induced long-term neuroadaptations in the Nac using c-Fos  bbbbb2 immuno eeeee2 histochemistry and an array of neurotransmission-related genes
CRP11	As the nucleus accumbe bbbbb1 ns (Nac eeeee1 ) is particularly involved in addic bbbbb2 tive  eeeee2 behavior, we analyzed IEI-induced long-term neuroadaptations in the Nac using c-Fos immunohistochemistry and an array of neurotransmission-related genes
CRP11	As the nucleus accumbe bbbbb1 ns (Nac eeeee1 ) is particularly involved in addictive behavior, we analyzed IEI-induced long-term neuroadaptations in the Nac usi bbbbb2 ng c eeeee2 -Fos immunohistochemistry and an array of neurotransmission-related genes
CRP11	Antidepressant use was not associated with increased levels of HbA1c, fasting blood sugar, 2-h oral  bbbbb1 glucose eeeee1  bbbbb2 HbA1c eeeee2 , fasting blood sugar, 2-h oral glucose tolerance test, reduced insulin sensitivity or increased prevalence of screen-positive diabetes
CRP11	Antidepressant use was not associated with increased levels of HbA1c, fasting blood sugar, 2-h oral  bbbbb1 glucose eeeee1  tolerance test, reduced  bbbbb2 insulin eeeee2  sensitivity or increased prevalence of screen-positive diabetes
CRP11	Antidepressant use was not associated with increased levels of HbA1c, fasting blood  bbbbb1 sugar eeeee1  bbbbb2 HbA1c eeeee2 , fasting blood sugar, 2-h oral glucose tolerance test, reduced insulin sensitivity or increased prevalence of screen-positive diabetes
CRP11	Antidepressant use was not associated with increased levels of HbA1c, fasting blood  bbbbb1 sugar eeeee1 , 2-h oral glucose tolerance test, reduced  bbbbb2 insulin eeeee2  sensitivity or increased prevalence of screen-positive diabetes
CRP11	In this work we describe the identification of potent and novel dual FLT3/PDGFR inhibitors that resulted from our efforts to screen a library of 25,607 small molecules against the FLT3 dependent cell line MOLM-13 and the P bbbbb1 DGFR dep eeeee1  bbbbb2 DGFR dependent c eeeee2 ell line EOL-1
CRP11	In this work we describe the identification of potent and novel dual FLT3/PDGFR inhibitors that resulted from our efforts to screen a library of 25,607 small molecules against the FLT3 dependent cell line MOLM-13 and the P bbbbb1 DGFR dep eeeee1  bbbbb2 d fr eeeee2 om our efforts to screen a library of 25,607 small molecules against the FLT3 dependent cell line MOLM-13 and the PDGFR dependent cell line EOL-1
CRP11	FLT3 and PDGFR  bbbbb1 tyrosine eeeee1  bbbbb2 PDGFR eeeee2  tyrosine kinases are important targets for therapy of different types of leukemia
CRP11	FLT3 and PDGFR  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinases eeeee2  are important targets for therapy of different types of leukemia
CRP11	FLT3 and PDGFR  bbbbb1 tyrosine eeeee1  bbbbb2 FLT3 eeeee2  and PDGFR tyrosine kinases are important targets for therapy of different types of leukemia
CRP11	Sirt1, an  bbbbb1 NAD(+) eeeee1  bbbbb2 Sirt1 eeeee2 , an NAD(+)-dependent deacetylase, was identified as a molecule necessary for caloric restriction-related anti-aging strategies
CRP11	Sirt1, an  bbbbb1 NAD(+) eeeee1  bbbbb2 NAD(+)-dependent deacetylase eeeee2 , was identified as a molecule necessary for caloric restriction-related anti-aging strategies
CRP11	Sirt1 functions as an intracellular energy sensor to detect the concentration of  bbbbb1 NAD(+) eeeee1 , and controls in vivo metabolic changes under caloric restriction and starvation through its deacetylase activity to many targets including  bbbbb2 histones eeeee2 , nuclear transcriptional factors, and enzymes
CRP11	Sirt1 functions as an intracellular energy sensor to detect the concentration of  bbbbb1 NAD(+) eeeee1 , and controls in vivo metabolic changes under caloric restriction and starvation through its  bbbbb2 deacetylase eeeee2  activity to many targets including histones, nuclear transcriptional factors, and enzymes
CRP11	Sirt1 functions as an intracellular energy sensor to detect the concentration of  bbbbb1 NAD(+) eeeee1  bbbbb2 Sirt1 eeeee2  functions as an intracellular energy sensor to detect the concentration of NAD(+), and controls in vivo metabolic changes under caloric restriction and starvation through its deacetylase activity to many targets including histones, nuclear transcriptional factors, and enzymes
CRP11	Circulating  bbbbb1 androgens eeeee1  and markers of  bbbbb2 insulin eeeee2  resistance (IR) were higher in women with PCOS than in controls
CRP11	Here we utilize transgenic and allograft breast cancer models to demonstrate that increased mammalian target of  bbbbb1 rapamycin eeeee1  ( bbbbb2 mTOR eeeee2 ) signalling can be a significant contributor to breast cancer progression in vivo
CRP11	Here we utilize transgenic and allograft breast cancer models to demonstrate that increased mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 mammalian target of rapamycin eeeee2  (mTOR) signalling can be a significant contributor to breast cancer progression in vivo
CRP11	Airway resistance (RI) and lung compliance (Cdyn) were measured, histological studies were evaluated by the  bbbbb1 hematoxylin eeeee1  and eosin staining, Th1/Th2, OVA-specific serum, and BALF  bbbbb2 IgE eeeee2  levels and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay, and Th17 cells was evaluated by flow cytometry (FCM)
CRP11	Airway resistance (RI) and lung compliance (Cdyn) were measured, histological studies were evaluated by the  bbbbb1 hematoxylin eeeee1  and eosin staining, Th1/Th2,  bbbbb2 OVA eeeee2 -specific serum, and BALF IgE levels and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay, and Th17 cells was evaluated by flow cytometry (FCM)
CRP11	Airway resistance (RI) and lung compliance (Cdyn) were measured, histological studies were evaluated by the  bbbbb1 hematoxylin eeeee1  and eosin staining, Th1/Th2, OVA-specific serum, and BALF IgE levels and Th17  bbbbb2 cytokines eeeee2  were evaluated by enzyme-linked immunosorbent assay, and Th17 cells was evaluated by flow cytometry (FCM)
CRP11	Airway resistance (RI) and lung compliance (Cdyn) were measured, histological studies were evaluated by the hematoxylin and  bbbbb1 eosin eeeee1  staining, Th1/Th2, OVA-specific serum, and BALF  bbbbb2 IgE eeeee2  levels and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay, and Th17 cells was evaluated by flow cytometry (FCM)
CRP11	Airway resistance (RI) and lung compliance (Cdyn) were measured, histological studies were evaluated by the hematoxylin and  bbbbb1 eosin eeeee1  staining, Th1/Th2,  bbbbb2 OVA eeeee2 -specific serum, and BALF IgE levels and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay, and Th17 cells was evaluated by flow cytometry (FCM)
CRP11	Airway resistance (RI) and lung compliance (Cdyn) were measured, histological studies were evaluated by the hematoxylin and  bbbbb1 eosin eeeee1  staining, Th1/Th2, OVA-specific serum, and BALF IgE levels and Th17  bbbbb2 cytokines eeeee2  were evaluated by enzyme-linked immunosorbent assay, and Th17 cells was evaluated by flow cytometry (FCM)
CRP11	Here, we found that expression of the PLP1-A243V mutant, which causes severe disease, depletes some ER chaperones with a KDEL ( bbbbb1 Lys-Asp-Glu-Leu eeeee1  bbbbb2 A243V eeeee2  mutant, which causes severe disease, depletes some ER chaperones with a KDEL (Lys-Asp-Glu-Leu) motif, in HeLa cells, MO3.13 oligodendrocytic cells, and primary oligodendrocytes
CRP11	Here, we found that expression of the PLP1-A243V mutant, which causes severe disease, depletes some ER chaperones with a KDEL ( bbbbb1 Lys-Asp-Glu-Leu eeeee1  bbbbb2 KDEL eeeee2  (Lys-Asp-Glu-Leu) motif, in HeLa cells, MO3.13 oligodendrocytic cells, and primary oligodendrocytes
CRP11	Here, we found that expression of the PLP1-A243V mutant, which causes severe disease, depletes some ER chaperones with a KDEL ( bbbbb1 Lys-Asp-Glu-Leu eeeee1  bbbbb2 PLP1 eeeee2 -A243V mutant, which causes severe disease, depletes some ER chaperones with a KDEL (Lys-Asp-Glu-Leu) motif, in HeLa cells, MO3.13 oligodendrocytic cells, and primary oligodendrocytes
CRP11	Here, we found that expression of the PLP1-A243V mutant, which causes severe disease, depletes some ER chaperones with a KDEL ( bbbbb1 Lys-Asp-Glu-Leu eeeee1  bbbbb2 Lys-Asp-Glu-Leu eeeee2 ) motif, in HeLa cells, MO3.13 oligodendrocytic cells, and primary oligodendrocytes
CRP11	Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2-receptor eeeee2  occupancy
CRP11	We describe here the putative influence of the dose of antipsychotic medication ( bbbbb1 chlorpromazine eeeee1  equivalents, CPZ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central dopamine D2-receptor occupancy (DA  bbbbb2 D2 eeeee2 -occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication ( bbbbb1 chlorpromazine eeeee1  equivalents, CPZ), the antipsychotic serum concentration of  bbbbb2 dopamine (DA) D2 eeeee2 -blocking activity and the approximated central dopamine D2-receptor occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication ( bbbbb1 chlorpromazine eeeee1  equivalents, CPZ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central dopamine  bbbbb2 D2-receptor eeeee2  occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central  bbbbb1 dopamine eeeee1  D2-receptor occupancy (DA  bbbbb2 D2 eeeee2 -occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central  bbbbb1 dopamine eeeee1  bbbbb2 dopamine (DA) D2 eeeee2 -blocking activity and the approximated central dopamine D2-receptor occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central  bbbbb1 dopamine eeeee1   bbbbb2 D2-receptor eeeee2  occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of dopamine ( bbbbb1 DA eeeee1 ) D2-blocking activity and the approximated central dopamine D2-receptor occupancy (DA  bbbbb2 D2 eeeee2 -occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of dopamine ( bbbbb1 DA eeeee1  bbbbb2 dopamine (DA) D2 eeeee2 -blocking activity and the approximated central dopamine D2-receptor occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of dopamine ( bbbbb1 DA eeeee1 ) D2-blocking activity and the approximated central dopamine  bbbbb2 D2-receptor eeeee2  occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of  bbbbb1 dopamine eeeee1  (DA) D2-blocking activity and the approximated central dopamine D2-receptor occupancy (DA  bbbbb2 D2 eeeee2 -occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of  bbbbb1 dopamine eeeee1  bbbbb2 dopamine (DA) D2 eeeee2 -blocking activity and the approximated central dopamine D2-receptor occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of  bbbbb1 dopamine eeeee1  (DA) D2-blocking activity and the approximated central dopamine  bbbbb2 D2-receptor eeeee2  occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central dopamine D2-receptor occupancy ( bbbbb1 DA eeeee1   bbbbb2 D2 eeeee2 -occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central dopamine D2-receptor occupancy ( bbbbb1 DA eeeee1  bbbbb2 dopamine (DA) D2 eeeee2 -blocking activity and the approximated central dopamine D2-receptor occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central dopamine D2-receptor occupancy ( bbbbb1 DA eeeee1  bbbbb2 D2-receptor eeeee2  occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents,  bbbbb1 CPZ eeeee1 ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central dopamine D2-receptor occupancy (DA  bbbbb2 D2 eeeee2 -occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents,  bbbbb1 CPZ eeeee1 ), the antipsychotic serum concentration of  bbbbb2 dopamine (DA) D2 eeeee2 -blocking activity and the approximated central dopamine D2-receptor occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents,  bbbbb1 CPZ eeeee1 ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central dopamine  bbbbb2 D2-receptor eeeee2  occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls)
CRP11	High estimates of central  bbbbb1 DA eeeee1   bbbbb2 D2 eeeee2 -occupancy were related to impaired verbal fluency but were associated with improved recall of stories, especially in paranoid patients
CRP11	Similar partial correlations for antipsychotic drug dose and serum levels of DA D2-blocking activity with performance of the trail-making and picture completion tests (negative) and the block-design task (positive) showed the functional importance of  bbbbb1 DA eeeee1  bbbbb2 D2 eeeee2 -blocking activity with performance of the trail-making and picture completion tests (negative) and the block-design task (positive) showed the functional importance of DA-related activity
CRP11	Similar partial correlations for antipsychotic drug dose and serum levels of  bbbbb1 DA eeeee1   bbbbb2 D2 eeeee2 -blocking activity with performance of the trail-making and picture completion tests (negative) and the block-design task (positive) showed the functional importance of DA-related activity
CRP11	Recent studies have provided consistent evidence that treatment with abatacept results in a rapid onset of efficacy that is maintained over the course of treatment in patients with inadequate response to  bbbbb1 methotrexate eeeee1  and anti- bbbbb2 tumor necrosis factor eeeee2  therapies
CRP11	In the AG+GG group, males with HDL  bbbbb1 cholesterol eeeee1  bbbbb2 HDL eeeee2  cholesterol levels <40 mg/dL are less frequent (P = 0.05) and obesity tends to be less prevalent (P = 0.07)
CRP11	In approximately 20% of the cases BrS is caused by mutations in the SCN5A gene on chromosome 3p21-23, encoding the cardiac  bbbbb1 sodium eeeee1  bbbbb2 sodium channel eeeee2 , a protein involved in the control of myocardial excitability
CRP11	In approximately 20% of the cases BrS is caused by mutations in the SCN5A gene on chromosome 3p21-23, encoding the cardiac  bbbbb1 sodium eeeee1  bbbbb2 SCN5A eeeee2  gene on chromosome 3p21-23, encoding the cardiac sodium channel, a protein involved in the control of myocardial excitability
CRP11	Synergistic neuromuscular blocking effects have been observed clinically with certain pairs of nicotinic  bbbbb1 acetylcholine eeeee1  bbbbb2 nicotinic acetylcholine receptor eeeee2  (nAChR) competitive antagonists
CRP11	Synergistic neuromuscular blocking effects have been observed clinically with certain pairs of nicotinic  bbbbb1 acetylcholine eeeee1  receptor ( bbbbb2 nAChR eeeee2 ) competitive antagonists
CRP11	Thereafter, the Alcalase hydrolysates were sequentially fractionated by ultra filtration membranes in cut-off molecular weight (MW) of 30, 10, and 1kDa, and tested their antioxidant activities in terms of RP ability, DPPH radical scavenging ability,  bbbbb1 ABTS eeeee1  bbbbb2 Alcalase eeeee2  hydrolysates were sequentially fractionated by ultra filtration membranes in cut-off molecular weight (MW) of 30, 10, and 1kDa, and tested their antioxidant activities in terms of RP ability, DPPH radical scavenging ability, ABTS radical scavenging ability, and FRAP assay
CRP11	Thereafter, the Alcalase hydrolysates were sequentially fractionated by ultra filtration membranes in cut-off molecular weight (MW) of 30, 10, and 1kDa, and tested their antioxidant activities in terms of RP ability,  bbbbb1 DPPH eeeee1  bbbbb2 Alcalase eeeee2  hydrolysates were sequentially fractionated by ultra filtration membranes in cut-off molecular weight (MW) of 30, 10, and 1kDa, and tested their antioxidant activities in terms of RP ability, DPPH radical scavenging ability, ABTS radical scavenging ability, and FRAP assay
CRP11	We provide here evidence that neurofibromin, via its Ras  bbbbb1 guanosine eeeee1  bbbbb2 neurofibromin eeeee2 , via its Ras guanosine triphosphatase -activating activity, controls ERK1/2-dependent fibroblast growth factor receptor (FGFR) signaling in chondrocytes
CRP11	We provide here evidence that neurofibromin, via its Ras  bbbbb1 guanosine eeeee1  triphosphatase -activating activity, controls ERK1/2-dependent  bbbbb2 fibroblast growth factor receptor eeeee2  (FGFR) signaling in chondrocytes
CRP11	We provide here evidence that neurofibromin, via its Ras  bbbbb1 guanosine eeeee1  bbbbb2 guanosine triphosphatase eeeee2  -activating activity, controls ERK1/2-dependent fibroblast growth factor receptor (FGFR) signaling in chondrocytes
CRP11	We provide here evidence that neurofibromin, via its Ras  bbbbb1 guanosine eeeee1  triphosphatase -activating activity, controls  bbbbb2 ERK1/2 eeeee2 -dependent fibroblast growth factor receptor (FGFR) signaling in chondrocytes
CRP11	We provide here evidence that neurofibromin, via its Ras  bbbbb1 guanosine eeeee1  bbbbb2 Ras eeeee2  guanosine triphosphatase -activating activity, controls ERK1/2-dependent fibroblast growth factor receptor (FGFR) signaling in chondrocytes
CRP11	We provide here evidence that neurofibromin, via its Ras  bbbbb1 guanosine eeeee1  triphosphatase -activating activity, controls ERK1/2-dependent fibroblast growth factor receptor ( bbbbb2 FGFR eeeee2 ) signaling in chondrocytes
CRP11	Patients were eligible regardless of site of disease,  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  status, or age
CRP11	Interestingly,  bbbbb1 FITC eeeee1 -labeled  bbbbb2 cytochrome C eeeee2  (FITC-CC) could be readily loaded into nanogels with remarkable loading efficiencies (up to 98.2%) and loading contents (up to 48.2 wt.%)
CRP11	Interestingly,  bbbbb1 FITC eeeee1 -labeled cytochrome C (FITC- bbbbb2 CC eeeee2 ) could be readily loaded into nanogels with remarkable loading efficiencies (up to 98.2%) and loading contents (up to 48.2 wt.%)
CRP11	Interestingly, FITC-labeled cytochrome C ( bbbbb1 FITC eeeee1  bbbbb2 cytochrome C eeeee2  (FITC-CC) could be readily loaded into nanogels with remarkable loading efficiencies (up to 98.2%) and loading contents (up to 48.2 wt.%)
CRP11	Interestingly, FITC-labeled cytochrome C ( bbbbb1 FITC eeeee1 - bbbbb2 CC eeeee2 ) could be readily loaded into nanogels with remarkable loading efficiencies (up to 98.2%) and loading contents (up to 48.2 wt.%)
CRP11	The in vitro release studies showed that release of  bbbbb1 FITC eeeee1 -CC was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM DTT with about 96.8% of FITC- bbbbb2 CC eeeee2  released in 22 h from nanogel 1
CRP11	The in vitro release studies showed that release of  bbbbb1 FITC eeeee1 - bbbbb2 CC eeeee2  was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM DTT with about 96.8% of FITC-CC released in 22 h from nanogel 1
CRP11	The in vitro release studies showed that release of FITC-CC was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM DTT with about 96.8% of  bbbbb1 FITC eeeee1 - bbbbb2 CC eeeee2  released in 22 h from nanogel 1
CRP11	The in vitro release studies showed that release of FITC-CC was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM DTT with about 96.8% of  bbbbb1 FITC eeeee1  bbbbb2 CC eeeee2  was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM DTT with about 96.8% of FITC-CC released in 22 h from nanogel 1
CRP11	The in vitro release studies showed that release of FITC-CC was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM  bbbbb1 DTT eeeee1  with about 96.8% of FITC- bbbbb2 CC eeeee2  released in 22 h from nanogel 1
CRP11	The in vitro release studies showed that release of FITC-CC was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM  bbbbb1 DTT eeeee1  bbbbb2 CC eeeee2  was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM DTT with about 96.8% of FITC-CC released in 22 h from nanogel 1
CRP11	Confocal microscopy results showed that nanogel 1 delivered and released  bbbbb1 FITC eeeee1 - bbbbb2 CC eeeee2  into the perinuclei region of HeLa cells following 8 h incubation
CRP11	Citrated blood from healthy subjects was stimulated: i) from passage through the "Platelet Function Analyzer" (PFA-100), a device that exposes blood to standardized high shear flow through collagen/ADP cartridges; ii) by collagen and  bbbbb1 ADP eeeee1  bbbbb2 collagen eeeee2 /ADP cartridges; ii) by collagen and ADP (2 and 50 mug/ml, respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant Tissue Factor, to generate thrombin concentrations able to activate platelets without inducing blood clotting, or iv) the Thrombin Receptor Activating Peptide-6 (TRAP-6)
CRP11	Citrated blood from healthy subjects was stimulated: i) from passage through the "Platelet Function Analyzer" (PFA-100), a device that exposes blood to standardized high shear flow through collagen/ADP cartridges; ii) by collagen and  bbbbb1 ADP eeeee1  (2 and 50 mug/ml, respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant Tissue Factor, to generate  bbbbb2 thrombin eeeee2  concentrations able to activate platelets without inducing blood clotting, or iv) the Thrombin Receptor Activating Peptide-6 (TRAP-6)
CRP11	Citrated blood from healthy subjects was stimulated: i) from passage through the "Platelet Function Analyzer" (PFA-100), a device that exposes blood to standardized high shear flow through collagen/ADP cartridges; ii) by collagen and  bbbbb1 ADP eeeee1  (2 and 50 mug/ml, respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant  bbbbb2 Tissue Factor eeeee2 , to generate thrombin concentrations able to activate platelets without inducing blood clotting, or iv) the Thrombin Receptor Activating Peptide-6 (TRAP-6)
CRP11	Citrated blood from healthy subjects was stimulated: i) from passage through the "Platelet Function Analyzer" (PFA-100), a device that exposes blood to standardized high shear flow through collagen/ bbbbb1 ADP eeeee1  bbbbb2 collagen eeeee2 /ADP cartridges; ii) by collagen and ADP (2 and 50 mug/ml, respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant Tissue Factor, to generate thrombin concentrations able to activate platelets without inducing blood clotting, or iv) the Thrombin Receptor Activating Peptide-6 (TRAP-6)
CRP11	Citrated blood from healthy subjects was stimulated: i) from passage through the "Platelet Function Analyzer" (PFA-100), a device that exposes blood to standardized high shear flow through collagen/ bbbbb1 ADP eeeee1  cartridges; ii) by collagen and ADP (2 and 50 mug/ml, respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant Tissue Factor, to generate  bbbbb2 thrombin eeeee2  concentrations able to activate platelets without inducing blood clotting, or iv) the Thrombin Receptor Activating Peptide-6 (TRAP-6)
CRP11	Citrated blood from healthy subjects was stimulated: i) from passage through the "Platelet Function Analyzer" (PFA-100), a device that exposes blood to standardized high shear flow through collagen/ bbbbb1 ADP eeeee1  cartridges; ii) by collagen and ADP (2 and 50 mug/ml, respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant  bbbbb2 Tissue Factor eeeee2 , to generate thrombin concentrations able to activate platelets without inducing blood clotting, or iv) the Thrombin Receptor Activating Peptide-6 (TRAP-6)
CRP11	A significant decrease in nitrite (T180) and  bbbbb1 nitrate eeeee1  (T90 and T180), as well as a significant increase in N(ε)-carboxymethyllisine, accompanied intake of AGE- bbbbb2 BLG eeeee2 
CRP11	A significant decrease in nitrite (T180) and nitrate (T90 and T180), as well as a significant increase in  bbbbb1 N(ε)-carboxymethyllisine eeeee1 , accompanied intake of AGE- bbbbb2 BLG eeeee2 
CRP11	A significant decrease in  bbbbb1 nitrite eeeee1  (T180) and nitrate (T90 and T180), as well as a significant increase in N(ε)-carboxymethyllisine, accompanied intake of AGE- bbbbb2 BLG eeeee2 
CRP11	No significant changes were observed among prednisolone-treated patients CONCLUSIONS: Myocard bbbbb1 ial d eeeee1  bbbbb2  wer eeeee2 e observed among prednisolone-treated patients CONCLUSIONS: Myocardial deformation is impaired in RA patients and is related to nitro-oxidative stress and endothelial dysfunction
CRP11	IVE: Inhibition of interleukin-1 activity improves  bbbbb1 nitro eeeee1  bbbbb2 interleukin-1 eeeee2  activity improves nitro-oxidative stress, endothelial and coronary function
CRP11	To determine the prevalence of people with diabetes who meet hemoglobin A(1c) (A1C), blood pressure (BP), and LDL  bbbbb1 cholesterol eeeee1  bbbbb2 hemoglobin A(1c) eeeee2  (A1C), blood pressure (BP), and LDL cholesterol (ABC) recommendations, and their current statin use, factors associated with goal achievement, and changes in the proportion achieving goals between 1988 and 2010.RESEARCH AND DESIGN METHODSData were cross-sectional from the National Health and Nutrition Examination Surveys (NHANES) from 1988-1994, 1999-2002, 2003-2006, and 2007-2010
CRP11	To determine the prevalence of people with diabetes who meet hemoglobin A(1c) (A1C), blood pressure (BP), and LDL  bbbbb1 cholesterol eeeee1  bbbbb2 A1C eeeee2 ), blood pressure (BP), and LDL cholesterol (ABC) recommendations, and their current statin use, factors associated with goal achievement, and changes in the proportion achieving goals between 1988 and 2010.RESEARCH AND DESIGN METHODSData were cross-sectional from the National Health and Nutrition Examination Surveys (NHANES) from 1988-1994, 1999-2002, 2003-2006, and 2007-2010
CRP11	To determine the prevalence of people with diabetes who meet hemoglobin A(1c) (A1C), blood pressure (BP), and LDL  bbbbb1 cholesterol eeeee1  bbbbb2 LDL eeeee2  cholesterol (ABC) recommendations, and their current statin use, factors associated with goal achievement, and changes in the proportion achieving goals between 1988 and 2010.RESEARCH AND DESIGN METHODSData were cross-sectional from the National Health and Nutrition Examination Surveys (NHANES) from 1988-1994, 1999-2002, 2003-2006, and 2007-2010
CRP11	Main outcome measures were A1C, BP, and LDL  bbbbb1 cholesterol eeeee1 , in accordance with the American Diabetes Association recommendations, and current use of statins.RESULTSIn 2007-2010, 52.5% of people with diabetes achieved  bbbbb2 A1C eeeee2  <7.0% (<53 mmol/mol), 51.1% achieved BP <130/80 mmHg, 56.2% achieved LDL <100 mg/dL, and 18.8% achieved all three ABCs
CRP11	Main outcome measures were A1C, BP, and LDL  bbbbb1 cholesterol eeeee1  bbbbb2 LDL eeeee2  cholesterol, in accordance with the American Diabetes Association recommendations, and current use of statins.RESULTSIn 2007-2010, 52.5% of people with diabetes achieved A1C <7.0% (<53 mmol/mol), 51.1% achieved BP <130/80 mmHg, 56.2% achieved LDL <100 mg/dL, and 18.8% achieved all three ABCs
CRP11	Main outcome measures were A1C, BP, and LDL  bbbbb1 cholesterol eeeee1  bbbbb2 A1C eeeee2 , BP, and LDL cholesterol, in accordance with the American Diabetes Association recommendations, and current use of statins.RESULTSIn 2007-2010, 52.5% of people with diabetes achieved A1C <7.0% (<53 mmol/mol), 51.1% achieved BP <130/80 mmHg, 56.2% achieved LDL <100 mg/dL, and 18.8% achieved all three ABCs
CRP11	Main outcome measures were A1C, BP, and LDL  bbbbb1 cholesterol eeeee1 , in accordance with the American Diabetes Association recommendations, and current use of statins.RESULTSIn 2007-2010, 52.5% of people with diabetes achieved A1C <7.0% (<53 mmol/mol), 51.1% achieved BP <130/80 mmHg, 56.2% achieved  bbbbb2 LDL eeeee2  <100 mg/dL, and 18.8% achieved all three ABCs
CRP11	Evidence indicates that nerve gas toxins operate in ways in addition to inhibition of  bbbbb1 acetylcholine eeeee1  bbbbb2 acetylcholine esterase eeeee2 
CRP11	In multivariate regression tests including age, gender, albumin ratio, number of the APOEɛ4 alleles, and diagnosis, p-tau181 levels independently predicted the CSF desmosterol, cholesterol and  bbbbb1 24S-hydroxycholesterol eeeee1  bbbbb2 p-tau181 eeeee2  levels independently predicted the CSF desmosterol, cholesterol and 24S-hydroxycholesterol concentrations
CRP11	In multivariate regression tests including age, gender, albumin ratio, number of the APOEɛ4 alleles, and diagnosis, p-tau181 levels independently predicted the CSF desmosterol, cholesterol and  bbbbb1 24S-hydroxycholesterol eeeee1  bbbbb2 APOEɛ4 eeeee2  alleles, and diagnosis, p-tau181 levels independently predicted the CSF desmosterol, cholesterol and 24S-hydroxycholesterol concentrations
CRP11	In multivariate regression tests including age, gender, albumin ratio, number of the APOEɛ4 alleles, and diagnosis, p-tau181 levels independently predicted the CSF  bbbbb1 desmosterol eeeee1  bbbbb2 p-tau181 eeeee2  levels independently predicted the CSF desmosterol, cholesterol and 24S-hydroxycholesterol concentrations
CRP11	In multivariate regression tests including age, gender, albumin ratio, number of the APOEɛ4 alleles, and diagnosis, p-tau181 levels independently predicted the CSF  bbbbb1 desmosterol eeeee1  bbbbb2 APOEɛ4 eeeee2  alleles, and diagnosis, p-tau181 levels independently predicted the CSF desmosterol, cholesterol and 24S-hydroxycholesterol concentrations
CRP11	In multivariate regression tests including age, gender, albumin ratio, number of the APOEɛ4 alleles, and diagnosis, p-tau181 levels independently predicted the CSF desmosterol,  bbbbb1 cholesterol eeeee1  bbbbb2 p-tau181 eeeee2  levels independently predicted the CSF desmosterol, cholesterol and 24S-hydroxycholesterol concentrations
CRP11	In multivariate regression tests including age, gender, albumin ratio, number of the APOEɛ4 alleles, and diagnosis, p-tau181 levels independently predicted the CSF desmosterol,  bbbbb1 cholesterol eeeee1  bbbbb2 APOEɛ4 eeeee2  alleles, and diagnosis, p-tau181 levels independently predicted the CSF desmosterol, cholesterol and 24S-hydroxycholesterol concentrations
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol, lathosterol and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and  bbbbb1 27-hydroxycholesterol eeeee1 , and the CSF markers for AD pathology  bbbbb2 Aβ1-42 eeeee2  and p-tau181 in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol, lathosterol and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and  bbbbb1 27-hydroxycholesterol eeeee1 , and the CSF markers for AD pathology Aβ1-42 and  bbbbb2 p-tau181 eeeee2  in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol, lathosterol and  bbbbb1 desmosterol eeeee1 , and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology  bbbbb2 Aβ1-42 eeeee2  and p-tau181 in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol, lathosterol and  bbbbb1 desmosterol eeeee1 , and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology Aβ1-42 and  bbbbb2 p-tau181 eeeee2  in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol, lathosterol and desmosterol, and the cholesterol elimination products  bbbbb1 24S-hydroxycholesterol eeeee1  and 27-hydroxycholesterol, and the CSF markers for AD pathology  bbbbb2 Aβ1-42 eeeee2  and p-tau181 in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol, lathosterol and desmosterol, and the cholesterol elimination products  bbbbb1 24S-hydroxycholesterol eeeee1  and 27-hydroxycholesterol, and the CSF markers for AD pathology Aβ1-42 and  bbbbb2 p-tau181 eeeee2  in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the  bbbbb1 cholesterol eeeee1  precursors lanosterol, lathosterol and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology  bbbbb2 Aβ1-42 eeeee2  and p-tau181 in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the  bbbbb1 cholesterol eeeee1  precursors lanosterol, lathosterol and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology Aβ1-42 and  bbbbb2 p-tau181 eeeee2  in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol, lathosterol and desmosterol, and the  bbbbb1 cholesterol eeeee1  elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology  bbbbb2 Aβ1-42 eeeee2  and p-tau181 in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol, lathosterol and desmosterol, and the  bbbbb1 cholesterol eeeee1  elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology Aβ1-42 and  bbbbb2 p-tau181 eeeee2  in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of  bbbbb1 cholesterol eeeee1 , the cholesterol precursors lanosterol, lathosterol and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology  bbbbb2 Aβ1-42 eeeee2  and p-tau181 in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of  bbbbb1 cholesterol eeeee1 , the cholesterol precursors lanosterol, lathosterol and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology Aβ1-42 and  bbbbb2 p-tau181 eeeee2  in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors  bbbbb1 lanosterol eeeee1 , lathosterol and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology  bbbbb2 Aβ1-42 eeeee2  and p-tau181 in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors  bbbbb1 lanosterol eeeee1 , lathosterol and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology Aβ1-42 and  bbbbb2 p-tau181 eeeee2  in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol,  bbbbb1 lathosterol eeeee1  and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology  bbbbb2 Aβ1-42 eeeee2  and p-tau181 in 86 subjects with normal cognition and in 107 AD patients
CRP11	We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol,  bbbbb1 lathosterol eeeee1  and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology Aβ1-42 and  bbbbb2 p-tau181 eeeee2  in 86 subjects with normal cognition and in 107 AD patients
CRP11	The associations remained significant for CS bbbbb1 F cholester eeeee1 ol and 24S-hydroxycholesterol when analyses were separately performed in the AD group bbbbb2  eeeee2 
CRP11	CSF desmosterol,  bbbbb1 cholesterol eeeee1  and 24S-hydroxycholesterol in the AD group, and CSF 24S-hydroxycholesterol in the control group correlated with the  bbbbb2 p-tau181 eeeee2  levels
CRP11	CSF  bbbbb1 desmosterol eeeee1 , cholesterol and 24S-hydroxycholesterol in the AD group, and CSF 24S-hydroxycholesterol in the control group correlated with the  bbbbb2 p-tau181 eeeee2  levels
CRP11	CSF desmosterol, cholesterol and  bbbbb1 24S-hydroxycholesterol eeeee1  in the AD group, and CSF 24S-hydroxycholesterol in the control group correlated with the  bbbbb2 p-tau181 eeeee2  levels
CRP11	CSF desmosterol, cholesterol and 24S-hydroxycholesterol in the AD group, and CSF  bbbbb1 24S-hydroxycholesterol eeeee1  in the control group correlated with the  bbbbb2 p-tau181 eeeee2  levels
CRP11	Isolated neutrophils and platelets resuspended in heparin-anticoagulated plasma were recirculated with and without blocking antibodies to CD62P, CD42b, or junctional adhesion molecule C (JAM-C) in  bbbbb1 polyvinyl chloride eeeee1  bbbbb2 CD62P eeeee2 , CD42b, or junctional adhesion molecule C (JAM-C) in polyvinyl chloride tubing using a roller pump
CRP11	Isolated neutrophils and platelets resuspended in heparin-anticoagulated plasma were recirculated with and without blocking antibodies to CD62P, CD42b, or junctional adhesion molecule C (JAM-C) in  bbbbb1 polyvinyl chloride eeeee1  bbbbb2 JAM-C eeeee2 ) in polyvinyl chloride tubing using a roller pump
CRP11	Isolated neutrophils and platelets resuspended in heparin-anticoagulated plasma were recirculated with and without blocking antibodies to CD62P, CD42b, or junctional adhesion molecule C (JAM-C) in  bbbbb1 polyvinyl chloride eeeee1  bbbbb2 junctional adhesion molecule C eeeee2  (JAM-C) in polyvinyl chloride tubing using a roller pump
CRP11	Isolated neutrophils and platelets resuspended in heparin-anticoagulated plasma were recirculated with and without blocking antibodies to CD62P, CD42b, or junctional adhesion molecule C (JAM-C) in  bbbbb1 polyvinyl chloride eeeee1  bbbbb2 CD42b eeeee2 , or junctional adhesion molecule C (JAM-C) in polyvinyl chloride tubing using a roller pump
CRP11	An earlier study showed that CRBN negatively regulates the functional activity of  bbbbb1 AMP eeeee1 -activated protein kinase ( bbbbb2 AMPK eeeee2 ) in vitro by binding directly to the α1 subunit of the AMPK complex
CRP11	An earlier study showed that CRBN negatively regulates the functional activity of  bbbbb1 AMP eeeee1  bbbbb2 CRBN eeeee2  negatively regulates the functional activity of AMP-activated protein kinase (AMPK) in vitro by binding directly to the α1 subunit of the AMPK complex
CRP11	An earlier study showed that CRBN negatively regulates the functional activity of  bbbbb1 AMP eeeee1 -activated protein kinase (AMPK) in vitro by binding directly to the  bbbbb2 α1 subunit of the AMPK eeeee2  complex
CRP11	An earlier study showed that CRBN negatively regulates the functional activity of  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) in vitro by binding directly to the α1 subunit of the AMPK complex
CRP11	Mice overexpressing PGC-1α exhibited at adult age impaired  bbbbb1 glucose eeeee1  bbbbb2 PGC-1α eeeee2  exhibited at adult age impaired glucose tolerance associated with reduced insulin secretion, decreased β-cell mass, and β-cell hypotrophy
CRP11	This functional fidelity has important implications in drug design, as the ability to predict ligands with predefined signali bbbbb1 ng prope eeeee1 rties is highl bbbbb2 y de eeeee2 sirable
CRP11	This functional fidelity has important implications in drug design, as the ability to predict ligands with predefined signali bbbbb1 ng prope eeeee1  bbbbb2 ng properties is hig eeeee2 hly desirable
CRP11	This functional fidelity has important implications in drug design, as the ability to predict ligands with predefined signali bbbbb1 ng prope eeeee1  bbbbb2 ined  eeeee2 signaling properties is highly desirable
CRP11	This functional fidelity has important implications in drug design, as the ability to predict ligands with predefined signali bbbbb1 ng prope eeeee1 rties is highly desirable bbbbb2  eeeee2 
CRP11	To characterise further the relationship between Txnip and torpor, we profiled Txnip expression in mice during prolonged fasting, cold exposure, and  bbbbb1 2-deoxyglucose eeeee1  bbbbb2 Txnip eeeee2  expression in mice during prolonged fasting, cold exposure, and 2-deoxyglucose-induced hypometabolism, as well as in naturally occurring torpor bouts in the Siberian hamster
CRP11	To characterise further the relationship between Txnip and torpor, we profiled Txnip expression in mice during prolonged fasting, cold exposure, and  bbbbb1 2-deoxyglucose eeeee1  bbbbb2 Txnip eeeee2  and torpor, we profiled Txnip expression in mice during prolonged fasting, cold exposure, and 2-deoxyglucose-induced hypometabolism, as well as in naturally occurring torpor bouts in the Siberian hamster
CRP11	We find that with use of  bbbbb1 [(35)S]guanosine 5'-(3-O-thio)triphosphate eeeee1 , first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of  bbbbb2 Gα(i) eeeee2  fused to the C terminus of each receptor, Smo is equivalent to the 5-HT(1A) receptor in the assay as it relates to capacity to activate G(i)
CRP11	We find that with use of  bbbbb1 [(35)S]guanosine 5'-(3-O-thio)triphosphate eeeee1 , first, with forms of  bbbbb2 G(i) eeeee2  endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the 5-HT(1A) receptor in the assay as it relates to capacity to activate G(i)
CRP11	We find that with use of  bbbbb1 [(35)S]guanosine 5'-(3-O-thio)triphosphate eeeee1 , first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the 5-HT(1A) receptor in the assay as it relates to capacity to activate  bbbbb2 G(i) eeeee2 
CRP11	We find that with use of  bbbbb1 [(35)S]guanosine 5'-(3-O-thio)triphosphate eeeee1 , first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor,  bbbbb2 Smo eeeee2  is equivalent to the 5-HT(1A) receptor in the assay as it relates to capacity to activate G(i)
CRP11	We find that with use of  bbbbb1 [(35)S]guanosine 5'-(3-O-thio)triphosphate eeeee1 , first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the  bbbbb2 5-HT(1A) eeeee2  receptor in the assay as it relates to capacity to activate G(i)
CRP11	We find that with use of [(35)S]guanosine 5'-(3-O-thio)triphosphate, first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the  bbbbb1 5-HT eeeee1  bbbbb2 Gα(i) eeeee2  fused to the C terminus of each receptor, Smo is equivalent to the 5-HT(1A) receptor in the assay as it relates to capacity to activate G(i)
CRP11	We find that with use of [(35)S]guanosine 5'-(3-O-thio)triphosphate, first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the  bbbbb1 5-HT eeeee1  bbbbb2 G(i) eeeee2  endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the 5-HT(1A) receptor in the assay as it relates to capacity to activate G(i)
CRP11	We find that with use of [(35)S]guanosine 5'-(3-O-thio)triphosphate, first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the  bbbbb1 5-HT eeeee1 (1A) receptor in the assay as it relates to capacity to activate  bbbbb2 G(i) eeeee2 
CRP11	We find that with use of [(35)S]guanosine 5'-(3-O-thio)triphosphate, first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the  bbbbb1 5-HT eeeee1  bbbbb2 Smo eeeee2  is equivalent to the 5-HT(1A) receptor in the assay as it relates to capacity to activate G(i)
CRP11	We find that with use of [(35)S]guanosine 5'-(3-O-thio)triphosphate, first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1A) eeeee2  receptor in the assay as it relates to capacity to activate G(i)
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the  bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 5-hydroxytryptamine(1A) eeeee2  (5-HT(1A)) receptor, a quintessential G(i)-coupled receptor
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the  bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 G(i) eeeee2 , by comparing Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessential G(i)-coupled receptor
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the  bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 Smo eeeee2  with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessential G(i)-coupled receptor
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the  bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 Smo eeeee2  as it relates to the activation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessential G(i)-coupled receptor
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the  bbbbb1 5-hydroxytryptamine eeeee1 (1A) ( bbbbb2 5-HT(1A) eeeee2 ) receptor, a quintessential G(i)-coupled receptor
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the  bbbbb1 5-hydroxytryptamine eeeee1 (1A) (5-HT(1A)) receptor, a quintessential  bbbbb2 G(i)-coupled receptor eeeee2 
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) ( bbbbb1 5-HT eeeee1  bbbbb2 5-hydroxytryptamine(1A) eeeee2  (5-HT(1A)) receptor, a quintessential G(i)-coupled receptor
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) ( bbbbb1 5-HT eeeee1  bbbbb2 G(i) eeeee2 , by comparing Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessential G(i)-coupled receptor
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) ( bbbbb1 5-HT eeeee1  bbbbb2 Smo eeeee2  with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessential G(i)-coupled receptor
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) ( bbbbb1 5-HT eeeee1  bbbbb2 Smo eeeee2  as it relates to the activation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessential G(i)-coupled receptor
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) ( bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1A) eeeee2 ) receptor, a quintessential G(i)-coupled receptor
CRP11	In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) ( bbbbb1 5-HT eeeee1 (1A)) receptor, a quintessential  bbbbb2 G(i)-coupled receptor eeeee2 
CRP11	Mammalian target of  bbbbb1 rapamycin eeeee1  complex 1 ( bbbbb2 mTORC1 eeeee2 ) regulates cell growth and may regulate organismal aging by controlling mRNA translation
CRP11	Mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 Mammalian target of rapamycin complex 1 eeeee2  (mTORC1) regulates cell growth and may regulate organismal aging by controlling mRNA translation
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT),  bbbbb1 triglyceride eeeee1  (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/ bbbbb2 JNK eeeee2  protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT),  bbbbb1 triglyceride eeeee1  bbbbb2 ALT eeeee2 ), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT),  bbbbb1 triglyceride eeeee1  (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of  bbbbb2 caspase-3 eeeee2  and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT),  bbbbb1 triglyceride eeeee1  bbbbb2 alanine aminotransferase eeeee2  (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT),  bbbbb1 triglyceride eeeee1  (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of  bbbbb2 TNF-α eeeee2  and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT),  bbbbb1 triglyceride eeeee1  (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and  bbbbb2 IL-6 eeeee2 ; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT),  bbbbb1 triglyceride eeeee1  (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and  bbbbb2 pJNK eeeee2 /JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and  bbbbb1 reduced glutathione eeeee1  (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/ bbbbb2 JNK eeeee2  protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and  bbbbb1 reduced glutathione eeeee1  bbbbb2 ALT eeeee2 ), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and  bbbbb1 reduced glutathione eeeee1  (GSH); expression levels of TNF-α and IL-6; and levels of  bbbbb2 caspase-3 eeeee2  and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and  bbbbb1 reduced glutathione eeeee1  bbbbb2 alanine aminotransferase eeeee2  (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and  bbbbb1 reduced glutathione eeeee1  (GSH); expression levels of  bbbbb2 TNF-α eeeee2  and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and  bbbbb1 reduced glutathione eeeee1  (GSH); expression levels of TNF-α and  bbbbb2 IL-6 eeeee2 ; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and  bbbbb1 reduced glutathione eeeee1  (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and  bbbbb2 pJNK eeeee2 /JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde ( bbbbb1 MDA eeeee1 ), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/ bbbbb2 JNK eeeee2  protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 ALT eeeee2 ), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde ( bbbbb1 MDA eeeee1 ), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of  bbbbb2 caspase-3 eeeee2  and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 alanine aminotransferase eeeee2  (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde ( bbbbb1 MDA eeeee1 ), and reduced glutathione (GSH); expression levels of  bbbbb2 TNF-α eeeee2  and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde ( bbbbb1 MDA eeeee1 ), and reduced glutathione (GSH); expression levels of TNF-α and  bbbbb2 IL-6 eeeee2 ; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde ( bbbbb1 MDA eeeee1 ), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and  bbbbb2 pJNK eeeee2 /JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG),  bbbbb1 malondialdehyde eeeee1  (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/ bbbbb2 JNK eeeee2  protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG),  bbbbb1 malondialdehyde eeeee1  bbbbb2 ALT eeeee2 ), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG),  bbbbb1 malondialdehyde eeeee1  (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of  bbbbb2 caspase-3 eeeee2  and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG),  bbbbb1 malondialdehyde eeeee1  bbbbb2 alanine aminotransferase eeeee2  (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG),  bbbbb1 malondialdehyde eeeee1  (MDA), and reduced glutathione (GSH); expression levels of  bbbbb2 TNF-α eeeee2  and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG),  bbbbb1 malondialdehyde eeeee1  (MDA), and reduced glutathione (GSH); expression levels of TNF-α and  bbbbb2 IL-6 eeeee2 ; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG),  bbbbb1 malondialdehyde eeeee1  (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and  bbbbb2 pJNK eeeee2 /JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of  bbbbb1 alanine eeeee1  aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/ bbbbb2 JNK eeeee2  protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of  bbbbb1 alanine eeeee1  aminotransferase ( bbbbb2 ALT eeeee2 ), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of  bbbbb1 alanine eeeee1  aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of  bbbbb2 caspase-3 eeeee2  and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of  bbbbb1 alanine eeeee1  bbbbb2 alanine aminotransferase eeeee2  (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of  bbbbb1 alanine eeeee1  aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of  bbbbb2 TNF-α eeeee2  and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of  bbbbb1 alanine eeeee1  aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and  bbbbb2 IL-6 eeeee2 ; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of  bbbbb1 alanine eeeee1  aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and  bbbbb2 pJNK eeeee2 /JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione ( bbbbb1 GSH eeeee1 ); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/ bbbbb2 JNK eeeee2  protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione ( bbbbb1 GSH eeeee1  bbbbb2 ALT eeeee2 ), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione ( bbbbb1 GSH eeeee1 ); expression levels of TNF-α and IL-6; and levels of  bbbbb2 caspase-3 eeeee2  and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione ( bbbbb1 GSH eeeee1  bbbbb2 alanine aminotransferase eeeee2  (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione (GSH); expression levels of TNF-α and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione ( bbbbb1 GSH eeeee1 ); expression levels of  bbbbb2 TNF-α eeeee2  and IL-6; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione ( bbbbb1 GSH eeeee1 ); expression levels of TNF-α and  bbbbb2 IL-6 eeeee2 ; and levels of caspase-3 and pJNK/JNK protein
CRP11	Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of alanine aminotransferase (ALT), triglyceride (TG), malondialdehyde (MDA), and reduced glutathione ( bbbbb1 GSH eeeee1 ); expression levels of TNF-α and IL-6; and levels of caspase-3 and  bbbbb2 pJNK eeeee2 /JNK protein
CRP11	Moreover, EDL led to a significant decrease in the serum levels of ALT, hepatic TG, and  bbbbb1 MDA eeeee1 , and in the expression levels of TNF-α, and  bbbbb2 IL-6 eeeee2 ; on the contrary, the levels of reduced GSH increased
CRP11	Moreover, EDL led to a significant decrease in the serum levels of ALT, hepatic TG, and  bbbbb1 MDA eeeee1 , and in the expression levels of  bbbbb2 TNF-α eeeee2 , and IL-6; on the contrary, the levels of reduced GSH increased
CRP11	Moreover, EDL led to a significant decrease in the serum levels of ALT, hepatic TG, and  bbbbb1 MDA eeeee1  bbbbb2 ALT eeeee2 , hepatic TG, and MDA, and in the expression levels of TNF-α, and IL-6; on the contrary, the levels of reduced GSH increased
CRP11	Moreover, EDL led to a significant decrease in the serum levels of ALT, hepatic TG, and MDA, and in the expression levels of TNF-α, and IL-6; on the contrary, the levels of  bbbbb1 reduced GSH eeeee1  bbbbb2 IL-6 eeeee2 ; on the contrary, the levels of reduced GSH increased
CRP11	Moreover, EDL led to a significant decrease in the serum levels of ALT, hepatic TG, and MDA, and in the expression levels of TNF-α, and IL-6; on the contrary, the levels of  bbbbb1 reduced GSH eeeee1  bbbbb2 TNF-α eeeee2 , and IL-6; on the contrary, the levels of reduced GSH increased
CRP11	Moreover, EDL led to a significant decrease in the serum levels of ALT, hepatic TG, and MDA, and in the expression levels of TNF-α, and IL-6; on the contrary, the levels of  bbbbb1 reduced GSH eeeee1  bbbbb2 ALT eeeee2 , hepatic TG, and MDA, and in the expression levels of TNF-α, and IL-6; on the contrary, the levels of reduced GSH increased
CRP11	Furthermore, acute  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  decreased motor stereotypy in C58/J and did not induce hypoactivity or anxiolytic-like effects in an open field test
CRP11	Acute oxytocin did not increase sociability in BALB/cByJ; however, sub-chronic  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  did not increase sociability in BALB/cByJ; however, sub-chronic oxytocin had significant prosocial effects in both BALB/cByJ and C58/J
CRP11	Acute oxytocin did not increase sociability in BALB/cByJ; however, sub-chronic  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  had significant prosocial effects in both BALB/cByJ and C58/J
CRP11	Acute  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  did not increase sociability in BALB/cByJ; however, sub-chronic oxytocin had significant prosocial effects in both BALB/cByJ and C58/J
CRP11	Acute  bbbbb1 oxytocin eeeee1  did not increase sociability in BALB/cByJ; however, sub-chronic  bbbbb2 oxytocin eeeee2  had significant prosocial effects in both BALB/cByJ and C58/J
CRP11	This study demonstrates that oxytocin administration can attenuate social deficits and repetitive behavior in mouse models of ASD, dependent on dose regimen and genotype bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Prosocial effects of  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  in two mouse models of autism spectrum disorders
CRP11	Mice from both strains were intraperitoneally administered  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2 , using either acute or sub-chronic regimens
CRP11	Clinical evidence suggests that  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  treatment improves social deficits and repetitive behavior in autism spectrum disorders (ASDs)
CRP11	Increased sociability was observed 24 hours following the final oxytocin dose in BALB/cByJ, while prosocial effects of  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  dose in BALB/cByJ, while prosocial effects of oxytocin emerged 1-2 weeks post-treatment in C58/J
CRP11	Increased sociability was observed 24 hours following the final  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  dose in BALB/cByJ, while prosocial effects of oxytocin emerged 1-2 weeks post-treatment in C58/J
CRP11	Increasing the cellular concentration of DNA topoisomerase II in yeast by expressing constitutively a plasmid-borne TOP2 gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and  bbbbb1 etoposide eeeee1  bbbbb2 DNA topoisomerase II eeeee2  in yeast by expressing constitutively a plasmid-borne TOP2 gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and etoposide (VP-16)
CRP11	Increasing the cellular concentration of DNA topoisomerase II in yeast by expressing constitutively a plasmid-borne TOP2 gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and  bbbbb1 etoposide eeeee1  bbbbb2 TOP2 eeeee2  gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and etoposide (VP-16)
CRP11	Increasing the cellular concentration of DNA topoisomerase II in yeast by expressing constitutively a plasmid-borne TOP2 gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and etoposide ( bbbbb1 VP-16 eeeee1  bbbbb2 DNA topoisomerase II eeeee2  in yeast by expressing constitutively a plasmid-borne TOP2 gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and etoposide (VP-16)
CRP11	Increasing the cellular concentration of DNA topoisomerase II in yeast by expressing constitutively a plasmid-borne TOP2 gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and etoposide ( bbbbb1 VP-16 eeeee1  bbbbb2 TOP2 eeeee2  gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and etoposide (VP-16)
CRP11	Increasing the cellular concentration of DNA topoisomerase II in yeast by expressing constitutively a plasmid-borne TOP2 gene encoding the enzyme greatly increases the sensitivity of the cells to  bbbbb1 amsacrine eeeee1  bbbbb2 DNA topoisomerase II eeeee2  in yeast by expressing constitutively a plasmid-borne TOP2 gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and etoposide (VP-16)
CRP11	Increasing the cellular concentration of DNA topoisomerase II in yeast by expressing constitutively a plasmid-borne TOP2 gene encoding the enzyme greatly increases the sensitivity of the cells to  bbbbb1 amsacrine eeeee1  bbbbb2 TOP2 eeeee2  gene encoding the enzyme greatly increases the sensitivity of the cells to amsacrine and etoposide (VP-16)
CRP11	Amsacrine and  bbbbb1 etoposide eeeee1  hypersensitivity of yeast cells overexpressing  bbbbb2 DNA topoisomerase II eeeee2 
CRP11	 bbbbb1 Amsacrine eeeee1  and etoposide hypersensitivity of yeast cells overexpressing  bbbbb2 DNA topoisomerase II eeeee2 
CRP11	By examining the relative effects of corticosterone ( bbbbb1 CORT eeeee1 ),  bbbbb2 arginine vasotocin eeeee2  (AVT, the avian homologue to arginine vasopressin) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone ( bbbbb1 CORT eeeee1 ), arginine vasotocin (AVT, the avian homologue to  bbbbb2 arginine vasopressin eeeee2 ) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone ( bbbbb1 CORT eeeee1 ), arginine vasotocin ( bbbbb2 AVT eeeee2 , the avian homologue to arginine vasopressin) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone ( bbbbb1 CORT eeeee1 ), arginine vasotocin (AVT, the avian homologue to arginine vasopressin) and  bbbbb2 corticotrophin-releasing factor eeeee2  (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone ( bbbbb1 CORT eeeee1 ), arginine vasotocin (AVT, the avian homologue to arginine vasopressin) and corticotrophin-releasing factor ( bbbbb2 CRF eeeee2 ), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT), arginine vasotocin (AVT, the avian homologue to  bbbbb1 arginine vasopressin eeeee1  bbbbb2 arginine vasotocin eeeee2  (AVT, the avian homologue to arginine vasopressin) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT), arginine vasotocin (AVT, the avian homologue to  bbbbb1 arginine vasopressin eeeee1  bbbbb2 arginine vasopressin eeeee2 ) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT), arginine vasotocin (AVT, the avian homologue to  bbbbb1 arginine vasopressin eeeee1  bbbbb2 AVT eeeee2 , the avian homologue to arginine vasopressin) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT), arginine vasotocin (AVT, the avian homologue to  bbbbb1 arginine vasopressin eeeee1 ) and  bbbbb2 corticotrophin-releasing factor eeeee2  (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT), arginine vasotocin (AVT, the avian homologue to  bbbbb1 arginine vasopressin eeeee1 ) and corticotrophin-releasing factor ( bbbbb2 CRF eeeee2 ), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT), arginine vasotocin ( bbbbb1 AVT eeeee1  bbbbb2 arginine vasotocin eeeee2  (AVT, the avian homologue to arginine vasopressin) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT), arginine vasotocin ( bbbbb1 AVT eeeee1 , the avian homologue to  bbbbb2 arginine vasopressin eeeee2 ) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT), arginine vasotocin ( bbbbb1 AVT eeeee1  bbbbb2 AVT eeeee2 , the avian homologue to arginine vasopressin) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT), arginine vasotocin ( bbbbb1 AVT eeeee1 , the avian homologue to arginine vasopressin) and  bbbbb2 corticotrophin-releasing factor eeeee2  (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT), arginine vasotocin ( bbbbb1 AVT eeeee1 , the avian homologue to arginine vasopressin) and corticotrophin-releasing factor ( bbbbb2 CRF eeeee2 ), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT),  bbbbb1 arginine vasotocin eeeee1  bbbbb2 arginine vasotocin eeeee2  (AVT, the avian homologue to arginine vasopressin) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT),  bbbbb1 arginine vasotocin eeeee1  (AVT, the avian homologue to  bbbbb2 arginine vasopressin eeeee2 ) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT),  bbbbb1 arginine vasotocin eeeee1  ( bbbbb2 AVT eeeee2 , the avian homologue to arginine vasopressin) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT),  bbbbb1 arginine vasotocin eeeee1  (AVT, the avian homologue to arginine vasopressin) and  bbbbb2 corticotrophin-releasing factor eeeee2  (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of corticosterone (CORT),  bbbbb1 arginine vasotocin eeeee1  (AVT, the avian homologue to arginine vasopressin) and corticotrophin-releasing factor ( bbbbb2 CRF eeeee2 ), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of  bbbbb1 corticosterone eeeee1  (CORT),  bbbbb2 arginine vasotocin eeeee2  (AVT, the avian homologue to arginine vasopressin) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of  bbbbb1 corticosterone eeeee1  (CORT), arginine vasotocin (AVT, the avian homologue to  bbbbb2 arginine vasopressin eeeee2 ) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of  bbbbb1 corticosterone eeeee1  (CORT), arginine vasotocin ( bbbbb2 AVT eeeee2 , the avian homologue to arginine vasopressin) and corticotrophin-releasing factor (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of  bbbbb1 corticosterone eeeee1  (CORT), arginine vasotocin (AVT, the avian homologue to arginine vasopressin) and  bbbbb2 corticotrophin-releasing factor eeeee2  (CRF), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	By examining the relative effects of  bbbbb1 corticosterone eeeee1  (CORT), arginine vasotocin (AVT, the avian homologue to arginine vasopressin) and corticotrophin-releasing factor ( bbbbb2 CRF eeeee2 ), the present study aimed to define the hormone profile regulating stress-induced increases in AA in the POM
CRP11	Similarly, in the female brain, the experimental effects were restricted to the POM but only CRF was capable of inducing the stress-like increases in AA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	We found that CORT,  bbbbb1 AVT eeeee1  bbbbb2 AVT eeeee2  and CRF all appear to play some role in these changes in the male brain
CRP11	We found that CORT,  bbbbb1 AVT eeeee1  and  bbbbb2 CRF eeeee2  all appear to play some role in these changes in the male brain
CRP11	We found that  bbbbb1 CORT eeeee1 ,  bbbbb2 AVT eeeee2  and CRF all appear to play some role in these changes in the male brain
CRP11	We found that  bbbbb1 CORT eeeee1 , AVT and  bbbbb2 CRF eeeee2  all appear to play some role in these changes in the male brain
CRP11	Plasma  bbbbb1 cholesterol eeeee1 , triglycerides and  bbbbb2 insulin eeeee2  were also significantly reduced (P<0.05)
CRP11	Plasma cholesterol,  bbbbb1 triglycerides eeeee1  and  bbbbb2 insulin eeeee2  were also significantly reduced (P<0.05)
CRP11	Somatic  bbbbb1 angiotensin I eeeee1 -converting enzyme (s- bbbbb2 ACE eeeee2 ) plays a central role in blood pressure regulation and has been the target of most antihypertensive drugs
CRP11	Somatic  bbbbb1 angiotensin I eeeee1  bbbbb2 angiotensin I-converting enzyme eeeee2  (s-ACE) plays a central role in blood pressure regulation and has been the target of most antihypertensive drugs
CRP11	Thermodynamic determination of the binding constants of  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  inhibitors by a displacement method
CRP11	Radix Glycyrrhizae inhibited HRSV mainly by preventing viral attachment, internalization, and by stimulating IFN secretion bbbbb1  eeeee1  bbbbb2 IFN eeeee2  secretion
CRP11	 bbbbb1 Gamma-glutamyl eeeee1  bbbbb2 Gamma-glutamyl transpeptidase eeeee2  deficiency has been found in patients with CNS involvement and glutathionuria. 5-Oxoprolinase deficiency is associated with 5-oxoprolinuria but without a clear association with other symptoms
CRP11	 bbbbb1 Gamma-glutamyl eeeee1  transpeptidase deficiency has been found in patients with CNS involvement and glutathionuria.  bbbbb2 5-Oxoprolinase eeeee2  deficiency is associated with 5-oxoprolinuria but without a clear association with other symptoms
CRP11	The aims of the treatment of glutathio bbbbb1 ne synthesis d eeeee1 efects are to avo bbbbb2 id hemolytic c eeeee2 rises and to increase the defense against reactive oxygen species
CRP11	The aims of the treatment of glutathio bbbbb1 ne synthesis d eeeee1  bbbbb2 ne synthesis defects are to a eeeee2 void hemolytic crises and to increase the defense against reactive oxygen species
CRP11	The aims of the treatment of glutathio bbbbb1 ne synthesis d eeeee1 efects are to avoid hemolytic crises bbbbb2  and to inc eeeee2 rease the defense against reactive oxygen species
CRP11	 bbbbb1 Gamma-glutamylcysteine eeeee1  bbbbb2 Gamma-glutamylcysteine synthetase eeeee2  deficiency is also associated with hemolytic anemia, and some patients with this disorder show defects of neuromuscular function and generalized aminoaciduria
CRP11	Diagnosis is made by measuring the concentration of different metabolites in the gamma-glutamyl cycle, enzyme activity and in glutathione synthetase and  bbbbb1 gamma-glutamylcysteine eeeee1  bbbbb2 gamma-glutamylcysteine synthetase eeeee2  deficiency, also by mutation analysis
CRP11	Diagnosis is made by measuring the concentration of different metabolites in the gamma-glutamyl cycle, enzyme activity and in glutathione synthetase and  bbbbb1 gamma-glutamylcysteine eeeee1  bbbbb2 glutathione synthetase eeeee2  and gamma-glutamylcysteine synthetase deficiency, also by mutation analysis
CRP11	Diagnosis is made by measuring the concentration of different metabolites in the  bbbbb1 gamma-glutamyl eeeee1  cycle, enzyme activity and in glutathione synthetase and  bbbbb2 gamma-glutamylcysteine synthetase eeeee2  deficiency, also by mutation analysis
CRP11	Diagnosis is made by measuring the concentration of different metabolites in the  bbbbb1 gamma-glutamyl eeeee1  cycle, enzyme activity and in  bbbbb2 glutathione synthetase eeeee2  and gamma-glutamylcysteine synthetase deficiency, also by mutation analysis
CRP11	Diagnosis is made by measuring the concentration of different metabolites in the gamma-glutamyl cycle, enzyme activity and in  bbbbb1 glutathione eeeee1  synthetase and  bbbbb2 gamma-glutamylcysteine synthetase eeeee2  deficiency, also by mutation analysis
CRP11	Diagnosis is made by measuring the concentration of different metabolites in the gamma-glutamyl cycle, enzyme activity and in  bbbbb1 glutathione eeeee1  bbbbb2 glutathione synthetase eeeee2  and gamma-glutamylcysteine synthetase deficiency, also by mutation analysis
CRP11	 bbbbb1 Glutathione eeeee1  bbbbb2 Glutathione synthetase eeeee2  deficiency is the most frequently recognized disorder and, in its severe form, it is associated with hemolytic anemia, metabolic acidosis, 5-oxoprolinuria, central nervous system (CNS) damage and recurrent bacterial infections
CRP11	Six children with  bbbbb1 pyridox(am)ine-5'-phosphate eeeee1  oxidase ( bbbbb2 PNPO eeeee2 ) deficiency presented with neonatal epileptic encephalopathy
CRP11	Six children with  bbbbb1 pyridox(am)ine-5'-phosphate eeeee1  bbbbb2 pyridox(am)ine-5'-phosphate oxidase eeeee2  (PNPO) deficiency presented with neonatal epileptic encephalopathy
CRP11	All of the children sh bbbbb1 owe eeeee1 d atypical biochemical findings bbbbb2  eeeee2 
CRP11	Cobalamin nonresponsive methylmalonic acidemia (MMA, mut complementation class) results from mutations in the nuclear gene MUT, which codes for the mitochondrial enzyme  bbbbb1 methylmalonyl CoA eeeee1  bbbbb2 MUT eeeee2 , which codes for the mitochondrial enzyme methylmalonyl CoA mutase (MCM)
CRP11	Cobalamin nonresponsive methylmalonic acidemia (MMA, mut complementation class) results from mutations in the nuclear gene MUT, which codes for the mitochondrial enzyme  bbbbb1 methylmalonyl CoA eeeee1  mutase ( bbbbb2 MCM eeeee2 )
CRP11	Cobalamin nonresponsive methylmalonic acidemia (MMA, mut complementation class) results from mutations in the nuclear gene MUT, which codes for the mitochondrial enzyme  bbbbb1 methylmalonyl CoA eeeee1  bbbbb2 methylmalonyl CoA mutase eeeee2  (MCM)
CRP11	 bbbbb1 Cobalamin eeeee1  nonresponsive methylmalonic acidemia (MMA, mut complementation class) results from mutations in the nuclear gene  bbbbb2 MUT eeeee2 , which codes for the mitochondrial enzyme methylmalonyl CoA mutase (MCM)
CRP11	 bbbbb1 Cobalamin eeeee1  nonresponsive methylmalonic acidemia (MMA, mut complementation class) results from mutations in the nuclear gene MUT, which codes for the mitochondrial enzyme methylmalonyl CoA mutase ( bbbbb2 MCM eeeee2 )
CRP11	 bbbbb1 Cobalamin eeeee1  nonresponsive methylmalonic acidemia (MMA, mut complementation class) results from mutations in the nuclear gene MUT, which codes for the mitochondrial enzyme  bbbbb2 methylmalonyl CoA mutase eeeee2  (MCM)
CRP11	Cells in which  bbbbb1 astrin eeeee1  was depleted had decreased murine double minute 2 (MDM2) abundance and increased  bbbbb2 p53 eeeee2  at the later stages of the DNA damage response
CRP11	Cells in which  bbbbb1 astrin eeeee1  bbbbb2 astrin eeeee2  was depleted had decreased murine double minute 2 (MDM2) abundance and increased p53 at the later stages of the DNA damage response
CRP11	Cells in which  bbbbb1 astrin eeeee1  was depleted had decreased murine double minute 2 ( bbbbb2 MDM2 eeeee2 ) abundance and increased p53 at the later stages of the DNA damage response
CRP11	Cells in which  bbbbb1 astrin eeeee1  was depleted had decreased  bbbbb2 murine double minute 2 eeeee2  (MDM2) abundance and increased p53 at the later stages of the DNA damage response
CRP11	 bbbbb1 Astrin eeeee1  bbbbb2 Astrin eeeee2 , a protein associated with the mitotic spindle, was among the potential regulators of recovery
CRP11	The  bbbbb1 K+ eeeee1  channel gene  bbbbb2 KvLQT1 eeeee2  is mutated in the heritable long QT (LQT) syndrome
CRP11	The  bbbbb1 K+ eeeee1  bbbbb2 K+ channel eeeee2  gene KvLQT1 is mutated in the heritable long QT (LQT) syndrome
CRP11	Functional consequences of the arrhythmogenic G306R KvLQT1  bbbbb1 K+ eeeee1  bbbbb2 G306R eeeee2  KvLQT1 K+ channel mutant probed by viral gene transfer in cardiomyocytes
CRP11	Functional consequences of the arrhythmogenic G306R KvLQT1  bbbbb1 K+ eeeee1  bbbbb2 KvLQT1 eeeee2  K+ channel mutant probed by viral gene transfer in cardiomyocytes
CRP11	Functional consequences of the arrhythmogenic G306R KvLQT1  bbbbb1 K+ eeeee1  bbbbb2 K+ channel eeeee2  mutant probed by viral gene transfer in cardiomyocytes
CRP11	Hepatic activities of 7-ethoxyresorufin- bbbbb1 O eeeee1 -deethylase,  bbbbb2 7-pentoxyresorufin-O-depentylase eeeee2 , and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin- bbbbb1 O eeeee1  bbbbb2 7-ethoxyresorufin-O-deethylase eeeee2 , 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin- bbbbb1 O eeeee1 -deethylase, 7-pentoxyresorufin-O-depentylase, and  bbbbb2 chlorzoxazone 6-hydroxylase eeeee2 , but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin- bbbbb1 O eeeee1 -deethylase, 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not  bbbbb2 midazolam hydroxylase eeeee2  were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin-O-depentylase, and  bbbbb1 chlorzoxazone eeeee1  bbbbb2 7-pentoxyresorufin-O-depentylase eeeee2 , and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin-O-depentylase, and  bbbbb1 chlorzoxazone eeeee1  bbbbb2 7-ethoxyresorufin-O-deethylase eeeee2 , 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin-O-depentylase, and  bbbbb1 chlorzoxazone eeeee1  bbbbb2 chlorzoxazone 6-hydroxylase eeeee2 , but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin-O-depentylase, and  bbbbb1 chlorzoxazone eeeee1  6-hydroxylase, but not  bbbbb2 midazolam hydroxylase eeeee2  were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin- bbbbb1 O eeeee1  bbbbb2 7-pentoxyresorufin-O-depentylase eeeee2 , and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin- bbbbb1 O eeeee1  bbbbb2 7-ethoxyresorufin-O-deethylase eeeee2 , 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin- bbbbb1 O eeeee1 -depentylase, and  bbbbb2 chlorzoxazone 6-hydroxylase eeeee2 , but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin- bbbbb1 O eeeee1 -depentylase, and chlorzoxazone 6-hydroxylase, but not  bbbbb2 midazolam hydroxylase eeeee2  were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase,  bbbbb1 7-pentoxyresorufin eeeee1  bbbbb2 7-pentoxyresorufin-O-depentylase eeeee2 , and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase,  bbbbb1 7-pentoxyresorufin eeeee1  bbbbb2 7-ethoxyresorufin-O-deethylase eeeee2 , 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase,  bbbbb1 7-pentoxyresorufin eeeee1 -O-depentylase, and  bbbbb2 chlorzoxazone 6-hydroxylase eeeee2 , but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase,  bbbbb1 7-pentoxyresorufin eeeee1 -O-depentylase, and chlorzoxazone 6-hydroxylase, but not  bbbbb2 midazolam hydroxylase eeeee2  were also elevated
CRP11	Hepatic activities of  bbbbb1 7-ethoxyresorufin eeeee1 -O-deethylase,  bbbbb2 7-pentoxyresorufin-O-depentylase eeeee2 , and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of  bbbbb1 7-ethoxyresorufin eeeee1  bbbbb2 7-ethoxyresorufin-O-deethylase eeeee2 , 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of  bbbbb1 7-ethoxyresorufin eeeee1 -O-deethylase, 7-pentoxyresorufin-O-depentylase, and  bbbbb2 chlorzoxazone 6-hydroxylase eeeee2 , but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of  bbbbb1 7-ethoxyresorufin eeeee1 -O-deethylase, 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not  bbbbb2 midazolam hydroxylase eeeee2  were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not  bbbbb1 midazolam eeeee1  bbbbb2 7-pentoxyresorufin-O-depentylase eeeee2 , and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not  bbbbb1 midazolam eeeee1  bbbbb2 7-ethoxyresorufin-O-deethylase eeeee2 , 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not  bbbbb1 midazolam eeeee1  bbbbb2 chlorzoxazone 6-hydroxylase eeeee2 , but not midazolam hydroxylase were also elevated
CRP11	Hepatic activities of 7-ethoxyresorufin-O-deethylase, 7-pentoxyresorufin-O-depentylase, and chlorzoxazone 6-hydroxylase, but not  bbbbb1 midazolam eeeee1  bbbbb2 midazolam hydroxylase eeeee2  were also elevated
CRP11	These results suggest that DAT-KO mice exhibit impu bbbbb1 lsive CAR beha eeeee1 vior that corr bbbbb2 ela eeeee2 tes with their PPI deficits
CRP11	These results suggest that DAT-KO mice exhibit impu bbbbb1 lsive CAR beha eeeee1  bbbbb2 lsive CAR behavior that co eeeee2 rrelates with their PPI deficits
CRP11	These results suggest that DAT-KO mice exhibit impu bbbbb1 lsive CAR beha eeeee1  bbbbb2 s suggest that DAT-KO  eeeee2 mice exhibit impulsive CAR behavior that correlates with their PPI deficits
CRP11	These result bbbbb1 s suggest eeeee1  that DAT-KO mice exhibit impulsive CAR behavior that corr bbbbb2 ela eeeee2 tes with their PPI deficits
CRP11	These result bbbbb1 s suggest eeeee1  that DAT-KO mice exhibit impu bbbbb2 lsive CAR behavior that co eeeee2 rrelates with their PPI deficits
CRP11	These result bbbbb1 s suggest eeeee1  bbbbb2 s suggest that DAT-KO  eeeee2 mice exhibit impulsive CAR behavior that correlates with their PPI deficits
CRP11	Here we report that KLF3 null mice are lean and protected from diet-induced obesity and  bbbbb1 glucose eeeee1  bbbbb2 KLF3 eeeee2  null mice are lean and protected from diet-induced obesity and glucose intolerance
CRP11	Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane  bbbbb1 tyrosine eeeee1 -kinase receptors, including insulin receptor ( bbbbb2 IR eeeee2 ) and insulin-like growth factor-1 receptor (IGF1-R)
CRP11	Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane  bbbbb1 tyrosine eeeee1  bbbbb2 Grb10 eeeee2 )is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane tyrosine-kinase receptors, including insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1-R)
CRP11	Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane  bbbbb1 tyrosine eeeee1  bbbbb2 Growth factor receptor-bound protein 10 eeeee2 (Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane tyrosine-kinase receptors, including insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1-R)
CRP11	Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane  bbbbb1 tyrosine eeeee1 -kinase receptors, including  bbbbb2 insulin receptor eeeee2  (IR) and insulin-like growth factor-1 receptor (IGF1-R)
CRP11	Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane  bbbbb1 tyrosine eeeee1 -kinase receptors, including insulin receptor (IR) and insulin-like growth factor-1 receptor ( bbbbb2 IGF1-R eeeee2 )
CRP11	Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine-kinase receptors eeeee2 , including insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1-R)
CRP11	Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane  bbbbb1 tyrosine eeeee1 -kinase receptors, including insulin receptor (IR) and  bbbbb2 insulin-like growth factor-1 receptor eeeee2  (IGF1-R)
CRP11	Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2) domain-containing protein and one of the binding partners for several trans-membrane  bbbbb1 tyrosine eeeee1  bbbbb2 Src homology 2 (SH2) domain eeeee2 -containing protein and one of the binding partners for several trans-membrane tyrosine-kinase receptors, including insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1-R)
CRP11	Recent studies have demonstrated the association between human leukocyte antigen (HLA) B*58:01 allele and  bbbbb1 allopurinol eeeee1  bbbbb2 human leukocyte antigen (HLA) B eeeee2 *58:01 allele and allopurinol-induced SCARs, which might explain ethnic differences in their incidences
CRP11	Furthermore, using an unbiased place conditioning procedure (CPP), intra-PLC D(1) receptor activation blocks the spontaneous expression of an associative morphine (5 mg/kg; i.p.) reward memory, while leaving  bbbbb1 morphine eeeee1  bbbbb2 D(1) receptor eeeee2  activation blocks the spontaneous expression of an associative morphine (5 mg/kg; i.p.) reward memory, while leaving morphine-primed memory expression intact
CRP11	Furthermore, using an unbiased place conditioning procedure (CPP), intra-PLC D(1) receptor activation blocks the spontaneous expression of an associative  bbbbb1 morphine eeeee1  bbbbb2 D(1) receptor eeeee2  activation blocks the spontaneous expression of an associative morphine (5 mg/kg; i.p.) reward memory, while leaving morphine-primed memory expression intact
CRP11	 bbbbb1 Dopamine eeeee1  bbbbb2 Dopamine (DA) receptor eeeee2  transmission through either D(1) or D(2)-like subtypes is involved critically in the processing of emotional information within the medial prefrontal cortex (mPFC)
CRP11	 bbbbb1 Dopamine eeeee1  (DA) receptor transmission through either D(1) or  bbbbb2 D(2) eeeee2 -like subtypes is involved critically in the processing of emotional information within the medial prefrontal cortex (mPFC)
CRP11	 bbbbb1 Dopamine eeeee1  (DA) receptor transmission through either  bbbbb2 D(1) eeeee2  or D(2)-like subtypes is involved critically in the processing of emotional information within the medial prefrontal cortex (mPFC)
CRP11	Supra-normal stimulation of  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D1 receptors eeeee2  in the prelimbic cortex blocks behavioral expression of both aversive and rewarding associative memories through a cyclic-AMP-dependent signaling pathway
CRP11	Supra-normal stimulation of dopamine D1 receptors in the prelimbic cortex blocks behavioral expression of both aversive and rewarding associative memories through a  bbbbb1 cyclic-AMP eeeee1  bbbbb2 dopamine D1 receptors eeeee2  in the prelimbic cortex blocks behavioral expression of both aversive and rewarding associative memories through a cyclic-AMP-dependent signaling pathway
CRP11	Interestingly, both intra-PLC D(1)-receptor mediated block of either fear-related or reward-related associative memories were dependent upon downstream cyclic-AMP (cAMP) signaling as both effects were rescued by co-administration of a  bbbbb1 cAMP eeeee1  bbbbb2 D(1)-receptor eeeee2  mediated block of either fear-related or reward-related associative memories were dependent upon downstream cyclic-AMP (cAMP) signaling as both effects were rescued by co-administration of a cAMP signaling inhibitor
CRP11	Interestingly, both intra-PLC D(1)-receptor mediated block of either fear-related or reward-related associative memories were dependent upon downstream cyclic-AMP ( bbbbb1 cAMP eeeee1  bbbbb2 D(1)-receptor eeeee2  mediated block of either fear-related or reward-related associative memories were dependent upon downstream cyclic-AMP (cAMP) signaling as both effects were rescued by co-administration of a cAMP signaling inhibitor
CRP11	Interestingly, both intra-PLC D(1)-receptor mediated block of either fear-related or reward-related associative memories were dependent upon downstream  bbbbb1 cyclic-AMP eeeee1  bbbbb2 D(1)-receptor eeeee2  mediated block of either fear-related or reward-related associative memories were dependent upon downstream cyclic-AMP (cAMP) signaling as both effects were rescued by co-administration of a cAMP signaling inhibitor
CRP11	The four stereoisomers of  bbbbb1 mesoridazine eeeee1  were synthesized and evaluated in D2, 5-HT1A, 5-HT2A, 5-HT2C, D1, and  bbbbb2 D3 receptor eeeee2  binding and functional assays
CRP11	The four stereoisomers of  bbbbb1 mesoridazine eeeee1  were synthesized and evaluated in D2, 5-HT1A, 5-HT2A, 5-HT2C,  bbbbb2 D1 eeeee2 , and D3 receptor binding and functional assays
CRP11	The four stereoisomers of  bbbbb1 mesoridazine eeeee1  were synthesized and evaluated in D2,  bbbbb2 5-HT1A eeeee2 , 5-HT2A, 5-HT2C, D1, and D3 receptor binding and functional assays
CRP11	The four stereoisomers of  bbbbb1 mesoridazine eeeee1  were synthesized and evaluated in D2, 5-HT1A,  bbbbb2 5-HT2A eeeee2 , 5-HT2C, D1, and D3 receptor binding and functional assays
CRP11	The four stereoisomers of  bbbbb1 mesoridazine eeeee1  were synthesized and evaluated in  bbbbb2 D2 eeeee2 , 5-HT1A, 5-HT2A, 5-HT2C, D1, and D3 receptor binding and functional assays
CRP11	The four stereoisomers of  bbbbb1 mesoridazine eeeee1  were synthesized and evaluated in D2, 5-HT1A, 5-HT2A,  bbbbb2 5-HT2C eeeee2 , D1, and D3 receptor binding and functional assays
CRP11	 bbbbb1 Bisulfite eeeee1  sequencing also demonstrated the presence of T-DMRs around the TSS in other Oatp1 genes: CpG dinucleotides at +149 relative to the  bbbbb2 TSS eeeee2  for Oatp1c1; -48, +101, and +356 for Oatp1a4; -572 and -550 for Oatp1a1; and -122 and +216 for Oatp1a6 were differentially methylated among the liver, kidney, and cerebrum
CRP11	 bbbbb1 Bisulfite eeeee1  sequencing also demonstrated the presence of T-DMRs around the TSS in other Oatp1 genes: CpG dinucleotides at +149 relative to the TSS for Oatp1c1; -48, +101, and +356 for Oatp1a4; -572 and -550 for Oatp1a1; and -122 and +216 for  bbbbb2 Oatp1a6 eeeee2  were differentially methylated among the liver, kidney, and cerebrum
CRP11	 bbbbb1 Bisulfite eeeee1  sequencing also demonstrated the presence of T-DMRs around the TSS in other  bbbbb2 Oatp1 eeeee2  genes: CpG dinucleotides at +149 relative to the TSS for Oatp1c1; -48, +101, and +356 for Oatp1a4; -572 and -550 for Oatp1a1; and -122 and +216 for Oatp1a6 were differentially methylated among the liver, kidney, and cerebrum
CRP11	 bbbbb1 Bisulfite eeeee1  sequencing also demonstrated the presence of T-DMRs around the  bbbbb2 TSS eeeee2  in other Oatp1 genes: CpG dinucleotides at +149 relative to the TSS for Oatp1c1; -48, +101, and +356 for Oatp1a4; -572 and -550 for Oatp1a1; and -122 and +216 for Oatp1a6 were differentially methylated among the liver, kidney, and cerebrum
CRP11	 bbbbb1 Bisulfite eeeee1  sequencing also demonstrated the presence of T-DMRs around the TSS in other Oatp1 genes: CpG dinucleotides at +149 relative to the TSS for Oatp1c1; -48, +101, and +356 for Oatp1a4; -572 and -550 for  bbbbb2 Oatp1a1 eeeee2 ; and -122 and +216 for Oatp1a6 were differentially methylated among the liver, kidney, and cerebrum
CRP11	 bbbbb1 Bisulfite eeeee1  sequencing also demonstrated the presence of T-DMRs around the TSS in other Oatp1 genes: CpG dinucleotides at +149 relative to the TSS for  bbbbb2 Oatp1c1 eeeee2 ; -48, +101, and +356 for Oatp1a4; -572 and -550 for Oatp1a1; and -122 and +216 for Oatp1a6 were differentially methylated among the liver, kidney, and cerebrum
CRP11	 bbbbb1 Bisulfite eeeee1  sequencing also demonstrated the presence of T-DMRs around the TSS in other Oatp1 genes: CpG dinucleotides at +149 relative to the TSS for Oatp1c1; -48, +101, and +356 for  bbbbb2 Oatp1a4 eeeee2 ; -572 and -550 for Oatp1a1; and -122 and +216 for Oatp1a6 were differentially methylated among the liver, kidney, and cerebrum
CRP11	 bbbbb1 Bisulfite eeeee1  sequencing also demonstrated the presence of  bbbbb2 T-DMRs eeeee2  around the TSS in other Oatp1 genes: CpG dinucleotides at +149 relative to the TSS for Oatp1c1; -48, +101, and +356 for Oatp1a4; -572 and -550 for Oatp1a1; and -122 and +216 for Oatp1a6 were differentially methylated among the liver, kidney, and cerebrum
CRP11	Osteoclast maturation and function primarily depend on receptor activator of NF-κB ligand (RANKL)-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular calcium ([ bbbbb1 Ca(2+) eeeee1  bbbbb2 nuclear factor of activated T cells c1 eeeee2  (NFATc1), which is further activated via increased intracellular calcium ([Ca(2+)](i)) oscillation
CRP11	Osteoclast maturation and function primarily depend on receptor activator of NF-κB ligand (RANKL)-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular calcium ([ bbbbb1 Ca(2+) eeeee1  bbbbb2 NFATc1 eeeee2 ), which is further activated via increased intracellular calcium ([Ca(2+)](i)) oscillation
CRP11	Osteoclast maturation and function primarily depend on receptor activator of NF-κB ligand (RANKL)-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular calcium ([ bbbbb1 Ca(2+) eeeee1  bbbbb2 receptor activator of NF-κB ligand eeeee2  (RANKL)-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular calcium ([Ca(2+)](i)) oscillation
CRP11	Osteoclast maturation and function primarily depend on receptor activator of NF-κB ligand (RANKL)-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular calcium ([ bbbbb1 Ca(2+) eeeee1  bbbbb2 RANKL eeeee2 )-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular calcium ([Ca(2+)](i)) oscillation
CRP11	Osteoclast maturation and function primarily depend on receptor activator of NF-κB ligand (RANKL)-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular  bbbbb1 calcium eeeee1  bbbbb2 nuclear factor of activated T cells c1 eeeee2  (NFATc1), which is further activated via increased intracellular calcium ([Ca(2+)](i)) oscillation
CRP11	Osteoclast maturation and function primarily depend on receptor activator of NF-κB ligand (RANKL)-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular  bbbbb1 calcium eeeee1  bbbbb2 NFATc1 eeeee2 ), which is further activated via increased intracellular calcium ([Ca(2+)](i)) oscillation
CRP11	Osteoclast maturation and function primarily depend on receptor activator of NF-κB ligand (RANKL)-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular  bbbbb1 calcium eeeee1  bbbbb2 receptor activator of NF-κB ligand eeeee2  (RANKL)-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular calcium ([Ca(2+)](i)) oscillation
CRP11	Osteoclast maturation and function primarily depend on receptor activator of NF-κB ligand (RANKL)-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular  bbbbb1 calcium eeeee1  bbbbb2 RANKL eeeee2 )-mediated induction of nuclear factor of activated T cells c1 (NFATc1), which is further activated via increased intracellular calcium ([Ca(2+)](i)) oscillation
CRP11	Tmem64 modulates  bbbbb1 calcium eeeee1  bbbbb2 Tmem64 eeeee2  modulates calcium signaling during RANKL-mediated osteoclast differentiation
CRP11	Tmem64 modulates  bbbbb1 calcium eeeee1  signaling during  bbbbb2 RANKL eeeee2 -mediated osteoclast differentiation
CRP11	Consequently, Tmem64 deficiency significantly diminishes RANKL-induced [Ca(2+)](i) oscillation, which results  bbbbb1 in red eeeee1  bbbbb2 ncy si eeeee2 gnificantly diminishes RANKL-induced [Ca(2+)](i) oscillation, which results in reduced Ca(2+)/calmodulin-dependent protein kinases (CaMK) IV and mitochondrial ROS, both of which contribute to achieving the CREB activity necessary for osteoclast formation
CRP11	Consequently, Tmem64 deficiency significantly diminishes RANKL-induced [Ca(2+)](i) oscillation, which results  bbbbb1 in red eeeee1  bbbbb2 n, whi eeeee2 ch results in reduced Ca(2+)/calmodulin-dependent protein kinases (CaMK) IV and mitochondrial ROS, both of which contribute to achieving the CREB activity necessary for osteoclast formation
CRP11	Here, we identified transmembrane protein 64 (Tmem64) as a regulator of  bbbbb1 Ca(2+) eeeee1  bbbbb2 Tmem64 eeeee2 ) as a regulator of Ca(2+) oscillation during osteoclastogenesis
CRP11	Here, we identified transmembrane protein 64 (Tmem64) as a regulator of  bbbbb1 Ca(2+) eeeee1  bbbbb2 transmembrane protein 64 eeeee2  (Tmem64) as a regulator of Ca(2+) oscillation during osteoclastogenesis
CRP11	Insulin-degrading enzyme (IDE) is a highly conserved  bbbbb1 zinc eeeee1  bbbbb2 zinc metallopeptidase eeeee2  that is ubiquitously distributed in human tissues, and particularly abundant in the brain, liver, and muscles
CRP11	Insulin-degrading enzyme (IDE) is a highly conserved  bbbbb1 zinc eeeee1  bbbbb2 IDE eeeee2 ) is a highly conserved zinc metallopeptidase that is ubiquitously distributed in human tissues, and particularly abundant in the brain, liver, and muscles
CRP11	Insulin-degrading enzyme (IDE) is a highly conserved  bbbbb1 zinc eeeee1  bbbbb2 Insulin-degrading enzyme eeeee2  (IDE) is a highly conserved zinc metallopeptidase that is ubiquitously distributed in human tissues, and particularly abundant in the brain, liver, and muscles
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood urea nitrogen,  bbbbb1 N-acetyl eeeee1  bbbbb2 uKIM-1 eeeee2  was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood urea nitrogen, N-acetyl-β-glucosaminidase (NAG), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood urea nitrogen,  bbbbb1 N-acetyl eeeee1 -β-glucosaminidase ( bbbbb2 NAG eeeee2 ), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood urea nitrogen,  bbbbb1 N-acetyl eeeee1  bbbbb2 N-acetyl-β-glucosaminidase eeeee2  (NAG), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood  bbbbb1 urea eeeee1  bbbbb2 uKIM-1 eeeee2  was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood urea nitrogen, N-acetyl-β-glucosaminidase (NAG), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood  bbbbb1 urea eeeee1  nitrogen, N-acetyl-β-glucosaminidase ( bbbbb2 NAG eeeee2 ), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood  bbbbb1 urea eeeee1  nitrogen,  bbbbb2 N-acetyl-β-glucosaminidase eeeee2  (NAG), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood urea  bbbbb1 nitrogen eeeee1  bbbbb2 uKIM-1 eeeee2  was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood urea nitrogen, N-acetyl-β-glucosaminidase (NAG), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood urea  bbbbb1 nitrogen eeeee1 , N-acetyl-β-glucosaminidase ( bbbbb2 NAG eeeee2 ), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood urea  bbbbb1 nitrogen eeeee1 ,  bbbbb2 N-acetyl-β-glucosaminidase eeeee2  (NAG), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum  bbbbb1 creatinine eeeee1  bbbbb2 uKIM-1 eeeee2  was significantly elevated by 13-fold, whereas serum creatinine (sCr), blood urea nitrogen, N-acetyl-β-glucosaminidase (NAG), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum  bbbbb1 creatinine eeeee1  (sCr), blood urea nitrogen, N-acetyl-β-glucosaminidase ( bbbbb2 NAG eeeee2 ), and proteinuria levels did not change
CRP11	After only 10-min ischemia followed by 24-h reperfusion, uKIM-1 was significantly elevated by 13-fold, whereas serum  bbbbb1 creatinine eeeee1  (sCr), blood urea nitrogen,  bbbbb2 N-acetyl-β-glucosaminidase eeeee2  (NAG), and proteinuria levels did not change
CRP11	Here, we report the development and validation of two different assays for quantitative assessment of mouse urinary KIM-1 (uKIM-1) and compare the sensitivity of KIM-1 relative to other standard markers in ischemia reperfusion and  bbbbb1 aristolochic acid eeeee1  bbbbb2 uKIM-1 eeeee2 ) and compare the sensitivity of KIM-1 relative to other standard markers in ischemia reperfusion and aristolochic acid (AA)-induced kidney injury in mice
CRP11	Here, we report the development and validation of two different assays for quantitative assessment of mouse urinary KIM-1 (uKIM-1) and compare the sensitivity of KIM-1 relative to other standard markers in ischemia reperfusion and  bbbbb1 aristolochic acid eeeee1  bbbbb2 KIM-1 eeeee2  relative to other standard markers in ischemia reperfusion and aristolochic acid (AA)-induced kidney injury in mice
CRP11	Here, we report the development and validation of two different assays for quantitative assessment of mouse urinary KIM-1 (uKIM-1) and compare the sensitivity of KIM-1 relative to other standard markers in ischemia reperfusion and  bbbbb1 aristolochic acid eeeee1  bbbbb2 mouse urinary KIM-1 eeeee2  (uKIM-1) and compare the sensitivity of KIM-1 relative to other standard markers in ischemia reperfusion and aristolochic acid (AA)-induced kidney injury in mice
CRP11	Previous reports have identified a role for the  bbbbb1 tyrosine eeeee1  kinase receptor EphB4 and its ligand,  bbbbb2 ephrinB2 eeeee2 , as potential mediators of both bone formation by osteoblasts and bone resorption by osteoclasts
CRP11	Previous reports have identified a role for the  bbbbb1 tyrosine eeeee1  kinase receptor  bbbbb2 EphB4 eeeee2  and its ligand, ephrinB2, as potential mediators of both bone formation by osteoblasts and bone resorption by osteoclasts
CRP11	Previous reports have identified a role for the  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase receptor eeeee2  EphB4 and its ligand, ephrinB2, as potential mediators of both bone formation by osteoblasts and bone resorption by osteoclasts
CRP11	 bbbbb1 Thyroid hormone eeeee1  bbbbb2 Thyroid hormone receptors eeeee2 /THR genes in human cancer
CRP11	 bbbbb1 Thyroid hormone eeeee1  receptors/ bbbbb2 THR eeeee2  genes in human cancer
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin,  bbbbb1 calcium eeeee1  bbbbb2 E-selectin eeeee2 , calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin,  bbbbb1 calcium eeeee1 -dependent binding of a subfraction to L-selectin and to P-selectin, and calcium-independent binding of a larger fraction to  bbbbb2 P-selectin eeeee2 , the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin,  bbbbb1 calcium eeeee1 -dependent binding of a subfraction to  bbbbb2 L-selectin eeeee2  and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin,  bbbbb1 calcium eeeee1 -dependent binding of a subfraction to L-selectin and to  bbbbb2 P-selectin eeeee2 , and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin, calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high  bbbbb1 EDTA eeeee1  bbbbb2 E-selectin eeeee2 , calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin, calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high  bbbbb1 EDTA eeeee1  bbbbb2 P-selectin eeeee2 , the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin, calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high  bbbbb1 EDTA eeeee1  bbbbb2 L-selectin eeeee2  and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin, calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high  bbbbb1 EDTA eeeee1  bbbbb2 P-selectin eeeee2 , and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin, calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and  bbbbb1 calcium eeeee1  bbbbb2 E-selectin eeeee2 , calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin, calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and  bbbbb1 calcium eeeee1 -independent binding of a larger fraction to  bbbbb2 P-selectin eeeee2 , the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin, calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and  bbbbb1 calcium eeeee1  bbbbb2 L-selectin eeeee2  and to P-selectin, and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high EDTA concentrations
CRP11	Porcine intestinal mucosal (mast cell-derived) heparin (PIM-heparin) shows similar properties, with no binding to E-selectin, calcium-dependent binding of a subfraction to L-selectin and to P-selectin, and  bbbbb1 calcium eeeee1  bbbbb2 P-selectin eeeee2 , and calcium-independent binding of a larger fraction to P-selectin, the latter being disrupted by high EDTA concentrations
CRP11	The selectins are  bbbbb1 calcium eeeee1 -dependent  bbbbb2 C-type lectins eeeee2  that bind certain sialylated, fucosylated, sulfated glycoprotein ligands
CRP11	The selectins are  bbbbb1 calcium eeeee1  bbbbb2 selectins eeeee2  are calcium-dependent C-type lectins that bind certain sialylated, fucosylated, sulfated glycoprotein ligands
CRP11	Despite this, HS chains bound to P-selectin are eluted by ethylenediamine tetraacetic acid ( bbbbb1 EDTA eeeee1  bbbbb2 P-selectin eeeee2  are eluted by ethylenediamine tetraacetic acid (EDTA), but only at high concentrations
CRP11	Despite this, HS chains bound to P-selectin are eluted by  bbbbb1 ethylenediamine tetraacetic acid eeeee1  bbbbb2 P-selectin eeeee2  are eluted by ethylenediamine tetraacetic acid (EDTA), but only at high concentrations
CRP11	Analysis of defined heparin fragment pools shows a size dependence for interaction, with  bbbbb1 tetradecasaccharides eeeee1  showing easily detectable binding to  bbbbb2 L- and P-selectin eeeee2  affinity columns
CRP11	L-selectin also recognizes endothelial proteoglycans in a calcium-dependent manner, via heparan sulfate (HS) glycosaminoglycan chains enriched in unsubstituted  bbbbb1 glucosamine eeeee1  bbbbb2 L-selectin eeeee2  also recognizes endothelial proteoglycans in a calcium-dependent manner, via heparan sulfate (HS) glycosaminoglycan chains enriched in unsubstituted glucosamine units
CRP11	L-selectin also recognizes endothelial proteoglycans in a  bbbbb1 calcium eeeee1  bbbbb2 L-selectin eeeee2  also recognizes endothelial proteoglycans in a calcium-dependent manner, via heparan sulfate (HS) glycosaminoglycan chains enriched in unsubstituted glucosamine units
CRP11	L-selectin binding fragments include more heavily sulfated and epimerized regions and, as with the endothelial HS chains, they are enriched in  bbbbb1 free amino eeeee1  bbbbb2 L-selectin eeeee2  binding fragments include more heavily sulfated and epimerized regions and, as with the endothelial HS chains, they are enriched in free amino groups
CRP11	The potential candidate biomarkers screened in ovarian tumors and found to be significantly up-regulated in comparison to normal tissues were as follows: NM23, annexin-1, protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK ( bbbbb1 N-acetyl glucosamine eeeee1  bbbbb2 NAGK eeeee2  (N-acetyl glucosamine kinase)
CRP11	The potential candidate biomarkers screened in ovarian tumors and found to be significantly up-regulated in comparison to normal tissues were as follows: NM23, annexin-1, protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK ( bbbbb1 N-acetyl glucosamine eeeee1  bbbbb2 ferritin light chain eeeee2 , proteasome alpha-6, and NAGK (N-acetyl glucosamine kinase)
CRP11	The potential candidate biomarkers screened in ovarian tumors and found to be significantly up-regulated in comparison to normal tissues were as follows: NM23, annexin-1, protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK ( bbbbb1 N-acetyl glucosamine eeeee1  bbbbb2 proteasome alpha-6 eeeee2 , and NAGK (N-acetyl glucosamine kinase)
CRP11	The potential candidate biomarkers screened in ovarian tumors and found to be significantly up-regulated in comparison to normal tissues were as follows: NM23, annexin-1, protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK ( bbbbb1 N-acetyl glucosamine eeeee1  bbbbb2 protein phosphatase-1 eeeee2 , ferritin light chain, proteasome alpha-6, and NAGK (N-acetyl glucosamine kinase)
CRP11	The potential candidate biomarkers screened in ovarian tumors and found to be significantly up-regulated in comparison to normal tissues were as follows: NM23, annexin-1, protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK ( bbbbb1 N-acetyl glucosamine eeeee1  bbbbb2 NM23 eeeee2 , annexin-1, protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK (N-acetyl glucosamine kinase)
CRP11	The potential candidate biomarkers screened in ovarian tumors and found to be significantly up-regulated in comparison to normal tissues were as follows: NM23, annexin-1, protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK ( bbbbb1 N-acetyl glucosamine eeeee1  bbbbb2 N-acetyl glucosamine kinase eeeee2 )
CRP11	The potential candidate biomarkers screened in ovarian tumors and found to be significantly up-regulated in comparison to normal tissues were as follows: NM23, annexin-1, protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK ( bbbbb1 N-acetyl glucosamine eeeee1  bbbbb2 annexin-1 eeeee2 , protein phosphatase-1, ferritin light chain, proteasome alpha-6, and NAGK (N-acetyl glucosamine kinase)
CRP11	Subjects were genotyped for the following single  bbbbb1 nucleotide eeeee1  polymorphisms (SNPs): (TNF -308, -238, and + 488);  bbbbb2 lymphotoxin-alpha eeeee2  (LTA) (LTA + 249, + 365, and + 720); and Fc gamma receptors FCGR2A 131 H/R; FCGR3A 176 F/V; and FCGR3B NA 1/2 and genotypes were correlated with infections
CRP11	Subjects were genotyped for the following single  bbbbb1 nucleotide eeeee1  polymorphisms (SNPs): ( bbbbb2 TNF eeeee2  -308, -238, and + 488); lymphotoxin-alpha (LTA) (LTA + 249, + 365, and + 720); and Fc gamma receptors FCGR2A 131 H/R; FCGR3A 176 F/V; and FCGR3B NA 1/2 and genotypes were correlated with infections
CRP11	Subjects were genotyped for the following single  bbbbb1 nucleotide eeeee1  polymorphisms (SNPs): (TNF -308, -238, and + 488); lymphotoxin-alpha (LTA) (LTA + 249, + 365, and + 720); and Fc gamma receptors  bbbbb2 FCGR2A eeeee2  131 H/R; FCGR3A 176 F/V; and FCGR3B NA 1/2 and genotypes were correlated with infections
CRP11	Subjects were genotyped for the following single  bbbbb1 nucleotide eeeee1  polymorphisms (SNPs): (TNF -308, -238, and + 488); lymphotoxin-alpha (LTA) (LTA + 249, + 365, and + 720); and  bbbbb2 Fc gamma receptors eeeee2  FCGR2A 131 H/R; FCGR3A 176 F/V; and FCGR3B NA 1/2 and genotypes were correlated with infections
CRP11	Subjects were genotyped for the following single  bbbbb1 nucleotide eeeee1  polymorphisms (SNPs): (TNF -308, -238, and + 488); lymphotoxin-alpha (LTA) (LTA + 249, + 365, and + 720); and Fc gamma receptors FCGR2A 131 H/R; FCGR3A 176 F/V; and  bbbbb2 FCGR3B eeeee2  NA 1/2 and genotypes were correlated with infections
CRP11	Subjects were genotyped for the following single  bbbbb1 nucleotide eeeee1  polymorphisms (SNPs): (TNF -308, -238, and + 488); lymphotoxin-alpha (LTA) ( bbbbb2 LTA eeeee2  + 249, + 365, and + 720); and Fc gamma receptors FCGR2A 131 H/R; FCGR3A 176 F/V; and FCGR3B NA 1/2 and genotypes were correlated with infections
CRP11	Subjects were genotyped for the following single  bbbbb1 nucleotide eeeee1  polymorphisms (SNPs): (TNF -308, -238, and + 488); lymphotoxin-alpha (LTA) (LTA + 249, + 365, and + 720); and Fc gamma receptors FCGR2A 131 H/R;  bbbbb2 FCGR3A eeeee2  176 F/V; and FCGR3B NA 1/2 and genotypes were correlated with infections
CRP11	Subjects were genotyped for the following single  bbbbb1 nucleotide eeeee1  polymorphisms (SNPs): (TNF -308, -238, and + 488); lymphotoxin-alpha ( bbbbb2 LTA eeeee2 ) (LTA + 249, + 365, and + 720); and Fc gamma receptors FCGR2A 131 H/R; FCGR3A 176 F/V; and FCGR3B NA 1/2 and genotypes were correlated with infections
CRP11	We analyzed clinical and genetic factors contributing to infections in 457 subjects with early rheumatoid arthritis (RA) enrolled in a prospective, 1-year clinical trial of  bbbbb1 methotrexate eeeee1  and the  bbbbb2 TNF eeeee2  inhibitor etanercept
CRP11	The disease has been associated with mutations in the  bbbbb1 glycine eeeee1  receptor subunit genes  bbbbb2 GLRA1 eeeee2  and GLRB
CRP11	The disease has been associated with mutations in the  bbbbb1 glycine eeeee1  bbbbb2 glycine receptor eeeee2  subunit genes GLRA1 and GLRB
CRP11	The disease has been associated with mutations in the  bbbbb1 glycine eeeee1  receptor subunit genes GLRA1 and  bbbbb2 GLRB eeeee2 
CRP11	Here, we describe mutations within the neuronal  bbbbb1 glycine eeeee1  transporter 2 gene (GLYT2, or  bbbbb2 SLC6A5 eeeee2 , ) of hyperekplexia patients, whose symptoms cannot be attributed to glycine receptor mutations
CRP11	Here, we describe mutations within the neuronal  bbbbb1 glycine eeeee1  transporter 2 gene ( bbbbb2 GLYT2 eeeee2 , or SLC6A5, ) of hyperekplexia patients, whose symptoms cannot be attributed to glycine receptor mutations
CRP11	Here, we describe mutations within the neuronal  bbbbb1 glycine eeeee1  bbbbb2 glycine transporter 2 eeeee2  gene (GLYT2, or SLC6A5, ) of hyperekplexia patients, whose symptoms cannot be attributed to glycine receptor mutations
CRP11	Here, we describe mutations within the neuronal  bbbbb1 glycine eeeee1  transporter 2 gene (GLYT2, or SLC6A5, ) of hyperekplexia patients, whose symptoms cannot be attributed to  bbbbb2 glycine receptor eeeee2  mutations
CRP11	Here, we describe mutations within the neuronal glycine transporter 2 gene (GLYT2, or SLC6A5, ) of hyperekplexia patients, whose symptoms cannot be attributed to  bbbbb1 glycine eeeee1  bbbbb2 SLC6A5 eeeee2 , ) of hyperekplexia patients, whose symptoms cannot be attributed to glycine receptor mutations
CRP11	Here, we describe mutations within the neuronal glycine transporter 2 gene (GLYT2, or SLC6A5, ) of hyperekplexia patients, whose symptoms cannot be attributed to  bbbbb1 glycine eeeee1  bbbbb2 GLYT2 eeeee2 , or SLC6A5, ) of hyperekplexia patients, whose symptoms cannot be attributed to glycine receptor mutations
CRP11	Here, we describe mutations within the neuronal glycine transporter 2 gene (GLYT2, or SLC6A5, ) of hyperekplexia patients, whose symptoms cannot be attributed to  bbbbb1 glycine eeeee1  bbbbb2 glycine transporter 2 eeeee2  gene (GLYT2, or SLC6A5, ) of hyperekplexia patients, whose symptoms cannot be attributed to glycine receptor mutations
CRP11	Here, we describe mutations within the neuronal glycine transporter 2 gene (GLYT2, or SLC6A5, ) of hyperekplexia patients, whose symptoms cannot be attributed to  bbbbb1 glycine eeeee1  bbbbb2 glycine receptor eeeee2  mutations
CRP11	Excessive level of  bbbbb1 estrogen eeeee1  is considered as a main cause of breast cancer, therefore, many studies have focused on estrogen receptor (ER)-positive breast cancer, even though ER-negative cancer has a poor prognosis than  bbbbb2 ER eeeee2 -positive breast cancer
CRP11	Excessive level of  bbbbb1 estrogen eeeee1  is considered as a main cause of breast cancer, therefore, many studies have focused on estrogen receptor (ER)-positive breast cancer, even though  bbbbb2 ER eeeee2 -negative cancer has a poor prognosis than ER-positive breast cancer
CRP11	Excessive level of  bbbbb1 estrogen eeeee1  is considered as a main cause of breast cancer, therefore, many studies have focused on estrogen receptor ( bbbbb2 ER eeeee2 )-positive breast cancer, even though ER-negative cancer has a poor prognosis than ER-positive breast cancer
CRP11	Excessive level of  bbbbb1 estrogen eeeee1  is considered as a main cause of breast cancer, therefore, many studies have focused on  bbbbb2 estrogen receptor eeeee2  (ER)-positive breast cancer, even though ER-negative cancer has a poor prognosis than ER-positive breast cancer
CRP11	Excessive level of estrogen is considered as a main cause of breast cancer, therefore, many studies have focused on  bbbbb1 estrogen eeeee1  receptor (ER)-positive breast cancer, even though ER-negative cancer has a poor prognosis than  bbbbb2 ER eeeee2 -positive breast cancer
CRP11	Excessive level of estrogen is considered as a main cause of breast cancer, therefore, many studies have focused on  bbbbb1 estrogen eeeee1  receptor (ER)-positive breast cancer, even though  bbbbb2 ER eeeee2 -negative cancer has a poor prognosis than ER-positive breast cancer
CRP11	Excessive level of estrogen is considered as a main cause of breast cancer, therefore, many studies have focused on  bbbbb1 estrogen eeeee1  receptor ( bbbbb2 ER eeeee2 )-positive breast cancer, even though ER-negative cancer has a poor prognosis than ER-positive breast cancer
CRP11	Excessive level of estrogen is considered as a main cause of breast cancer, therefore, many studies have focused on  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  (ER)-positive breast cancer, even though ER-negative cancer has a poor prognosis than ER-positive breast cancer
CRP11	Recent evidence suggests that a substantial portion of the passive stiffness of an in vitro preparation of tracheal smooth muscle is  bbbbb1 calcium eeeee1  sensitive and is regulated by  bbbbb2 Rho-kinase eeeee2 , although the underlying mechanism and the details of regulation for the development of this intracellular passive stiffness are still largely unknown
CRP11	Few studies have addressed the delivery of lipoprotein-derived cholesterol to the adrenals for  bbbbb1 steroid eeeee1  bbbbb2 lipoprotein eeeee2 -derived cholesterol to the adrenals for steroid production in humans
CRP11	Few studies have addressed the delivery of lipoprotein-derived  bbbbb1 cholesterol eeeee1  bbbbb2 lipoprotein eeeee2 -derived cholesterol to the adrenals for steroid production in humans
CRP11	In conclusion, this study shows that basal but not  bbbbb1 stimulated  eeeee1  bbbbb2  bu eeeee2 t not stimulated corticosteroid metabolism is attenuated in subjects with low HDL-C, irrespective of its molecular origin
CRP11	In all groups with low HDL-C levels, urinary excretion of  bbbbb1 17-ketogenic steroids eeeee1  bbbbb2 HDL eeeee2 -C levels, urinary excretion of 17-ketogenic steroids was reduced by 33%, 27%, and 32% compared with controls (all P < 0.04)
CRP11	High density lipoprotein as a source of  bbbbb1 cholesterol eeeee1  bbbbb2 High density lipoprotein eeeee2  as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C
CRP11	High density lipoprotein as a source of  bbbbb1 cholesterol eeeee1  for adrenal steroidogenesis: a study in individuals with low plasma  bbbbb2 HDL eeeee2 -C
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL  bbbbb1 cholesterol eeeee1  bbbbb2 ATP binding cassette transporter A1 eeeee2  (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL  bbbbb1 cholesterol eeeee1  (HDL-C) without  bbbbb2 ABCA1 eeeee2 /LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL  bbbbb1 cholesterol eeeee1  bbbbb2 ABCA1 eeeee2 ) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL  bbbbb1 cholesterol eeeee1  bbbbb2 HDL eeeee2  cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL  bbbbb1 cholesterol eeeee1  (HDL-C) without ABCA1/ bbbbb2 LCAT eeeee2  mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL  bbbbb1 cholesterol eeeee1  bbbbb2 lecithin:cholesterol acyltransferase eeeee2  (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL  bbbbb1 cholesterol eeeee1  bbbbb2 LCAT eeeee2 ) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL  bbbbb1 cholesterol eeeee1  ( bbbbb2 HDL eeeee2 -C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in  bbbbb1 ATP eeeee1  bbbbb2 ATP binding cassette transporter A1 eeeee2  (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in  bbbbb1 ATP eeeee1  binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without  bbbbb2 ABCA1 eeeee2 /LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in  bbbbb1 ATP eeeee1  binding cassette transporter A1 ( bbbbb2 ABCA1 eeeee2 ) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in  bbbbb1 ATP eeeee1  binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low  bbbbb2 HDL eeeee2  cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in  bbbbb1 ATP eeeee1  binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/ bbbbb2 LCAT eeeee2  mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in  bbbbb1 ATP eeeee1  binding cassette transporter A1 (ABCA1) (n = 24),  bbbbb2 lecithin:cholesterol acyltransferase eeeee2  (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in  bbbbb1 ATP eeeee1  binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase ( bbbbb2 LCAT eeeee2 ) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in  bbbbb1 ATP eeeee1  binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol ( bbbbb2 HDL eeeee2 -C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin: bbbbb1 cholesterol eeeee1  bbbbb2 ATP binding cassette transporter A1 eeeee2  (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin: bbbbb1 cholesterol eeeee1  acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without  bbbbb2 ABCA1 eeeee2 /LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin: bbbbb1 cholesterol eeeee1  bbbbb2 ABCA1 eeeee2 ) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin: bbbbb1 cholesterol eeeee1  acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low  bbbbb2 HDL eeeee2  cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin: bbbbb1 cholesterol eeeee1  acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/ bbbbb2 LCAT eeeee2  mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin: bbbbb1 cholesterol eeeee1  bbbbb2 lecithin:cholesterol acyltransferase eeeee2  (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin: bbbbb1 cholesterol eeeee1  acyltransferase ( bbbbb2 LCAT eeeee2 ) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin: bbbbb1 cholesterol eeeee1  acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol ( bbbbb2 HDL eeeee2 -C) without ABCA1/LCAT mutations
CRP11	To study this,  bbbbb1 steroid hormone eeeee1  profiles in urine were assessed in male subjects suffering from functional mutations in  bbbbb2 ATP binding cassette transporter A1 eeeee2  (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this,  bbbbb1 steroid hormone eeeee1  profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without  bbbbb2 ABCA1 eeeee2 /LCAT mutations
CRP11	To study this,  bbbbb1 steroid hormone eeeee1  profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 ( bbbbb2 ABCA1 eeeee2 ) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this,  bbbbb1 steroid hormone eeeee1  profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low  bbbbb2 HDL eeeee2  cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this,  bbbbb1 steroid hormone eeeee1  profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/ bbbbb2 LCAT eeeee2  mutations
CRP11	To study this,  bbbbb1 steroid hormone eeeee1  profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24),  bbbbb2 lecithin:cholesterol acyltransferase eeeee2  (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this,  bbbbb1 steroid hormone eeeee1  profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase ( bbbbb2 LCAT eeeee2 ) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations
CRP11	To study this,  bbbbb1 steroid hormone eeeee1  profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol ( bbbbb2 HDL eeeee2 -C) without ABCA1/LCAT mutations
CRP11	Glutathione S-transferases (GSTs) are involved in the detoxification of xenobiotics by conjugation with  bbbbb1 glutathione eeeee1  bbbbb2 Glutathione S-transferases eeeee2  (GSTs) are involved in the detoxification of xenobiotics by conjugation with glutathione
CRP11	Glutathione S-transferases (GSTs) are involved in the detoxification of xenobiotics by conjugation with  bbbbb1 glutathione eeeee1  bbbbb2 GSTs eeeee2 ) are involved in the detoxification of xenobiotics by conjugation with glutathione
CRP11	 bbbbb1 Glutathione eeeee1  bbbbb2 Glutathione S-transferases eeeee2  (GSTs) are involved in the detoxification of xenobiotics by conjugation with glutathione
CRP11	 bbbbb1 Glutathione eeeee1  S-transferases ( bbbbb2 GSTs eeeee2 ) are involved in the detoxification of xenobiotics by conjugation with glutathione
CRP11	Testing chemicals for their endocrine-disrupting potential, including interference with  bbbbb1 estrogen eeeee1  receptor ( bbbbb2 ER eeeee2 ) signaling, is an important aspect of chemical safety testing
CRP11	Testing chemicals for their endocrine-disrupting potential, including interference with  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  (ER) signaling, is an important aspect of chemical safety testing
CRP11	In the present study, the reproducibility and robustness of this coregulator binding assay was determined by measuring the binding profiles of 14 model compounds that are recommended by the Office of Prevention, Pesticides and Toxic Substances for testing laboratory proficiency in  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  transactivation assays
CRP11	Alkaptonuria, a rare autosomal recessive disorder caused by mutations in the HGD gene and deficiency of homogentisate 1,2 dioxygenase, is characterized by ochronosis, arthritis, and daily excretion of gram quantities of homogentisic acid ( bbbbb1 HGA eeeee1  bbbbb2 HGD eeeee2  gene and deficiency of homogentisate 1,2 dioxygenase, is characterized by ochronosis, arthritis, and daily excretion of gram quantities of homogentisic acid (HGA)
CRP11	Alkaptonuria, a rare autosomal recessive disorder caused by mutations in the HGD gene and deficiency of homogentisate 1,2 dioxygenase, is characterized by ochronosis, arthritis, and daily excretion of gram quantities of homogentisic acid ( bbbbb1 HGA eeeee1  bbbbb2 homogentisate 1,2 dioxygenase eeeee2 , is characterized by ochronosis, arthritis, and daily excretion of gram quantities of homogentisic acid (HGA)
CRP11	Alkaptonuria, a rare autosomal recessive disorder caused by mutations in the HGD gene and deficiency of homogentisate 1,2 dioxygenase, is characterized by ochronosis, arthritis, and daily excretion of gram quantities of  bbbbb1 homogentisic acid eeeee1  bbbbb2 HGD eeeee2  gene and deficiency of homogentisate 1,2 dioxygenase, is characterized by ochronosis, arthritis, and daily excretion of gram quantities of homogentisic acid (HGA)
CRP11	Alkaptonuria, a rare autosomal recessive disorder caused by mutations in the HGD gene and deficiency of homogentisate 1,2 dioxygenase, is characterized by ochronosis, arthritis, and daily excretion of gram quantities of  bbbbb1 homogentisic acid eeeee1  bbbbb2 homogentisate 1,2 dioxygenase eeeee2 , is characterized by ochronosis, arthritis, and daily excretion of gram quantities of homogentisic acid (HGA)
CRP11	Alkaptonuria, a rare autosomal recessive disorder caused by mutations in the HGD gene and deficiency of  bbbbb1 homogentisate eeeee1  bbbbb2 HGD eeeee2  gene and deficiency of homogentisate 1,2 dioxygenase, is characterized by ochronosis, arthritis, and daily excretion of gram quantities of homogentisic acid (HGA)
CRP11	Alkaptonuria, a rare autosomal recessive disorder caused by mutations in the HGD gene and deficiency of  bbbbb1 homogentisate eeeee1  bbbbb2 homogentisate 1,2 dioxygenase eeeee2 , is characterized by ochronosis, arthritis, and daily excretion of gram quantities of homogentisic acid (HGA)
CRP11	Nitisinone, an inhibitor of the enzyme  bbbbb1 4-hydroxyphenylpyruvate eeeee1  bbbbb2 4-hydroxyphenylpyruvate dioxygenase eeeee2 , can drastically reduce urinary excretion of HGA in individuals with alkaptonuria
CRP11	Nitisinone, an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase, can drastically reduce urinary excretion of  bbbbb1 HGA eeeee1  bbbbb2 4-hydroxyphenylpyruvate dioxygenase eeeee2 , can drastically reduce urinary excretion of HGA in individuals with alkaptonuria
CRP11	They are homozygous for a point mutation at codon 307 (CTT→CCT) resulting in the substitution of  bbbbb1 leucine eeeee1  bbbbb2 CCT eeeee2 ) resulting in the substitution of leucine 307 by proline
CRP11	They are homozygous for a point mutation at codon 307 (CTT→CCT) resulting in the substitution of  bbbbb1 leucine eeeee1  bbbbb2 CTT eeeee2 →CCT) resulting in the substitution of leucine 307 by proline
CRP11	They are homozygous for a point mutation at codon 307 (CTT→CCT) resulting in the substitution of  bbbbb1 leucine eeeee1  bbbbb2 leucine 307 by proline eeeee2 
CRP11	They are homozygous for a point mutation at codon 307 (CTT→CCT) resulting in the substitution of leucine 307 by  bbbbb1 proline eeeee1  bbbbb2 CCT eeeee2 ) resulting in the substitution of leucine 307 by proline
CRP11	They are homozygous for a point mutation at codon 307 (CTT→CCT) resulting in the substitution of leucine 307 by  bbbbb1 proline eeeee1  bbbbb2 CTT eeeee2 →CCT) resulting in the substitution of leucine 307 by proline
CRP11	They are homozygous for a point mutation at codon 307 (CTT→CCT) resulting in the substitution of leucine 307 by  bbbbb1 proline eeeee1  bbbbb2 leucine 307 by proline eeeee2 
CRP11	The distance between δ nitrogen of His438 to ε oxygen of Glu325 and ε nitrogen of His438 to γ  bbbbb1 oxygen eeeee1  of Ser198 were highly altered in  bbbbb2 L307P eeeee2  mutant than the wild and other three variants throughout the simulation
CRP11	The distance between δ nitrogen of  bbbbb1 His eeeee1 438 to ε oxygen of Glu325 and ε nitrogen of His438 to γ oxygen of Ser198 were highly altered in  bbbbb2 L307P eeeee2  mutant than the wild and other three variants throughout the simulation
CRP11	The distance between δ  bbbbb1 nitrogen eeeee1  of His438 to ε oxygen of Glu325 and ε nitrogen of His438 to γ oxygen of Ser198 were highly altered in  bbbbb2 L307P eeeee2  mutant than the wild and other three variants throughout the simulation
CRP11	The distance between δ nitrogen of His438 to ε oxygen of  bbbbb1 Glu eeeee1 325 and ε nitrogen of His438 to γ oxygen of Ser198 were highly altered in  bbbbb2 L307P eeeee2  mutant than the wild and other three variants throughout the simulation
CRP11	The distance between δ nitrogen of His438 to ε oxygen of Glu325 and ε  bbbbb1 nitrogen eeeee1  of His438 to γ oxygen of Ser198 were highly altered in  bbbbb2 L307P eeeee2  mutant than the wild and other three variants throughout the simulation
CRP11	The distance between δ nitrogen of His438 to ε oxygen of Glu325 and ε nitrogen of His438 to γ oxygen of  bbbbb1 Ser eeeee1 198 were highly altered in  bbbbb2 L307P eeeee2  mutant than the wild and other three variants throughout the simulation
CRP11	The distance between δ nitrogen of His438 to ε  bbbbb1 oxygen eeeee1  of Glu325 and ε nitrogen of His438 to γ oxygen of Ser198 were highly altered in  bbbbb2 L307P eeeee2  mutant than the wild and other three variants throughout the simulation
CRP11	The distance between δ nitrogen of His438 to ε oxygen of Glu325 and ε nitrogen of  bbbbb1 His eeeee1 438 to γ oxygen of Ser198 were highly altered in  bbbbb2 L307P eeeee2  mutant than the wild and other three variants throughout the simulation
CRP11	Alteration of  bbbbb1 α-tocopherol eeeee1  bbbbb2 α-tocopherol-associated protein eeeee2  (TAP) expression in human breast epithelial cells during breast cancer development
CRP11	Alteration of  bbbbb1 α-tocopherol eeeee1 -associated protein ( bbbbb2 TAP eeeee2 ) expression in human breast epithelial cells during breast cancer development
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of α-tocopherol, the main and most active form of natural vitamin E. α-Tocopherol-associated protein (TAP) was found to be one of the major  bbbbb1 α-tocopherol eeeee1  bbbbb2 TAP eeeee2 ) was found to be one of the major α-tocopherol binding proteins in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of α-tocopherol, the main and most active form of natural vitamin E. α-Tocopherol-associated protein (TAP) was found to be one of the major  bbbbb1 α-tocopherol eeeee1  bbbbb2 α-tocopherol binding proteins eeeee2  in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of α-tocopherol, the main and most active form of natural vitamin E. α-Tocopherol-associated protein (TAP) was found to be one of the major  bbbbb1 α-tocopherol eeeee1  bbbbb2 α-Tocopherol-associated protein eeeee2  (TAP) was found to be one of the major α-tocopherol binding proteins in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of α-tocopherol, the main and most active form of natural  bbbbb1 vitamin E eeeee1 . α-Tocopherol-associated protein ( bbbbb2 TAP eeeee2 ) was found to be one of the major α-tocopherol binding proteins in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of α-tocopherol, the main and most active form of natural  bbbbb1 vitamin E eeeee1 . α-Tocopherol-associated protein (TAP) was found to be one of the major  bbbbb2 α-tocopherol binding proteins eeeee2  in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of α-tocopherol, the main and most active form of natural  bbbbb1 vitamin E eeeee1 .  bbbbb2 α-Tocopherol-associated protein eeeee2  (TAP) was found to be one of the major α-tocopherol binding proteins in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of α-tocopherol, the main and most active form of natural vitamin E.  bbbbb1 α-Tocopherol eeeee1 -associated protein ( bbbbb2 TAP eeeee2 ) was found to be one of the major α-tocopherol binding proteins in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of α-tocopherol, the main and most active form of natural vitamin E.  bbbbb1 α-Tocopherol eeeee1 -associated protein (TAP) was found to be one of the major  bbbbb2 α-tocopherol binding proteins eeeee2  in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of α-tocopherol, the main and most active form of natural vitamin E.  bbbbb1 α-Tocopherol eeeee1  bbbbb2 α-Tocopherol-associated protein eeeee2  (TAP) was found to be one of the major α-tocopherol binding proteins in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of  bbbbb1 α-tocopherol eeeee1 , the main and most active form of natural vitamin E. α-Tocopherol-associated protein ( bbbbb2 TAP eeeee2 ) was found to be one of the major α-tocopherol binding proteins in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of  bbbbb1 α-tocopherol eeeee1 , the main and most active form of natural vitamin E. α-Tocopherol-associated protein (TAP) was found to be one of the major  bbbbb2 α-tocopherol binding proteins eeeee2  in human serum and in liver, brain, and prostate tissues
CRP11	Over the last decade, many studies have demonstrated the anticancer activity of  bbbbb1 α-tocopherol eeeee1 , the main and most active form of natural vitamin E.  bbbbb2 α-Tocopherol-associated protein eeeee2  (TAP) was found to be one of the major α-tocopherol binding proteins in human serum and in liver, brain, and prostate tissues
CRP11	 bbbbb1 Oxytocin eeeee1  bbbbb2 Oxytocin eeeee2  levels in cerebrospinal fluid (CSF), but also in plasma or urine, have been shown to be negatively associated with childhood traumata, aggressive behavior, and suicide attempts
CRP11	The neuropeptide  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  is involved in social cognition and interaction across species and plays a crucial role in the regulation of affiliative behaviors
CRP11	Reduced plasma  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  levels in female patients with borderline personality disorder
CRP11	In addition, plasma  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  correlated negatively with experiences of childhood traumata, in particular with emotional neglect and abuse
CRP11	In the present study, we compared plasma  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  levels of women with and without BPD in the follicular phase and assessed the relationship between oxytocin concentrations and childhood traumata
CRP11	In the present study, we compared plasma  bbbbb1 oxytocin eeeee1  levels of women with and without BPD in the follicular phase and assessed the relationship between  bbbbb2 oxytocin eeeee2  concentrations and childhood traumata
CRP11	In the present study, we compared plasma oxytocin levels of women with and without BPD in the follicular phase and assessed the relationship between  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  levels of women with and without BPD in the follicular phase and assessed the relationship between oxytocin concentrations and childhood traumata
CRP11	In the present study, we compared plasma oxytocin levels of women with and without BPD in the follicular phase and assessed the relationship between  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  concentrations and childhood traumata
CRP11	The results of mediation analyses do not support a bbbbb1  model o eeeee1  bbbbb2  model o eeeee2 f oxytocin being a prominent mediator in the link between childhood trauma and BPD
CRP11	The results of mediation analyses do not support a bbbbb1  model o eeeee1 f oxytocin being a prominent mediator in the link between childhood trauma and BPD bbbbb2  eeeee2 
CRP11	The results of mediation analyses do not support a model of oxytocin being a prominent mediator in the link between childhood trauma and BPD bbbbb1  eeeee1  bbbbb2  model o eeeee2 f oxytocin being a prominent mediator in the link between childhood trauma and BPD
CRP11	The results of mediation analyses do not support a model of oxytocin being a prominent mediator in the link between childhood trauma and BPD bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Recently, an altered activity of the  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  system has been discussed to play a prominent role in borderline personality disorder (BPD), which is thought to be closely related to traumatic experiences in childhood and is characterized by (para)suicidal behaviors as well as aggressive outbursts
CRP11	Women diagnosed with BPD had significantly reduced  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  concentrations, even after controlling for estrogen, progesterone, and contraceptive intake
CRP11	Women diagnosed with BPD had significantly reduced oxytocin concentrations, even after controlling for  bbbbb1 estrogen eeeee1  bbbbb2 oxytocin eeeee2  concentrations, even after controlling for estrogen, progesterone, and contraceptive intake
CRP11	Women diagnosed with BPD had significantly reduced oxytocin concentrations, even after controlling for estrogen,  bbbbb1 progesterone eeeee1  bbbbb2 oxytocin eeeee2  concentrations, even after controlling for estrogen, progesterone, and contraceptive intake
CRP11	Accordingly, the production rates of albumin and  bbbbb1 glucose eeeee1  bbbbb2 albumin eeeee2  and glucose, as well as CYP2E1 activity, were significantly higher in the 3D versus the 2D cultures
CRP11	Accordingly, the production rates of albumin and  bbbbb1 glucose eeeee1 , as well as  bbbbb2 CYP2E1 eeeee2  activity, were significantly higher in the 3D versus the 2D cultures
CRP11	Furthermore, a non-selective beta-receptor antagonist oxprenolol and a beta2-selective antagonist acebutalol, but bbbbb1  not eeeee1  a beta1-selective antagonis bbbbb2 t butoxamine, counteracte eeeee2 d the suppressive effects of the beta-agonists on microglial proliferation
CRP11	The effects of several cyclic adenosine monophosphate ( bbbbb1 cAMP eeeee1 )-elevating agents on the proliferation of cultured rat microglia were investigated by immunocytochemical staining with an antibody against  bbbbb2 proliferating cell nuclear antigen eeeee2  (PCNA)
CRP11	The effects of several cyclic adenosine monophosphate ( bbbbb1 cAMP eeeee1 )-elevating agents on the proliferation of cultured rat microglia were investigated by immunocytochemical staining with an antibody against proliferating cell nuclear antigen ( bbbbb2 PCNA eeeee2 )
CRP11	The effects of several  bbbbb1 cyclic adenosine monophosphate eeeee1  (cAMP)-elevating agents on the proliferation of cultured rat microglia were investigated by immunocytochemical staining with an antibody against  bbbbb2 proliferating cell nuclear antigen eeeee2  (PCNA)
CRP11	The effects of several  bbbbb1 cyclic adenosine monophosphate eeeee1  (cAMP)-elevating agents on the proliferation of cultured rat microglia were investigated by immunocytochemical staining with an antibody against proliferating cell nuclear antigen ( bbbbb2 PCNA eeeee2 )
CRP11	Transcription factors, such as the Liver X receptors (LXRs), regulate both cholesterol and  bbbbb1 fatty acid eeeee1  bbbbb2 LXRs eeeee2 ), regulate both cholesterol and fatty acid metabolism in several tissues including the nervous system
CRP11	Transcription factors, such as the Liver X receptors (LXRs), regulate both cholesterol and  bbbbb1 fatty acid eeeee1  bbbbb2 Liver X receptors eeeee2  (LXRs), regulate both cholesterol and fatty acid metabolism in several tissues including the nervous system
CRP11	Transcription factors, such as the Liver X receptors (LXRs), regulate both  bbbbb1 cholesterol eeeee1  bbbbb2 LXRs eeeee2 ), regulate both cholesterol and fatty acid metabolism in several tissues including the nervous system
CRP11	Transcription factors, such as the Liver X receptors (LXRs), regulate both  bbbbb1 cholesterol eeeee1  bbbbb2 Liver X receptors eeeee2  (LXRs), regulate both cholesterol and fatty acid metabolism in several tissues including the nervous system
CRP11	SS rats had lower plasma testosterone concentrations than CTL rats (p=0.05), but did not differ in  bbbbb1 androgen eeeee1  receptor,  bbbbb2 estrogen receptor alpha eeeee2 , or Fos immunoreactive cell counts in the medial preoptic area
CRP11	SS rats had lower plasma testosterone concentrations than CTL rats (p=0.05), but did not differ in  bbbbb1 androgen eeeee1  receptor, estrogen receptor alpha, or  bbbbb2 Fos eeeee2  immunoreactive cell counts in the medial preoptic area
CRP11	SS rats had lower plasma testosterone concentrations than CTL rats (p=0.05), but did not differ in  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2 , estrogen receptor alpha, or Fos immunoreactive cell counts in the medial preoptic area
CRP11	SS rats had lower plasma  bbbbb1 testosterone eeeee1  concentrations than CTL rats (p=0.05), but did not differ in androgen receptor,  bbbbb2 estrogen receptor alpha eeeee2 , or Fos immunoreactive cell counts in the medial preoptic area
CRP11	SS rats had lower plasma  bbbbb1 testosterone eeeee1  concentrations than CTL rats (p=0.05), but did not differ in androgen receptor, estrogen receptor alpha, or  bbbbb2 Fos eeeee2  immunoreactive cell counts in the medial preoptic area
CRP11	SS rats had lower plasma  bbbbb1 testosterone eeeee1  concentrations than CTL rats (p=0.05), but did not differ in  bbbbb2 androgen receptor eeeee2 , estrogen receptor alpha, or Fos immunoreactive cell counts in the medial preoptic area
CRP11	SS rats had lower plasma testosterone concentrations than CTL rats (p=0.05), but did not differ in androgen receptor,  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor alpha eeeee2 , or Fos immunoreactive cell counts in the medial preoptic area
CRP11	SS rats had lower plasma testosterone concentrations than CTL rats (p=0.05), but did not differ in androgen receptor,  bbbbb1 estrogen eeeee1  receptor alpha, or  bbbbb2 Fos eeeee2  immunoreactive cell counts in the medial preoptic area
CRP11	SS rats had lower plasma testosterone concentrations than CTL rats (p=0.05), but did not differ in androgen receptor,  bbbbb1 estrogen eeeee1  bbbbb2 androgen receptor eeeee2 , estrogen receptor alpha, or Fos immunoreactive cell counts in the medial preoptic area
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts 25-hydroxyvitamin D 1-hydroxylase (Cyp27b1) and  bbbbb1 l-pyruvate eeeee1  kinase (Pklr), transcripts involved in tissue cohesion such as  bbbbb2 fibronectin eeeee2  (Fn1) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts 25-hydroxyvitamin D 1-hydroxylase (Cyp27b1) and  bbbbb1 l-pyruvate eeeee1  bbbbb2 Cyp27b1 eeeee2 ) and l-pyruvate kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts 25-hydroxyvitamin D 1-hydroxylase (Cyp27b1) and  bbbbb1 l-pyruvate eeeee1  kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin ( bbbbb2 Fn1 eeeee2 ) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts 25-hydroxyvitamin D 1-hydroxylase (Cyp27b1) and  bbbbb1 l-pyruvate eeeee1  bbbbb2 25-hydroxyvitamin D 1-hydroxylase eeeee2  (Cyp27b1) and l-pyruvate kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts 25-hydroxyvitamin D 1-hydroxylase (Cyp27b1) and  bbbbb1 l-pyruvate eeeee1  kinase ( bbbbb2 Pklr eeeee2 ), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts 25-hydroxyvitamin D 1-hydroxylase (Cyp27b1) and  bbbbb1 l-pyruvate eeeee1  bbbbb2 l-pyruvate kinase eeeee2  (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts 25-hydroxyvitamin D 1-hydroxylase (Cyp27b1) and  bbbbb1 l-pyruvate eeeee1  kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and  bbbbb2 N-cadherin eeeee2  (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts 25-hydroxyvitamin D 1-hydroxylase (Cyp27b1) and  bbbbb1 l-pyruvate eeeee1  kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin ( bbbbb2 Cdh2 eeeee2 ), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts 25-hydroxyvitamin D 1-hydroxylase (Cyp27b1) and  bbbbb1 l-pyruvate eeeee1  kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin (Cdh2), and  bbbbb2 non-muscle-type myosin eeeee2  transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts  bbbbb1 25-hydroxyvitamin D eeeee1  1-hydroxylase (Cyp27b1) and l-pyruvate kinase (Pklr), transcripts involved in tissue cohesion such as  bbbbb2 fibronectin eeeee2  (Fn1) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts  bbbbb1 25-hydroxyvitamin D eeeee1  1-hydroxylase ( bbbbb2 Cyp27b1 eeeee2 ) and l-pyruvate kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts  bbbbb1 25-hydroxyvitamin D eeeee1  1-hydroxylase (Cyp27b1) and l-pyruvate kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin ( bbbbb2 Fn1 eeeee2 ) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts  bbbbb1 25-hydroxyvitamin D eeeee1  bbbbb2 25-hydroxyvitamin D 1-hydroxylase eeeee2  (Cyp27b1) and l-pyruvate kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts  bbbbb1 25-hydroxyvitamin D eeeee1  1-hydroxylase (Cyp27b1) and l-pyruvate kinase ( bbbbb2 Pklr eeeee2 ), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts  bbbbb1 25-hydroxyvitamin D eeeee1  1-hydroxylase (Cyp27b1) and  bbbbb2 l-pyruvate kinase eeeee2  (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts  bbbbb1 25-hydroxyvitamin D eeeee1  1-hydroxylase (Cyp27b1) and l-pyruvate kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and  bbbbb2 N-cadherin eeeee2  (Cdh2), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts  bbbbb1 25-hydroxyvitamin D eeeee1  1-hydroxylase (Cyp27b1) and l-pyruvate kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin ( bbbbb2 Cdh2 eeeee2 ), and non-muscle-type myosin transcripts
CRP11	Normoxia was required for full expression of the proximal tubule-specific transcripts  bbbbb1 25-hydroxyvitamin D eeeee1  1-hydroxylase (Cyp27b1) and l-pyruvate kinase (Pklr), transcripts involved in tissue cohesion such as fibronectin (Fn1) and N-cadherin (Cdh2), and  bbbbb2 non-muscle-type myosin eeeee2  transcripts
CRP11	Conversely, severe hypoxia increased transcripts involved in extracellular matrix remodeling, those of muscle-type myosins, and others involved in creatine  bbbbb1 phosphate eeeee1  synthesis and lactate transport ( bbbbb2 Slc16a7 eeeee2 )
CRP11	Conversely, severe hypoxia increased transcripts involved in extracellular matrix remodeling, those of muscle-type myosins, and others involved in creatine  bbbbb1 phosphate eeeee1  bbbbb2 muscle-type myosins eeeee2 , and others involved in creatine phosphate synthesis and lactate transport (Slc16a7)
CRP11	Cytotoxic 1-methyladenine (1-meA) and 3-methylcytosine ( bbbbb1 3-meC eeeee1 ) lesions induced in DNA and RNA in vitro and in pre-damaged DNA and RNA bacteriophages in vivo are repaired by the Escherichia coli (E. coli) protein AlkB and a  bbbbb2 human homolog, ALKBH3 eeeee2 
CRP11	Cytotoxic 1-methyladenine (1-meA) and 3-methylcytosine ( bbbbb1 3-meC eeeee1 ) lesions induced in DNA and RNA in vitro and in pre-damaged DNA and RNA bacteriophages in vivo are repaired by the  bbbbb2 Escherichia coli (E. coli) protein AlkB eeeee2  and a human homolog, ALKBH3
CRP11	Cytotoxic 1-methyladenine (1-meA) and  bbbbb1 3-methylcytosine eeeee1  (3-meC) lesions induced in DNA and RNA in vitro and in pre-damaged DNA and RNA bacteriophages in vivo are repaired by the Escherichia coli (E. coli) protein AlkB and a  bbbbb2 human homolog, ALKBH3 eeeee2 
CRP11	Cytotoxic 1-methyladenine (1-meA) and  bbbbb1 3-methylcytosine eeeee1  (3-meC) lesions induced in DNA and RNA in vitro and in pre-damaged DNA and RNA bacteriophages in vivo are repaired by the  bbbbb2 Escherichia coli (E. coli) protein AlkB eeeee2  and a human homolog, ALKBH3
CRP11	Cytotoxic 1-methyladenine ( bbbbb1 1-meA eeeee1 ) and 3-methylcytosine (3-meC) lesions induced in DNA and RNA in vitro and in pre-damaged DNA and RNA bacteriophages in vivo are repaired by the Escherichia coli (E. coli) protein AlkB and a  bbbbb2 human homolog, ALKBH3 eeeee2 
CRP11	Cytotoxic 1-methyladenine ( bbbbb1 1-meA eeeee1 ) and 3-methylcytosine (3-meC) lesions induced in DNA and RNA in vitro and in pre-damaged DNA and RNA bacteriophages in vivo are repaired by the  bbbbb2 Escherichia coli (E. coli) protein AlkB eeeee2  and a human homolog, ALKBH3
CRP11	Cytotoxic  bbbbb1 1-methyladenine eeeee1  (1-meA) and 3-methylcytosine (3-meC) lesions induced in DNA and RNA in vitro and in pre-damaged DNA and RNA bacteriophages in vivo are repaired by the Escherichia coli (E. coli) protein AlkB and a  bbbbb2 human homolog, ALKBH3 eeeee2 
CRP11	Cytotoxic  bbbbb1 1-methyladenine eeeee1  (1-meA) and 3-methylcytosine (3-meC) lesions induced in DNA and RNA in vitro and in pre-damaged DNA and RNA bacteriophages in vivo are repaired by the  bbbbb2 Escherichia coli (E. coli) protein AlkB eeeee2  and a human homolog, ALKBH3
CRP11	Here, we demonstrate AlkB-mediated repair of endogenous RNA in vivo by measuring differences in lesion-accumulation in two independent AlkB-proficient and deficient E. coli strains during exposure to methyl methanesulfonate ( bbbbb1 MMS eeeee1  bbbbb2 AlkB eeeee2 -mediated repair of endogenous RNA in vivo by measuring differences in lesion-accumulation in two independent AlkB-proficient and deficient E. coli strains during exposure to methyl methanesulfonate (MMS)
CRP11	Here, we demonstrate AlkB-mediated repair of endogenous RNA in vivo by measuring differences in lesion-accumulation in two independent AlkB-proficient and deficient E. coli strains during exposure to methyl methanesulfonate ( bbbbb1 MMS eeeee1  bbbbb2 AlkB eeeee2 -proficient and deficient E. coli strains during exposure to methyl methanesulfonate (MMS)
CRP11	Here, we demonstrate AlkB-mediated repair of endogenous RNA in vivo by measuring differences in lesion-accumulation in two independent AlkB-proficient and deficient E. coli strains during exposure to  bbbbb1 methyl methanesulfonate eeeee1  bbbbb2 AlkB eeeee2 -mediated repair of endogenous RNA in vivo by measuring differences in lesion-accumulation in two independent AlkB-proficient and deficient E. coli strains during exposure to methyl methanesulfonate (MMS)
CRP11	Here, we demonstrate AlkB-mediated repair of endogenous RNA in vivo by measuring differences in lesion-accumulation in two independent AlkB-proficient and deficient E. coli strains during exposure to  bbbbb1 methyl methanesulfonate eeeee1  bbbbb2 AlkB eeeee2 -proficient and deficient E. coli strains during exposure to methyl methanesulfonate (MMS)
CRP11	The results showed that  bbbbb1 Pb(2+) eeeee1  increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an  bbbbb2 inositol-1,4,5-triphosphate receptor eeeee2  (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that  bbbbb1 Pb(2+) eeeee1  increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a  bbbbb2 ryanodine receptor eeeee2  (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that  bbbbb1 Pb(2+) eeeee1  increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor ( bbbbb2 RyR eeeee2 ) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that  bbbbb1 Pb(2+) eeeee1  increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an inositol-1,4,5-triphosphate receptor ( bbbbb2 IP(3)R eeeee2 ) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [ bbbbb1 Ca(2+) eeeee1 ](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an  bbbbb2 inositol-1,4,5-triphosphate receptor eeeee2  (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [ bbbbb1 Ca(2+) eeeee1 ](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a  bbbbb2 ryanodine receptor eeeee2  (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [ bbbbb1 Ca(2+) eeeee1 ](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor ( bbbbb2 RyR eeeee2 ) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [ bbbbb1 Ca(2+) eeeee1 ](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an inositol-1,4,5-triphosphate receptor ( bbbbb2 IP(3)R eeeee2 ) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an  bbbbb1 inositol-1,4,5-triphosphate eeeee1  bbbbb2 inositol-1,4,5-triphosphate receptor eeeee2  (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an  bbbbb1 inositol-1,4,5-triphosphate eeeee1  bbbbb2 ryanodine receptor eeeee2  (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an  bbbbb1 inositol-1,4,5-triphosphate eeeee1  bbbbb2 RyR eeeee2 ) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an  bbbbb1 inositol-1,4,5-triphosphate eeeee1  receptor ( bbbbb2 IP(3)R eeeee2 ) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [ bbbbb1 Ca(2+) eeeee1 ](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an  bbbbb2 inositol-1,4,5-triphosphate receptor eeeee2  (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [ bbbbb1 Ca(2+) eeeee1 ](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a  bbbbb2 ryanodine receptor eeeee2  (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [ bbbbb1 Ca(2+) eeeee1 ](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor ( bbbbb2 RyR eeeee2 ) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [ bbbbb1 Ca(2+) eeeee1 ](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an inositol-1,4,5-triphosphate receptor ( bbbbb2 IP(3)R eeeee2 ) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and  bbbbb1 Pb(2+) eeeee1  addition after the applying of a ryanodine receptor (RyR) antagonist and an  bbbbb2 inositol-1,4,5-triphosphate receptor eeeee2  (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and  bbbbb1 Pb(2+) eeeee1  addition after the applying of a  bbbbb2 ryanodine receptor eeeee2  (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and  bbbbb1 Pb(2+) eeeee1  addition after the applying of a ryanodine receptor ( bbbbb2 RyR eeeee2 ) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and  bbbbb1 Pb(2+) eeeee1  addition after the applying of a ryanodine receptor (RyR) antagonist and an inositol-1,4,5-triphosphate receptor ( bbbbb2 IP(3)R eeeee2 ) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a  bbbbb1 ryanodine eeeee1  receptor (RyR) antagonist and an  bbbbb2 inositol-1,4,5-triphosphate receptor eeeee2  (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a  bbbbb1 ryanodine eeeee1  bbbbb2 ryanodine receptor eeeee2  (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a  bbbbb1 ryanodine eeeee1  receptor ( bbbbb2 RyR eeeee2 ) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a  bbbbb1 ryanodine eeeee1  receptor (RyR) antagonist and an inositol-1,4,5-triphosphate receptor ( bbbbb2 IP(3)R eeeee2 ) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [ bbbbb1 Ca(2+) eeeee1  bbbbb2 inositol-1,4,5-triphosphate receptor eeeee2  (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [ bbbbb1 Ca(2+) eeeee1  bbbbb2 ryanodine receptor eeeee2  (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [ bbbbb1 Ca(2+) eeeee1  bbbbb2 RyR eeeee2 ) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [Ca(2+)](i)
CRP11	The results showed that Pb(2+) increased [Ca(2+)](i) and decreased [Ca(2+)](ER) linearly in a time- and concentration-dependant manner, and Pb(2+) addition after the applying of a ryanodine receptor (RyR) antagonist and an inositol-1,4,5-triphosphate receptor (IP(3)R) antagonist did not increase [ bbbbb1 Ca(2+) eeeee1  bbbbb2 IP(3)R eeeee2 ) antagonist did not increase [Ca(2+)](i)
CRP11	Inbred mouse strains display significant differences in their levels of brain alpha7 nicotinic  bbbbb1 acetylcholine eeeee1  receptor ( bbbbb2 alpha7 nAChR eeeee2 ) expression, as measured by binding of the alpha7-selective antagonist alpha-bungarotoxin
CRP11	Inbred mouse strains display significant differences in their levels of brain alpha7 nicotinic  bbbbb1 acetylcholine eeeee1  bbbbb2 alpha7 nicotinic acetylcholine receptor eeeee2  (alpha7 nAChR) expression, as measured by binding of the alpha7-selective antagonist alpha-bungarotoxin
CRP11	Variations in alpha-bungarotoxin binding have been shown to correlate with an animal's sensitivity to  bbbbb1 nicotine eeeee1  bbbbb2 alpha-bungarotoxin eeeee2  binding have been shown to correlate with an animal's sensitivity to nicotine-induced seizures and sensory gating
CRP11	The trypsin-like  bbbbb1 serine eeeee1  bbbbb2 serine protease eeeee2  plasmin is a target for the development of antifibrinolytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to reduce excessive blood loss
CRP11	The trypsin-like  bbbbb1 serine eeeee1  bbbbb2 trypsin eeeee2 -like serine protease plasmin is a target for the development of antifibrinolytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to reduce excessive blood loss
CRP11	The trypsin-like  bbbbb1 serine eeeee1  protease  bbbbb2 plasmin eeeee2  is a target for the development of antifibrinolytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to reduce excessive blood loss
CRP11	The most potent inhibitor 8 binds to plasmin with an inhibition constant of 0.2 nM, whereas K(i) values >1 μM were determined for nearly all other tested trypsin-like  bbbbb1 serine eeeee1  bbbbb2 trypsin-like serine proteases eeeee2 , with the exception of trypsin, which is also inhibited in the nanomolar range
CRP11	The most potent inhibitor 8 binds to plasmin with an inhibition constant of 0.2 nM, whereas K(i) values >1 μM were determined for nearly all other tested trypsin-like  bbbbb1 serine eeeee1  bbbbb2 plasmin eeeee2  with an inhibition constant of 0.2 nM, whereas K(i) values >1 μM were determined for nearly all other tested trypsin-like serine proteases, with the exception of trypsin, which is also inhibited in the nanomolar range
CRP11	The most potent inhibitor 8 binds to plasmin with an inhibition constant of 0.2 nM, whereas K(i) values >1 μM were determined for nearly all other tested trypsin-like  bbbbb1 serine eeeee1  proteases, with the exception of  bbbbb2 trypsin eeeee2 , which is also inhibited in the nanomolar range
CRP11	Association of  bbbbb1 ATP eeeee1  bbbbb2 ATP-binding cassette transporter eeeee2  variants with the risk of Alzheimer's disease
CRP11	In obese db/db mice, SBE treatment also reduced plasma  bbbbb1 alanine eeeee1  bbbbb2 alanine aminotransferase eeeee2  levels
CRP11	As a first step in this process, we have characterized the DNA-binding specificities of 129  bbbbb1 zinc eeeee1  bbbbb2 zinc finger eeeee2  sets from Drosophila using a bacterial one-hybrid system
CRP11	Global analysis of Drosophila  bbbbb1 Cys eeeee1  bbbbb2 Drosophila Cys2-His2 zinc finger proteins eeeee2  reveals a multitude of novel recognition motifs and binding determinants
CRP11	Global analysis of Drosophila Cys2-His2  bbbbb1 zinc eeeee1  bbbbb2 Drosophila Cys2-His2 zinc finger proteins eeeee2  reveals a multitude of novel recognition motifs and binding determinants
CRP11	Global analysis of Drosophila Cys2- bbbbb1 His eeeee1  bbbbb2 Drosophila Cys2-His2 zinc finger proteins eeeee2  reveals a multitude of novel recognition motifs and binding determinants
CRP11	To confirm the utility of our finger recognition models, we employed subsets of D bbbbb1 roso eeeee1  bbbbb2 rosophila fingers in  eeeee2 combination with an existing archive of artificial zinc finger modules to create ZFPs with novel DNA-binding specificity
CRP11	Cys2-His2  bbbbb1 zinc eeeee1  finger proteins ( bbbbb2 ZFPs eeeee2 ) are the largest group of transcription factors in higher metazoans
CRP11	Cys2-His2  bbbbb1 zinc eeeee1  bbbbb2 Cys2-His2 zinc finger proteins eeeee2  (ZFPs) are the largest group of transcription factors in higher metazoans
CRP11	Diffusion did not vary significantly with pH but doubled when temperature rose from 10°C to 37°C bbbbb1  eeeee1  bbbbb2  when temperature ro eeeee2 se from 10°C to 37°C
CRP11	 bbbbb1 Ornithine eeeee1  bbbbb2 Ornithine decarboxylase eeeee2  (ODC) mRNAs were localized by in situ hybridization
CRP11	 bbbbb1 Ornithine eeeee1  decarboxylase ( bbbbb2 ODC eeeee2 ) mRNAs were localized by in situ hybridization
CRP11	In the kidney,  bbbbb1 L-ornithine eeeee1  is reabsorbed along the proximal convoluted tubule (PCT), transported by basolateral carriers, and produced by arginase II ( bbbbb2 AII eeeee2 )
CRP11	In the kidney,  bbbbb1 L-ornithine eeeee1  is reabsorbed along the proximal convoluted tubule (PCT), transported by basolateral carriers, and produced by  bbbbb2 arginase II eeeee2  (AII)
CRP11	Because OAT and AII proteins overlapped in PST mitochondria, L-arginine-derived  bbbbb1 ornithine eeeee1  bbbbb2 OAT eeeee2  and AII proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by ornithine oxidation
CRP11	Because OAT and AII proteins overlapped in PST mitochondria, L-arginine-derived  bbbbb1 ornithine eeeee1  bbbbb2 AII eeeee2  proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by ornithine oxidation
CRP11	Because OAT and AII proteins overlapped in PST mitochondria,  bbbbb1 L-arginine eeeee1  bbbbb2 OAT eeeee2  and AII proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by ornithine oxidation
CRP11	Because OAT and AII proteins overlapped in PST mitochondria,  bbbbb1 L-arginine eeeee1  bbbbb2 AII eeeee2  proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by ornithine oxidation
CRP11	Because OAT and AII proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by  bbbbb1 ornithine eeeee1  bbbbb2 OAT eeeee2  and AII proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by ornithine oxidation
CRP11	Because OAT and AII proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by  bbbbb1 ornithine eeeee1  bbbbb2 AII eeeee2  proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by ornithine oxidation
CRP11	Because OAT and AII proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to  bbbbb1 L-glutamate eeeee1  bbbbb2 OAT eeeee2  and AII proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by ornithine oxidation
CRP11	Because OAT and AII proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to  bbbbb1 L-glutamate eeeee1  bbbbb2 AII eeeee2  proteins overlapped in PST mitochondria, L-arginine-derived ornithine may be preferentially converted to L-glutamate, as proven by ornithine oxidation
CRP11	Ornithine metabolism in male and female rat kidney: mitochondrial expression of  bbbbb1 ornithine eeeee1  bbbbb2 ornithine aminotransferase eeeee2  and arginase II
CRP11	Ornithine metabolism in male and female rat kidney: mitochondrial expression of  bbbbb1 ornithine eeeee1  aminotransferase and  bbbbb2 arginase II eeeee2 
CRP11	 bbbbb1 Ornithine eeeee1  metabolism in male and female rat kidney: mitochondrial expression of  bbbbb2 ornithine aminotransferase eeeee2  and arginase II
CRP11	 bbbbb1 Ornithine eeeee1  metabolism in male and female rat kidney: mitochondrial expression of ornithine aminotransferase and  bbbbb2 arginase II eeeee2 
CRP11	 bbbbb1 Ornithine eeeee1  bbbbb2 Ornithine aminotransferase eeeee2  (OAT) and AII were localized using specific antibodies
CRP11	 bbbbb1 Ornithine eeeee1  aminotransferase (OAT) and  bbbbb2 AII eeeee2  were localized using specific antibodies
CRP11	 bbbbb1 Ornithine eeeee1  aminotransferase ( bbbbb2 OAT eeeee2 ) and AII were localized using specific antibodies
CRP11	To evaluate analgesic effects of CRH via release of POMC derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after  bbbbb1 naloxone eeeee1  bbbbb2 beta-END eeeee2 -immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after naloxone (or placebo) administration which was administered 40 min after CRH (or placebo) injection
CRP11	To evaluate analgesic effects of CRH via release of POMC derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after  bbbbb1 naloxone eeeee1  bbbbb2 CRH eeeee2  (or placebo), and 5 min after naloxone (or placebo) administration which was administered 40 min after CRH (or placebo) injection
CRP11	To evaluate analgesic effects of CRH via release of POMC derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after  bbbbb1 naloxone eeeee1  bbbbb2 POMC eeeee2  derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after naloxone (or placebo) administration which was administered 40 min after CRH (or placebo) injection
CRP11	To evaluate analgesic effects of CRH via release of POMC derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after  bbbbb1 naloxone eeeee1  bbbbb2 beta-LPH eeeee2  IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after naloxone (or placebo) administration which was administered 40 min after CRH (or placebo) injection
CRP11	To evaluate analgesic effects of CRH via release of POMC derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after  bbbbb1 naloxone eeeee1  bbbbb2 beta-END eeeee2  (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after naloxone (or placebo) administration which was administered 40 min after CRH (or placebo) injection
CRP11	To evaluate analgesic effects of CRH via release of POMC derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after  bbbbb1 naloxone eeeee1  (or placebo) administration which was administered 40 min after  bbbbb2 CRH eeeee2  (or placebo) injection
CRP11	To evaluate analgesic effects of CRH via release of POMC derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after  bbbbb1 naloxone eeeee1  bbbbb2 beta-END(1-31) eeeee2 ) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after naloxone (or placebo) administration which was administered 40 min after CRH (or placebo) injection
CRP11	To evaluate analgesic effects of CRH via release of POMC derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after  bbbbb1 naloxone eeeee1  bbbbb2 CRH eeeee2  via release of POMC derivatives, we determined plasma concentrations of beta-END-immunoreactive material (IRM), authentic beta-END (beta-END(1-31)) and beta-LPH IRM, in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with CRH (or placebo), and 5 min after naloxone (or placebo) administration which was administered 40 min after CRH (or placebo) injection
CRP11	In 16 healthy volunteers we studied the effects of 100 microg intravenously administered CRH in absence or presence of 12 mg  bbbbb1 naloxone eeeee1  bbbbb2 CRH eeeee2  in absence or presence of 12 mg naloxone on heat or pressure pain sensitivity, using a double-blind, cross-over and placebo-controlled design
CRP11	Furthermore, CRH did not induce increases of heat pain tolerance thresholds, but of pressure pain tolerance thresholds, which, however, were not reversible by  bbbbb1 naloxone eeeee1  bbbbb2 CRH eeeee2  did not induce increases of heat pain tolerance thresholds, but of pressure pain tolerance thresholds, which, however, were not reversible by naloxone
CRP11	RAb-003, a fully humanized monoclonal antibody against the  bbbbb1 folate eeeee1  bbbbb2 folate receptor alpha eeeee2 , for the potential treatment of epithelial ovarian cancer
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of histidine- bbbbb1 lysine eeeee1  (HK):siRNA nanoplexes modified with PEG and a cyclic RGD (cRGD) ligand targeting  bbbbb2 αvβ3 eeeee2  and αvβ5 integrins
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of histidine- bbbbb1 lysine eeeee1  (HK):siRNA nanoplexes modified with PEG and a cyclic  bbbbb2 RGD eeeee2  (cRGD) ligand targeting αvβ3 and αvβ5 integrins
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of histidine- bbbbb1 lysine eeeee1  (HK):siRNA nanoplexes modified with PEG and a cyclic RGD ( bbbbb2 cRGD eeeee2 ) ligand targeting αvβ3 and αvβ5 integrins
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of histidine- bbbbb1 lysine eeeee1  (HK):siRNA nanoplexes modified with PEG and a cyclic RGD (cRGD) ligand targeting αvβ3 and  bbbbb2 αvβ5 integrins eeeee2 
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of histidine-lysine (HK):siRNA nanoplexes modified with  bbbbb1 PEG eeeee1  and a cyclic RGD (cRGD) ligand targeting  bbbbb2 αvβ3 eeeee2  and αvβ5 integrins
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of histidine-lysine (HK):siRNA nanoplexes modified with  bbbbb1 PEG eeeee1  and a cyclic  bbbbb2 RGD eeeee2  (cRGD) ligand targeting αvβ3 and αvβ5 integrins
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of histidine-lysine (HK):siRNA nanoplexes modified with  bbbbb1 PEG eeeee1  and a cyclic RGD ( bbbbb2 cRGD eeeee2 ) ligand targeting αvβ3 and αvβ5 integrins
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of histidine-lysine (HK):siRNA nanoplexes modified with  bbbbb1 PEG eeeee1  and a cyclic RGD (cRGD) ligand targeting αvβ3 and  bbbbb2 αvβ5 integrins eeeee2 
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of  bbbbb1 histidine eeeee1 -lysine (HK):siRNA nanoplexes modified with PEG and a cyclic RGD (cRGD) ligand targeting  bbbbb2 αvβ3 eeeee2  and αvβ5 integrins
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of  bbbbb1 histidine eeeee1 -lysine (HK):siRNA nanoplexes modified with PEG and a cyclic  bbbbb2 RGD eeeee2  (cRGD) ligand targeting αvβ3 and αvβ5 integrins
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of  bbbbb1 histidine eeeee1 -lysine (HK):siRNA nanoplexes modified with PEG and a cyclic RGD ( bbbbb2 cRGD eeeee2 ) ligand targeting αvβ3 and αvβ5 integrins
CRP11	We characterized in this study the pharmacokinetics and antitumor efficacy of  bbbbb1 histidine eeeee1 -lysine (HK):siRNA nanoplexes modified with PEG and a cyclic RGD (cRGD) ligand targeting αvβ3 and  bbbbb2 αvβ5 integrins eeeee2 
CRP11	The expression of mRNA for NF-κB,  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  subunits p22phox and p47phox in renal tissue was examined by realtime PCR
CRP11	The expression of mRNA for NF-κB,  bbbbb1 NADPH eeeee1  oxidase subunits p22phox and  bbbbb2 p47phox eeeee2  in renal tissue was examined by realtime PCR
CRP11	The expression of mRNA for NF-κB,  bbbbb1 NADPH eeeee1  oxidase subunits  bbbbb2 p22phox eeeee2  and p47phox in renal tissue was examined by realtime PCR
CRP11	The expression of mRNA for NF-κB,  bbbbb1 NADPH eeeee1  bbbbb2 NF-κB eeeee2 , NADPH oxidase subunits p22phox and p47phox in renal tissue was examined by realtime PCR
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in  bbbbb1 GSH eeeee1  bbbbb2 p22phox eeeee2  and p47phox, and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in  bbbbb1 GSH eeeee1  bbbbb2 NF-κB eeeee2 , p22phox and p47phox, and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in  bbbbb1 GSH eeeee1  bbbbb2 p47phox eeeee2 , and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in  bbbbb1 GSH eeeee1 ,  bbbbb2 SOD eeeee2 , vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion,  bbbbb1 MDA eeeee1  levels and the expression of mRNA of NF-κB,  bbbbb2 p22phox eeeee2  and p47phox, and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion,  bbbbb1 MDA eeeee1  levels and the expression of mRNA of  bbbbb2 NF-κB eeeee2 , p22phox and p47phox, and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion,  bbbbb1 MDA eeeee1  levels and the expression of mRNA of NF-κB, p22phox and  bbbbb2 p47phox eeeee2 , and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion,  bbbbb1 MDA eeeee1  levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH,  bbbbb2 SOD eeeee2 , vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH, SOD, vitamin C and  bbbbb1 vitamin E eeeee1  bbbbb2 p22phox eeeee2  and p47phox, and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH, SOD, vitamin C and  bbbbb1 vitamin E eeeee1  bbbbb2 NF-κB eeeee2 , p22phox and p47phox, and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH, SOD, vitamin C and  bbbbb1 vitamin E eeeee1  bbbbb2 p47phox eeeee2 , and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH, SOD, vitamin C and  bbbbb1 vitamin E eeeee1  bbbbb2 SOD eeeee2 , vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH, SOD,  bbbbb1 vitamin C eeeee1  bbbbb2 p22phox eeeee2  and p47phox, and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH, SOD,  bbbbb1 vitamin C eeeee1  bbbbb2 NF-κB eeeee2 , p22phox and p47phox, and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH, SOD,  bbbbb1 vitamin C eeeee1  bbbbb2 p47phox eeeee2 , and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH, SOD,  bbbbb1 vitamin C eeeee1  bbbbb2 SOD eeeee2 , vitamin C and vitamin E levels in the diabetic control group compared with the normal control group
CRP11	 bbbbb1 Malonaldehyde eeeee1  (MDA), ascorbic acid (vitamin C), vitamin E, glutathione (GSH) and superoxide dismutase ( bbbbb2 SOD eeeee2 ) levels in renal homogenate, and urine protein excretion were measured
CRP11	 bbbbb1 Malonaldehyde eeeee1  (MDA), ascorbic acid (vitamin C), vitamin E, glutathione (GSH) and  bbbbb2 superoxide dismutase eeeee2  (SOD) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA), ascorbic acid (vitamin C), vitamin E, glutathione (GSH) and  bbbbb1 superoxide eeeee1  dismutase ( bbbbb2 SOD eeeee2 ) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA), ascorbic acid (vitamin C), vitamin E, glutathione (GSH) and  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA), ascorbic acid ( bbbbb1 vitamin C eeeee1 ), vitamin E, glutathione (GSH) and superoxide dismutase ( bbbbb2 SOD eeeee2 ) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA), ascorbic acid ( bbbbb1 vitamin C eeeee1 ), vitamin E, glutathione (GSH) and  bbbbb2 superoxide dismutase eeeee2  (SOD) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA),  bbbbb1 ascorbic acid eeeee1  (vitamin C), vitamin E, glutathione (GSH) and superoxide dismutase ( bbbbb2 SOD eeeee2 ) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA),  bbbbb1 ascorbic acid eeeee1  (vitamin C), vitamin E, glutathione (GSH) and  bbbbb2 superoxide dismutase eeeee2  (SOD) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde ( bbbbb1 MDA eeeee1 ), ascorbic acid (vitamin C), vitamin E, glutathione (GSH) and superoxide dismutase ( bbbbb2 SOD eeeee2 ) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde ( bbbbb1 MDA eeeee1 ), ascorbic acid (vitamin C), vitamin E, glutathione (GSH) and  bbbbb2 superoxide dismutase eeeee2  (SOD) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA), ascorbic acid (vitamin C),  bbbbb1 vitamin E eeeee1 , glutathione (GSH) and superoxide dismutase ( bbbbb2 SOD eeeee2 ) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA), ascorbic acid (vitamin C),  bbbbb1 vitamin E eeeee1 , glutathione (GSH) and  bbbbb2 superoxide dismutase eeeee2  (SOD) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA), ascorbic acid (vitamin C), vitamin E,  bbbbb1 glutathione eeeee1  (GSH) and superoxide dismutase ( bbbbb2 SOD eeeee2 ) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA), ascorbic acid (vitamin C), vitamin E,  bbbbb1 glutathione eeeee1  (GSH) and  bbbbb2 superoxide dismutase eeeee2  (SOD) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA), ascorbic acid (vitamin C), vitamin E, glutathione ( bbbbb1 GSH eeeee1 ) and superoxide dismutase ( bbbbb2 SOD eeeee2 ) levels in renal homogenate, and urine protein excretion were measured
CRP11	Malonaldehyde (MDA), ascorbic acid (vitamin C), vitamin E, glutathione ( bbbbb1 GSH eeeee1 ) and  bbbbb2 superoxide dismutase eeeee2  (SOD) levels in renal homogenate, and urine protein excretion were measured
CRP11	Catalase activity was significantly higher in survivors (238.8±51.5) than non-survivors (166.4±40.2; p=0.005), while protein  bbbbb1 carbonyls eeeee1  bbbbb2 Catalase eeeee2  activity was significantly higher in survivors (238.8±51.5) than non-survivors (166.4±40.2; p=0.005), while protein carbonyls levels were significantly lower in survivors (0.32±0.09) than non-survivors (0.48±0.16; p=0.036) on the 1stday
CRP11	However, genome-wide studies reveal that  bbbbb1 steroid eeeee1  bbbbb2 steroid receptors-binding sites eeeee2  are mainly located at intragenic regions
CRP11	To determine the role of these sites, we examined the effect of progestins on the transcription of the bcl-x gene, where only intragenic  bbbbb1 progesterone eeeee1  bbbbb2 bcl-x eeeee2  gene, where only intragenic progesterone receptor-binding sites (PRbs) were identified
CRP11	To determine the role of these sites, we examined the effect of progestins on the transcription of the bcl-x gene, where only intragenic  bbbbb1 progesterone eeeee1  bbbbb2 intragenic progesterone receptor-binding sites eeeee2  (PRbs) were identified
CRP11	To determine the role of these sites, we examined the effect of progestins on the transcription of the bcl-x gene, where only intragenic  bbbbb1 progesterone eeeee1  receptor-binding sites ( bbbbb2 PRbs eeeee2 ) were identified
CRP11	 bbbbb1 Progesterone eeeee1  receptor induces bcl-x expression through intragenic binding sites favoring  bbbbb2 RNA polymerase II eeeee2  elongation
CRP11	 bbbbb1 Progesterone eeeee1  receptor induces bcl-x expression through  bbbbb2 intragenic binding sites eeeee2  favoring RNA polymerase II elongation
CRP11	 bbbbb1 Progesterone eeeee1  bbbbb2 Progesterone receptor eeeee2  induces bcl-x expression through intragenic binding sites favoring RNA polymerase II elongation
CRP11	 bbbbb1 Progesterone eeeee1  receptor induces  bbbbb2 bcl-x eeeee2  expression through intragenic binding sites favoring RNA polymerase II elongation
CRP11	 bbbbb1 Steroid eeeee1  bbbbb2 Steroid receptors eeeee2  were classically described for regulating transcription by binding to target gene promoters
CRP11	Steroidal and nonsteroidal  bbbbb1 progesterone eeeee1  bbbbb2 progesterone receptor eeeee2  (PR) agonists have been synthesized as well, although the latter are still in a very early stage of development
CRP11	Steroidal and nonsteroidal  bbbbb1 progesterone eeeee1  receptor ( bbbbb2 PR eeeee2 ) agonists have been synthesized as well, although the latter are still in a very early stage of development
CRP11	 bbbbb1 Steroidal eeeee1  and nonsteroidal  bbbbb2 progesterone receptor eeeee2  (PR) agonists have been synthesized as well, although the latter are still in a very early stage of development
CRP11	 bbbbb1 Steroidal eeeee1  and nonsteroidal progesterone receptor ( bbbbb2 PR eeeee2 ) agonists have been synthesized as well, although the latter are still in a very early stage of development
CRP11	However, phospho-p38 mitogen-activated protein kinase (p-p38 MAPK) and phospho-c-Jun  bbbbb1 amino eeeee1  bbbbb2 mitogen-activated protein kinase eeeee2  (p-p38 MAPK) and phospho-c-Jun amino-terminal kinase (p-JNK) expression increased at 8-24 h
CRP11	However, phospho-p38 mitogen-activated protein kinase (p-p38 MAPK) and phospho-c-Jun  bbbbb1 amino eeeee1  bbbbb2 phospho-c-Jun amino-terminal kinase eeeee2  (p-JNK) expression increased at 8-24 h
CRP11	However, phospho-p38 mitogen-activated protein kinase (p-p38 MAPK) and phospho-c-Jun  bbbbb1 amino eeeee1  bbbbb2 phospho-p38 eeeee2  mitogen-activated protein kinase (p-p38 MAPK) and phospho-c-Jun amino-terminal kinase (p-JNK) expression increased at 8-24 h
CRP11	However, phospho-p38 mitogen-activated protein kinase (p-p38 MAPK) and phospho-c-Jun  bbbbb1 amino eeeee1  bbbbb2 p-p38 eeeee2  MAPK) and phospho-c-Jun amino-terminal kinase (p-JNK) expression increased at 8-24 h
CRP11	However, phospho-p38 mitogen-activated protein kinase (p-p38 MAPK) and phospho-c-Jun  bbbbb1 amino eeeee1  bbbbb2 MAPK eeeee2 ) and phospho-c-Jun amino-terminal kinase (p-JNK) expression increased at 8-24 h
CRP11	However, phospho-p38 mitogen-activated protein kinase (p-p38 MAPK) and phospho-c-Jun  bbbbb1 amino eeeee1 -terminal kinase ( bbbbb2 p-JNK eeeee2 ) expression increased at 8-24 h
CRP11	ECH-induced apoptotic changes were evaluated by terminal deoxynucleotidyl transferase  bbbbb1 dUTP eeeee1  bbbbb2 terminal deoxynucleotidyl transferase eeeee2  dUTP nick end labeling (TUNEL) assay and its related mechanism was confirmed by Western blot analysis and colorimetric assay
CRP11	 bbbbb1 ECH eeeee1 -induced apoptotic changes were evaluated by  bbbbb2 terminal deoxynucleotidyl transferase eeeee2  dUTP nick end labeling (TUNEL) assay and its related mechanism was confirmed by Western blot analysis and colorimetric assay
CRP11	The 90% CI for the AUC0-t ratio of omeprazole but not for omeprazole/5-OH-omeprazole plasma ratio 3 hours post-dose or omeprazole/ bbbbb1 5-OH-omeprazole eeeee1  AUC0-t ratio (secondary  bbbbb2 CYP2C19 eeeee2  metrics) was above the predefined threshold of 1.43, probably caused by the inherent high variability of omeprazole pharmacokinetics
CRP11	The 90% CI for the AUC0-t ratio of omeprazole but not for omeprazole/ bbbbb1 5-OH-omeprazole eeeee1  plasma ratio 3 hours post-dose or omeprazole/5-OH-omeprazole AUC0-t ratio (secondary  bbbbb2 CYP2C19 eeeee2  metrics) was above the predefined threshold of 1.43, probably caused by the inherent high variability of omeprazole pharmacokinetics
CRP11	The 90% CI for the AUC0-t ratio of omeprazole but not for omeprazole/5-OH-omeprazole plasma ratio 3 hours post-dose or omeprazole/5-OH-omeprazole AUC0-t ratio (secondary CYP2C19 metrics) was above the predefined threshold of 1.43, probably caused by the inherent high variability of  bbbbb1 omeprazole eeeee1  bbbbb2 CYP2C19 eeeee2  metrics) was above the predefined threshold of 1.43, probably caused by the inherent high variability of omeprazole pharmacokinetics
CRP11	The 90% CI for the AUC0-t ratio of  bbbbb1 omeprazole eeeee1  but not for omeprazole/5-OH-omeprazole plasma ratio 3 hours post-dose or omeprazole/5-OH-omeprazole AUC0-t ratio (secondary  bbbbb2 CYP2C19 eeeee2  metrics) was above the predefined threshold of 1.43, probably caused by the inherent high variability of omeprazole pharmacokinetics
CRP11	The 90% CI for the AUC0-t ratio of omeprazole but not for omeprazole/5-OH-omeprazole plasma ratio 3 hours post-dose or  bbbbb1 omeprazole eeeee1 /5-OH-omeprazole AUC0-t ratio (secondary  bbbbb2 CYP2C19 eeeee2  metrics) was above the predefined threshold of 1.43, probably caused by the inherent high variability of omeprazole pharmacokinetics
CRP11	The 90% CI for the AUC0-t ratio of omeprazole but not for  bbbbb1 omeprazole eeeee1 /5-OH-omeprazole plasma ratio 3 hours post-dose or omeprazole/5-OH-omeprazole AUC0-t ratio (secondary  bbbbb2 CYP2C19 eeeee2  metrics) was above the predefined threshold of 1.43, probably caused by the inherent high variability of omeprazole pharmacokinetics
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg  bbbbb1 tolbutamide eeeee1  ( bbbbb2 CYP2C9 eeeee2 ), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg  bbbbb1 tolbutamide eeeee1  (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam ( bbbbb2 CYP3A4 eeeee2 ) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg  bbbbb1 tolbutamide eeeee1  bbbbb2 CYP1A2 eeeee2 ), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg  bbbbb1 tolbutamide eeeee1  (CYP2C9), 20 mg omeprazole ( bbbbb2 CYP2C19 eeeee2 ), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg  bbbbb1 tolbutamide eeeee1  (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr ( bbbbb2 CYP2D6 eeeee2 ), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg  bbbbb1 caffeine eeeee1  (CYP1A2), 125 mg tolbutamide ( bbbbb2 CYP2C9 eeeee2 ), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg  bbbbb1 caffeine eeeee1  (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam ( bbbbb2 CYP3A4 eeeee2 ) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg  bbbbb1 caffeine eeeee1  ( bbbbb2 CYP1A2 eeeee2 ), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg  bbbbb1 caffeine eeeee1  (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole ( bbbbb2 CYP2C19 eeeee2 ), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg  bbbbb1 caffeine eeeee1  (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr ( bbbbb2 CYP2D6 eeeee2 ), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg  bbbbb1 dextromethorphan-HBr eeeee1  bbbbb2 CYP2C9 eeeee2 ), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg  bbbbb1 dextromethorphan-HBr eeeee1  (CYP2D6), and 2 mg midazolam ( bbbbb2 CYP3A4 eeeee2 ) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg  bbbbb1 dextromethorphan-HBr eeeee1  bbbbb2 CYP1A2 eeeee2 ), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg  bbbbb1 dextromethorphan-HBr eeeee1  bbbbb2 CYP2C19 eeeee2 ), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg  bbbbb1 dextromethorphan-HBr eeeee1  ( bbbbb2 CYP2D6 eeeee2 ), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg  bbbbb1 omeprazole eeeee1  bbbbb2 CYP2C9 eeeee2 ), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg  bbbbb1 omeprazole eeeee1  (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam ( bbbbb2 CYP3A4 eeeee2 ) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg  bbbbb1 omeprazole eeeee1  bbbbb2 CYP1A2 eeeee2 ), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg  bbbbb1 omeprazole eeeee1  ( bbbbb2 CYP2C19 eeeee2 ), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg  bbbbb1 omeprazole eeeee1  (CYP2C19), 30 mg dextromethorphan-HBr ( bbbbb2 CYP2D6 eeeee2 ), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg  bbbbb1 midazolam eeeee1  bbbbb2 CYP2C9 eeeee2 ), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg  bbbbb1 midazolam eeeee1  ( bbbbb2 CYP3A4 eeeee2 ) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg  bbbbb1 midazolam eeeee1  bbbbb2 CYP1A2 eeeee2 ), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg  bbbbb1 midazolam eeeee1  bbbbb2 CYP2C19 eeeee2 ), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Additionally, on day 11 of both study periods, 150 mg caffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole (CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mg  bbbbb1 midazolam eeeee1  bbbbb2 CYP2D6 eeeee2 ), and 2 mg midazolam (CYP3A4) were administered orally
CRP11	Overall, this study emphasizes the impor bbbbb1 tance of eeeee1  bbbbb2 tance of brain ox eeeee2 ytocinergic signaling for regulating intermale offensive aggression
CRP11	Our data clearly demonstrate that acute icv administered  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  produces dose-dependent and receptor-selective changes in social behavior, reducing aggression and potentiating social exploration
CRP11	NS: These results suggest that transiently enhancing brain  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  function has potent antiaggressive effects, whereas its attenuation tends to enhance aggressiveness
CRP11	ALE: A substantial body of research suggests that the neuropeptide  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  promotes social affiliative behaviors in a wide range of animals including humans
CRP11	In vitro insulin release studies were performed in phosphate buffer pH 7.4 and also in  bbbbb1 HCl eeeee1  pH 2 with and without  bbbbb2 trypsin eeeee2 
CRP11	In vitro insulin release studies were performed in phosphate buffer pH 7.4 and also in  bbbbb1 HCl eeeee1  bbbbb2 insulin eeeee2  release studies were performed in phosphate buffer pH 7.4 and also in HCl pH 2 with and without trypsin
CRP11	In vitro insulin release studies were performed in  bbbbb1 phosphate eeeee1  buffer pH 7.4 and also in HCl pH 2 with and without  bbbbb2 trypsin eeeee2 
CRP11	In vitro insulin release studies were performed in  bbbbb1 phosphate eeeee1  bbbbb2 insulin eeeee2  release studies were performed in phosphate buffer pH 7.4 and also in HCl pH 2 with and without trypsin
CRP11	Type II metabotropic glutamate receptors (mGluRs) and  bbbbb1 serotonin eeeee1  bbbbb2 mGluRs eeeee2 ) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and  bbbbb1 serotonin eeeee1  5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and  bbbbb2 5-HT(2A) eeeee2  homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and  bbbbb1 serotonin eeeee1  bbbbb2 Type II metabotropic glutamate receptors eeeee2  (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and  bbbbb1 serotonin eeeee1  5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to  bbbbb2 mGluR2 eeeee2  and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and  bbbbb1 serotonin eeeee1   bbbbb2 5-HT(2A) eeeee2  receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and  bbbbb1 serotonin eeeee1  5-HT(2A) receptors have been reported to form heterodimers that modulate  bbbbb2 G-protein eeeee2 -mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and  bbbbb1 5-HT eeeee1  bbbbb2 mGluRs eeeee2 ) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(2A) eeeee2  homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and  bbbbb1 5-HT eeeee1  bbbbb2 Type II metabotropic glutamate receptors eeeee2  (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and  bbbbb1 5-HT eeeee1  bbbbb2 mGluR2 eeeee2  and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(2A) eeeee2  receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and  bbbbb1 5-HT eeeee1  bbbbb2 G-protein eeeee2 -mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin  bbbbb1 5-HT eeeee1  bbbbb2 mGluRs eeeee2 ) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin  bbbbb1 5-HT eeeee1 (2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and  bbbbb2 5-HT(2A) eeeee2  homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin  bbbbb1 5-HT eeeee1  bbbbb2 Type II metabotropic glutamate receptors eeeee2  (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin  bbbbb1 5-HT eeeee1 (2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to  bbbbb2 mGluR2 eeeee2  and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(2A) eeeee2  receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic glutamate receptors (mGluRs) and serotonin  bbbbb1 5-HT eeeee1 (2A) receptors have been reported to form heterodimers that modulate  bbbbb2 G-protein eeeee2 -mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic  bbbbb1 glutamate eeeee1  receptors ( bbbbb2 mGluRs eeeee2 ) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic  bbbbb1 glutamate eeeee1  receptors (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and  bbbbb2 5-HT(2A) eeeee2  homomers
CRP11	Type II metabotropic  bbbbb1 glutamate eeeee1  bbbbb2 Type II metabotropic glutamate receptors eeeee2  (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic  bbbbb1 glutamate eeeee1  receptors (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to  bbbbb2 mGluR2 eeeee2  and 5-HT(2A) homomers
CRP11	Type II metabotropic  bbbbb1 glutamate eeeee1  receptors (mGluRs) and serotonin  bbbbb2 5-HT(2A) eeeee2  receptors have been reported to form heterodimers that modulate G-protein-mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Type II metabotropic  bbbbb1 glutamate eeeee1  receptors (mGluRs) and serotonin 5-HT(2A) receptors have been reported to form heterodimers that modulate  bbbbb2 G-protein eeeee2 -mediated intracellular signaling differentially compared to mGluR2 and 5-HT(2A) homomers
CRP11	Signaling molecules, such as Akt and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine,  bbbbb1 serotonin eeeee1  bbbbb2 GSK-3 eeeee2 ), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and glutamate neurotransmission
CRP11	Signaling molecules, such as Akt and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine,  bbbbb1 serotonin eeeee1  bbbbb2 Akt eeeee2  and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and glutamate neurotransmission
CRP11	Signaling molecules, such as Akt and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine,  bbbbb1 serotonin eeeee1  bbbbb2 glycogen-synthase-kinase-3 eeeee2  (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and glutamate neurotransmission
CRP11	Signaling molecules, such as Akt and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and  bbbbb1 glutamate eeeee1  bbbbb2 GSK-3 eeeee2 ), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and glutamate neurotransmission
CRP11	Signaling molecules, such as Akt and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and  bbbbb1 glutamate eeeee1  bbbbb2 Akt eeeee2  and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and glutamate neurotransmission
CRP11	Signaling molecules, such as Akt and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and  bbbbb1 glutamate eeeee1  bbbbb2 glycogen-synthase-kinase-3 eeeee2  (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and glutamate neurotransmission
CRP11	Signaling molecules, such as Akt and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting  bbbbb1 dopamine eeeee1  bbbbb2 GSK-3 eeeee2 ), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and glutamate neurotransmission
CRP11	Signaling molecules, such as Akt and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting  bbbbb1 dopamine eeeee1  bbbbb2 Akt eeeee2  and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and glutamate neurotransmission
CRP11	Signaling molecules, such as Akt and glycogen-synthase-kinase-3 (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting  bbbbb1 dopamine eeeee1  bbbbb2 glycogen-synthase-kinase-3 eeeee2  (GSK-3), could be involved in the mechanism of action of antipsychotics, targeting dopamine, serotonin, and glutamate neurotransmission
CRP11	Homer1a, the inducible member of the Homer family of PSD proteins that is implicated in glutamatergic signal transduction, is induced in striatum by antipsychotics with high  bbbbb1 dopamine eeeee1  bbbbb2 Homer eeeee2  family of PSD proteins that is implicated in glutamatergic signal transduction, is induced in striatum by antipsychotics with high dopamine receptor affinity and in the cortex by antipsychotics with mixed serotonergic/dopaminergic profile
CRP11	Moving from receptors to postsynaptic density (PSD) scenario, the scaffolding protein PSD-95 is known to interact with N-methyl-D-aspartate ( bbbbb1 NMDA eeeee1  bbbbb2 N-methyl-D-aspartate (NMDA), D(2) and 5-HT(2) receptors eeeee2 , regulating their activation state
CRP11	Moving from receptors to postsynaptic density (PSD) scenario, the scaffolding protein PSD-95 is known to interact with  bbbbb1 N-methyl-D-aspartate eeeee1  bbbbb2 N-methyl-D-aspartate (NMDA), D(2) and 5-HT(2) receptors eeeee2 , regulating their activation state
CRP11	Moving from receptors to postsynaptic density (PSD) scenario, the scaffolding protein PSD-95 is known to interact with N-methyl-D-aspartate (NMDA), D(2) and  bbbbb1 5-HT eeeee1  bbbbb2 N-methyl-D-aspartate (NMDA), D(2) and 5-HT(2) receptors eeeee2 , regulating their activation state
CRP11	Additionally, direct evidence has been provided that D(2) and  bbbbb1 5-HT eeeee1  bbbbb2 D(2) and 5-HT(2A) receptors eeeee2  form physical heterocomplexes which exert a functional cross-talk, as demonstrated by studies on hallucinogen-induced signaling
CRP11	No significant difference was observed in the placebo group bbbbb1  eeeee1  bbbbb2 oup eeeee2 
CRP11	No significant difference was observed in the placebo gr bbbbb1 oup eeeee1  bbbbb2 oup eeeee2 
CRP11	ALE: A common polymorphism (5HTTLPR) within the promoter region of the  bbbbb1 serotonin eeeee1  transporter gene ( bbbbb2 LSC6A4 eeeee2 ) has been shown to influence response time as well as overall response to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder
CRP11	ALE: A common polymorphism (5HTTLPR) within the promoter region of the  bbbbb1 serotonin eeeee1  bbbbb2 5HTTLPR eeeee2 ) within the promoter region of the serotonin transporter gene (LSC6A4) has been shown to influence response time as well as overall response to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder
CRP11	ALE: A common polymorphism (5HTTLPR) within the promoter region of the  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  gene (LSC6A4) has been shown to influence response time as well as overall response to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder
CRP11	ALE: A common polymorphism (5HTTLPR) within the promoter region of the serotonin transporter gene (LSC6A4) has been shown to influence response time as well as overall response to selective  bbbbb1 serotonin eeeee1  bbbbb2 LSC6A4 eeeee2 ) has been shown to influence response time as well as overall response to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder
CRP11	ALE: A common polymorphism (5HTTLPR) within the promoter region of the serotonin transporter gene (LSC6A4) has been shown to influence response time as well as overall response to selective  bbbbb1 serotonin eeeee1  bbbbb2 5HTTLPR eeeee2 ) within the promoter region of the serotonin transporter gene (LSC6A4) has been shown to influence response time as well as overall response to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder
CRP11	ALE: A common polymorphism (5HTTLPR) within the promoter region of the serotonin transporter gene (LSC6A4) has been shown to influence response time as well as overall response to selective  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  gene (LSC6A4) has been shown to influence response time as well as overall response to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder
CRP11	This construct (SEPT3-GC), which includes the GTP-binding and C-terminal domains, purifies as a  bbbbb1 nucleotide eeeee1  bbbbb2 SEPT3 eeeee2 -GC), which includes the GTP-binding and C-terminal domains, purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis
CRP11	This construct (SEPT3-GC), which includes the GTP-binding and C-terminal domains, purifies as a  bbbbb1 nucleotide eeeee1  bbbbb2 GTP-binding and C-terminal domains eeeee2 , purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis
CRP11	This construct (SEPT3-GC), which includes the GTP-binding and  bbbbb1 C eeeee1  bbbbb2 SEPT3 eeeee2 -GC), which includes the GTP-binding and C-terminal domains, purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis
CRP11	This construct (SEPT3-GC), which includes the GTP-binding and  bbbbb1 C eeeee1  bbbbb2 GTP-binding and C-terminal domains eeeee2 , purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis
CRP11	This construct (SEPT3-GC), which includes the GTP-binding and C-terminal domains, purifies as a nucleotide-free monomer, allowing for its characterization in terms of  bbbbb1 GTP eeeee1  bbbbb2 SEPT3 eeeee2 -GC), which includes the GTP-binding and C-terminal domains, purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis
CRP11	This construct (SEPT3-GC), which includes the GTP-binding and C-terminal domains, purifies as a nucleotide-free monomer, allowing for its characterization in terms of  bbbbb1 GTP eeeee1  bbbbb2 GTP-binding and C-terminal domains eeeee2 , purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis
CRP11	This construct (SEPT3-GC), which includes the  bbbbb1 GTP eeeee1  bbbbb2 SEPT3 eeeee2 -GC), which includes the GTP-binding and C-terminal domains, purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis
CRP11	This construct (SEPT3-GC), which includes the  bbbbb1 GTP eeeee1  bbbbb2 GTP-binding and C-terminal domains eeeee2 , purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis
CRP11	The human genome codes for 13 members of a family of filament-forming  bbbbb1 GTP eeeee1  bbbbb2 GTP-binding proteins eeeee2  known as septins
CRP11	The human genome codes for 13 members of a family of filament-forming  bbbbb1 GTP eeeee1 -binding proteins known as  bbbbb2 septins eeeee2 
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2 , glutathione peroxidase (GSH-Px) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GSH-Px) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and  bbbbb1 glutathione eeeee1  reductase ( bbbbb2 GSH-Rd eeeee2 ) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and  bbbbb1 glutathione eeeee1  bbbbb2 GSH-Px eeeee2 ) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione reductase eeeee2  (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase ( bbbbb1 GSH eeeee1  bbbbb2 catalase eeeee2 , glutathione peroxidase (GSH-Px) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase ( bbbbb1 GSH eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GSH-Px) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase ( bbbbb1 GSH eeeee1 -Px) and glutathione reductase ( bbbbb2 GSH-Rd eeeee2 ) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase ( bbbbb1 GSH eeeee1  bbbbb2 GSH-Px eeeee2 ) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase ( bbbbb1 GSH eeeee1 -Px) and  bbbbb2 glutathione reductase eeeee2  (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase,  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2 , glutathione peroxidase (GSH-Px) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase,  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GSH-Px) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase,  bbbbb1 glutathione eeeee1  peroxidase (GSH-Px) and glutathione reductase ( bbbbb2 GSH-Rd eeeee2 ) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase,  bbbbb1 glutathione eeeee1  peroxidase ( bbbbb2 GSH-Px eeeee2 ) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase,  bbbbb1 glutathione eeeee1  peroxidase (GSH-Px) and  bbbbb2 glutathione reductase eeeee2  (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and glutathione reductase ( bbbbb1 GSH eeeee1  bbbbb2 catalase eeeee2 , glutathione peroxidase (GSH-Px) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and glutathione reductase ( bbbbb1 GSH eeeee1  bbbbb2 glutathione peroxidase eeeee2  (GSH-Px) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and glutathione reductase ( bbbbb1 GSH eeeee1  bbbbb2 GSH-Rd eeeee2 ) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and glutathione reductase ( bbbbb1 GSH eeeee1  bbbbb2 GSH-Px eeeee2 ) and glutathione reductase (GSH-Rd) in the liver
CRP11	Moreover, green tea extract administration significantly increased (p<0.05) the activities of catalase, glutathione peroxidase (GSH-Px) and glutathione reductase ( bbbbb1 GSH eeeee1  bbbbb2 glutathione reductase eeeee2  (GSH-Rd) in the liver
CRP11	A single residue in leucyl-tRNA synthetase affecting  bbbbb1 amino acid eeeee1  bbbbb2 leucyl-tRNA synthetase eeeee2  affecting amino acid specificity and tRNA aminoacylation
CRP11	A single residue in  bbbbb1 leucyl eeeee1  bbbbb2 leucyl-tRNA synthetase eeeee2  affecting amino acid specificity and tRNA aminoacylation
CRP11	Here we describe studies indicating that this particular residue (K600 in hs mt LeuRS and L570 in E. coli LeuRS) strongly impacts aminoacylation in two ways: it affects both  bbbbb1 amino acid eeeee1  bbbbb2 hs mt LeuRS eeeee2  and L570 in E. coli LeuRS) strongly impacts aminoacylation in two ways: it affects both amino acid discrimination and transfer RNA (tRNA) binding
CRP11	Here we describe studies indicating that this particular residue (K600 in hs mt LeuRS and L570 in E. coli LeuRS) strongly impacts aminoacylation in two ways: it affects both  bbbbb1 amino acid eeeee1  bbbbb2 E. coli LeuRS eeeee2 ) strongly impacts aminoacylation in two ways: it affects both amino acid discrimination and transfer RNA (tRNA) binding
CRP11	Human mitochondrial  bbbbb1 leucyl eeeee1 -tRNA synthetase ( bbbbb2 hs mt LeuRS eeeee2 ) achieves high aminoacylation fidelity without a functional editing active site, representing a rare example of a class I aminoacyl-tRNA synthetase (aaRS) that does not proofread its products
CRP11	Human mitochondrial  bbbbb1 leucyl eeeee1  bbbbb2 Human mitochondrial leucyl-tRNA synthetase eeeee2  (hs mt LeuRS) achieves high aminoacylation fidelity without a functional editing active site, representing a rare example of a class I aminoacyl-tRNA synthetase (aaRS) that does not proofread its products
CRP11	Human mitochondrial  bbbbb1 leucyl eeeee1 -tRNA synthetase (hs mt LeuRS) achieves high aminoacylation fidelity without a functional editing active site, representing a rare example of a class I aminoacyl-tRNA synthetase ( bbbbb2 aaRS eeeee2 ) that does not proofread its products
CRP11	Human mitochondrial  bbbbb1 leucyl eeeee1 -tRNA synthetase (hs mt LeuRS) achieves high aminoacylation fidelity without a functional editing active site, representing a rare example of a  bbbbb2 class I aminoacyl-tRNA synthetase eeeee2  (aaRS) that does not proofread its products
CRP11	Human mitochondrial leucyl-tRNA synthetase (hs mt LeuRS) achieves high aminoacylation fidelity without a functional editing active site, representing a rare example of a class I  bbbbb1 aminoacyl eeeee1  bbbbb2 hs mt LeuRS eeeee2 ) achieves high aminoacylation fidelity without a functional editing active site, representing a rare example of a class I aminoacyl-tRNA synthetase (aaRS) that does not proofread its products
CRP11	Human mitochondrial leucyl-tRNA synthetase (hs mt LeuRS) achieves high aminoacylation fidelity without a functional editing active site, representing a rare example of a class I  bbbbb1 aminoacyl eeeee1  bbbbb2 Human mitochondrial leucyl-tRNA synthetase eeeee2  (hs mt LeuRS) achieves high aminoacylation fidelity without a functional editing active site, representing a rare example of a class I aminoacyl-tRNA synthetase (aaRS) that does not proofread its products
CRP11	Human mitochondrial leucyl-tRNA synthetase (hs mt LeuRS) achieves high aminoacylation fidelity without a functional editing active site, representing a rare example of a class I  bbbbb1 aminoacyl eeeee1 -tRNA synthetase ( bbbbb2 aaRS eeeee2 ) that does not proofread its products
CRP11	Human mitochondrial leucyl-tRNA synthetase (hs mt LeuRS) achieves high aminoacylation fidelity without a functional editing active site, representing a rare example of a class I  bbbbb1 aminoacyl eeeee1  bbbbb2 class I aminoacyl-tRNA synthetase eeeee2  (aaRS) that does not proofread its products
CRP11	Here we show that drug-specific differences in receptor internalization are determined by a conserved, 10-residue sequence in the receptor's  bbbbb1 carboxyl eeeee1  bbbbb2 carboxyl-terminal cytoplasmic tail eeeee2 
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  kinases at the cell membrane and contributes to activation of the PI3KAKT and mitogen-activated protein kinase kinase ( bbbbb2 MEK eeeee2 )extracellular signal-regulated kinase (ERK) pathways
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  kinases at the cell membrane and contributes to activation of the  bbbbb2 PI3K eeeee2 AKT and mitogen-activated protein kinase kinase (MEK)extracellular signal-regulated kinase (ERK) pathways
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  bbbbb2 MUC1-C eeeee2  interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor tyrosine kinases at the cell membrane and contributes to activation of the PI3KAKT and mitogen-activated protein kinase kinase (MEK)extracellular signal-regulated kinase (ERK) pathways
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  kinases at the cell membrane and contributes to activation of the PI3KAKT and  bbbbb2 mitogen-activated protein kinase kinase eeeee2  (MEK)extracellular signal-regulated kinase (ERK) pathways
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  bbbbb2 epidermal growth factor receptor eeeee2 ), ErbB2 and other receptor tyrosine kinases at the cell membrane and contributes to activation of the PI3KAKT and mitogen-activated protein kinase kinase (MEK)extracellular signal-regulated kinase (ERK) pathways
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  kinases at the cell membrane and contributes to activation of the PI3K bbbbb2 AKT eeeee2  and mitogen-activated protein kinase kinase (MEK)extracellular signal-regulated kinase (ERK) pathways
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  kinases at the cell membrane and contributes to activation of the PI3KAKT and mitogen-activated protein kinase kinase (MEK)extracellular signal-regulated kinase ( bbbbb2 ERK eeeee2 ) pathways
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  bbbbb2 EGFR eeeee2  (epidermal growth factor receptor), ErbB2 and other receptor tyrosine kinases at the cell membrane and contributes to activation of the PI3KAKT and mitogen-activated protein kinase kinase (MEK)extracellular signal-regulated kinase (ERK) pathways
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  bbbbb2 ErbB2 eeeee2  and other receptor tyrosine kinases at the cell membrane and contributes to activation of the PI3KAKT and mitogen-activated protein kinase kinase (MEK)extracellular signal-regulated kinase (ERK) pathways
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  kinases at the cell membrane and contributes to activation of the PI3KAKT and mitogen-activated protein kinase kinase (MEK) bbbbb2 extracellular signal-regulated kinase eeeee2  (ERK) pathways
CRP11	MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor  bbbbb1 tyrosine eeeee1  bbbbb2 receptor tyrosine kinases eeeee2  at the cell membrane and contributes to activation of the PI3KAKT and mitogen-activated protein kinase kinase (MEK)extracellular signal-regulated kinase (ERK) pathways
CRP11	CLA treatment increased serum parathyroid hormone (PTH) significantly (p=0.0172), while serum  bbbbb1 1,25-dihydroxyvitamin D3 eeeee1  bbbbb2 PTH eeeee2 ) significantly (p=0.0172), while serum 1,25-dihydroxyvitamin D3 concentration was not changed by CLA
CRP11	CLA treatment increased serum parathyroid hormone (PTH) significantly (p=0.0172), while serum  bbbbb1 1,25-dihydroxyvitamin D3 eeeee1  bbbbb2 parathyroid hormone eeeee2  (PTH) significantly (p=0.0172), while serum 1,25-dihydroxyvitamin D3 concentration was not changed by CLA
CRP11	However, HBsAg-positive cells exhibited increased cell death with exposure to the  bbbbb1 poly(ADP-ribose) eeeee1  bbbbb2 poly(ADP-ribose) polymerase eeeee2  inhibitor that blocks single-strand DNA repair
CRP11	However, HBsAg-positive cells exhibited increased cell death with exposure to the  bbbbb1 poly(ADP-ribose) eeeee1  bbbbb2 HBsAg eeeee2 -positive cells exhibited increased cell death with exposure to the poly(ADP-ribose) polymerase inhibitor that blocks single-strand DNA repair
CRP11	The  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  (AR) is a steroid hormone receptor that functions as a ligand-dependent transcriptional factor, which plays a key role in the development and progression of prostate cancer
CRP11	The  bbbbb1 androgen eeeee1  receptor (AR) is a  bbbbb2 steroid hormone receptor eeeee2  that functions as a ligand-dependent transcriptional factor, which plays a key role in the development and progression of prostate cancer
CRP11	The  bbbbb1 androgen eeeee1  receptor ( bbbbb2 AR eeeee2 ) is a steroid hormone receptor that functions as a ligand-dependent transcriptional factor, which plays a key role in the development and progression of prostate cancer
CRP11	The androgen receptor (AR) is a  bbbbb1 steroid eeeee1  bbbbb2 androgen receptor eeeee2  (AR) is a steroid hormone receptor that functions as a ligand-dependent transcriptional factor, which plays a key role in the development and progression of prostate cancer
CRP11	The androgen receptor (AR) is a  bbbbb1 steroid eeeee1  bbbbb2 steroid hormone receptor eeeee2  that functions as a ligand-dependent transcriptional factor, which plays a key role in the development and progression of prostate cancer
CRP11	The androgen receptor (AR) is a  bbbbb1 steroid eeeee1  bbbbb2 AR eeeee2 ) is a steroid hormone receptor that functions as a ligand-dependent transcriptional factor, which plays a key role in the development and progression of prostate cancer
CRP11	Recent advancement in high throughput technologies including microarrays and deep-sequencing provides unbiased genome-wide knowledge on the AR signaling including datasets for  bbbbb1 androgen eeeee1  bbbbb2 AR eeeee2  signaling including datasets for androgen-regulated gene expression and genomic binding sites for AR
CRP11	Recent advancement in high throughput technologies including microarrays and deep-sequencing provides unbiased genome-wide knowledge on the AR signaling including datasets for  bbbbb1 androgen eeeee1 -regulated gene expression and genomic binding sites for  bbbbb2 AR eeeee2 
CRP11	Genome-wide integrated analyses of  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  signaling in prostate cancer based on high-throughput technology
CRP11	C3 fed hamsters showed reduced whole-blood aggregation response to  bbbbb1 ADP eeeee1  and  bbbbb2 collagen eeeee2  compared to HC-fed hamsters
CRP11	In rat PRP, C3 reduced  bbbbb1 ADP eeeee1  and  bbbbb2 collagen eeeee2 -induced platelet aggregation
CRP11	Administration of C3 (16 mg/kg) offered 70% protection against collagen- and  bbbbb1 epinephrine eeeee1  bbbbb2 collagen eeeee2 - and epinephrine-induced pulmonary thromboembolism and 30% protection against arachidonic acid-induced death in mice, without adversely affecting bleeding time
CRP11	Administration of C3 (16 mg/kg) offered 70% protection against collagen- and epinephrine-induced pulmonary thromboembolism and 30% protection against  bbbbb1 arachidonic acid eeeee1  bbbbb2 collagen eeeee2 - and epinephrine-induced pulmonary thromboembolism and 30% protection against arachidonic acid-induced death in mice, without adversely affecting bleeding time
CRP11	 bbbbb1 Iron eeeee1  plays a direct and causal role in diabetes pathogenesis mediated both by β cell failure and  bbbbb2 insulin eeeee2  resistance
CRP11	ORX mice fed HFD showed increased hepatic steatosis, markedly decreased serum  bbbbb1 triglyceride eeeee1  (TG) and TG-VLDL content, and increased serum very small- bbbbb2 LDL eeeee2  content
CRP11	ORX mice fed HFD showed increased hepatic steatosis, markedly decreased serum  bbbbb1 triglyceride eeeee1  (TG) and TG- bbbbb2 VLDL eeeee2  content, and increased serum very small-LDL content
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1,  bbbbb1 diacylglycerol eeeee1  bbbbb2 sterol regulatory element-binding protein-1 eeeee2 , diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1,  bbbbb1 diacylglycerol eeeee1  bbbbb2 lipin-1 eeeee2 , peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1,  bbbbb1 diacylglycerol eeeee1  bbbbb2 diacylglycerol acyltransferase-2 eeeee2  and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1,  bbbbb1 diacylglycerol eeeee1  bbbbb2 PPAR-γ coactivator 1-α eeeee2 , and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1,  bbbbb1 diacylglycerol eeeee1  bbbbb2 peroxisome proliferator-activated receptor (PPAR)-α eeeee2  and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1,  bbbbb1 diacylglycerol eeeee1  acyltransferase-2 and  bbbbb2 fatty acid synthase eeeee2 
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1,  bbbbb1 diacylglycerol eeeee1  bbbbb2 microsomal triglyceride transfer protein eeeee2 , lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal  bbbbb1 triglyceride eeeee1  transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased  bbbbb2 sterol regulatory element-binding protein-1 eeeee2 , diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal  bbbbb1 triglyceride eeeee1  transfer protein,  bbbbb2 lipin-1 eeeee2 , peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal  bbbbb1 triglyceride eeeee1  transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1,  bbbbb2 diacylglycerol acyltransferase-2 eeeee2  and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal  bbbbb1 triglyceride eeeee1  transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and  bbbbb2 PPAR-γ coactivator 1-α eeeee2 , and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal  bbbbb1 triglyceride eeeee1  transfer protein, lipin-1,  bbbbb2 peroxisome proliferator-activated receptor (PPAR)-α eeeee2  and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal  bbbbb1 triglyceride eeeee1  transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and  bbbbb2 fatty acid synthase eeeee2 
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal  bbbbb1 triglyceride eeeee1  bbbbb2 microsomal triglyceride transfer protein eeeee2 , lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and  bbbbb1 fatty acid eeeee1  bbbbb2 sterol regulatory element-binding protein-1 eeeee2 , diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and  bbbbb1 fatty acid eeeee1  bbbbb2 lipin-1 eeeee2 , peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and  bbbbb1 fatty acid eeeee1  bbbbb2 diacylglycerol acyltransferase-2 eeeee2  and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and  bbbbb1 fatty acid eeeee1  bbbbb2 PPAR-γ coactivator 1-α eeeee2 , and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and  bbbbb1 fatty acid eeeee1  bbbbb2 peroxisome proliferator-activated receptor (PPAR)-α eeeee2  and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and  bbbbb1 fatty acid eeeee1  bbbbb2 fatty acid synthase eeeee2 
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and  bbbbb1 fatty acid eeeee1  bbbbb2 microsomal triglyceride transfer protein eeeee2 , lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased  bbbbb1 sterol eeeee1  bbbbb2 sterol regulatory element-binding protein-1 eeeee2 , diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased  bbbbb1 sterol eeeee1  bbbbb2 lipin-1 eeeee2 , peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased  bbbbb1 sterol eeeee1  regulatory element-binding protein-1,  bbbbb2 diacylglycerol acyltransferase-2 eeeee2  and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased  bbbbb1 sterol eeeee1  bbbbb2 PPAR-γ coactivator 1-α eeeee2 , and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased  bbbbb1 sterol eeeee1  bbbbb2 peroxisome proliferator-activated receptor (PPAR)-α eeeee2  and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased  bbbbb1 sterol eeeee1  regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and  bbbbb2 fatty acid synthase eeeee2 
CRP11	Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal triglyceride transfer protein, lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased  bbbbb1 sterol eeeee1  bbbbb2 microsomal triglyceride transfer protein eeeee2 , lipin-1, peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ coactivator 1-α, and significantly increased sterol regulatory element-binding protein-1, diacylglycerol acyltransferase-2 and fatty acid synthase
CRP11	Competitive displacement binding assays using t-BBN/BVD15-DO3A against  bbbbb1 (125)I eeeee1 -Tyr(4)-BBN yielded an IC(50) value of 18 ± 0.7 nM for  bbbbb2 GRPR eeeee2  in T-47D cells, a human breast cancer cell line
CRP11	Competitive displacement binding assays using t-BBN/BVD15-DO3A against  bbbbb1 (125)I eeeee1  bbbbb2 (125)I-Tyr(4)-BBN eeeee2  yielded an IC(50) value of 18 ± 0.7 nM for GRPR in T-47D cells, a human breast cancer cell line
CRP11	Competitive displacement binding assays using t-BBN/BVD15-DO3A against  bbbbb1 (125)I eeeee1  bbbbb2 t-BBN eeeee2 /BVD15-DO3A against (125)I-Tyr(4)-BBN yielded an IC(50) value of 18 ± 0.7 nM for GRPR in T-47D cells, a human breast cancer cell line
CRP11	Competitive displacement binding assays using t-BBN/BVD15-DO3A against (125)I- bbbbb1 Tyr eeeee1 (4)-BBN yielded an IC(50) value of 18 ± 0.7 nM for  bbbbb2 GRPR eeeee2  in T-47D cells, a human breast cancer cell line
CRP11	Competitive displacement binding assays using t-BBN/BVD15-DO3A against (125)I- bbbbb1 Tyr eeeee1  bbbbb2 (125)I-Tyr(4)-BBN eeeee2  yielded an IC(50) value of 18 ± 0.7 nM for GRPR in T-47D cells, a human breast cancer cell line
CRP11	Competitive displacement binding assays using t-BBN/BVD15-DO3A against (125)I- bbbbb1 Tyr eeeee1  bbbbb2 t-BBN eeeee2 /BVD15-DO3A against (125)I-Tyr(4)-BBN yielded an IC(50) value of 18 ± 0.7 nM for GRPR in T-47D cells, a human breast cancer cell line
CRP11	We describe here the design and development of a new heterobivalent peptide ligand, truncated  bbbbb1 bombesin eeeee1  bbbbb2 truncated bombesin eeeee2  (t-BBN)/BVD15-DO3A, for dual-targeting of GRPR and Y1, and validation of its dual binding capability
CRP11	We describe here the design and development of a new heterobivalent peptide ligand, truncated  bbbbb1 bombesin eeeee1  (t-BBN)/BVD15-DO3A, for dual-targeting of GRPR and  bbbbb2 Y1 eeeee2 , and validation of its dual binding capability
CRP11	We describe here the design and development of a new heterobivalent peptide ligand, truncated  bbbbb1 bombesin eeeee1  ( bbbbb2 t-BBN eeeee2 )/BVD15-DO3A, for dual-targeting of GRPR and Y1, and validation of its dual binding capability
CRP11	We describe here the design and development of a new heterobivalent peptide ligand, truncated  bbbbb1 bombesin eeeee1  (t-BBN)/BVD15-DO3A, for dual-targeting of  bbbbb2 GRPR eeeee2  and Y1, and validation of its dual binding capability
CRP11	Specifically, light microscopy revealed a decrease in tyrosine hydroxylase-expressing ( bbbbb1 dopamine eeeee1  bbbbb2 tyrosine hydroxylase eeeee2 -expressing (dopamine) neurons in the midbrain of BPA-exposed fetuses and electron microscopy identified a reduction in spine synapses in the CA1 region of hippocampus
CRP11	Specifically, light microscopy revealed a decrease in tyrosine hydroxylase-expressing (dopamine) neurons in the midbrain of  bbbbb1 BPA eeeee1  bbbbb2 tyrosine hydroxylase eeeee2 -expressing (dopamine) neurons in the midbrain of BPA-exposed fetuses and electron microscopy identified a reduction in spine synapses in the CA1 region of hippocampus
CRP11	Specifically, light microscopy revealed a decrease in  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine hydroxylase eeeee2 -expressing (dopamine) neurons in the midbrain of BPA-exposed fetuses and electron microscopy identified a reduction in spine synapses in the CA1 region of hippocampus
CRP11	Inhibition of TrkB  bbbbb1 tyrosine eeeee1  kinase signaling with k252a, or with the selective BDNF scavenger TrkB-Fc, both inhibited MF-LTP to the same extent as observed in  bbbbb2 BDNF eeeee2 +/- mice
CRP11	Inhibition of TrkB  bbbbb1 tyrosine eeeee1  bbbbb2 TrkB eeeee2  tyrosine kinase signaling with k252a, or with the selective BDNF scavenger TrkB-Fc, both inhibited MF-LTP to the same extent as observed in BDNF+/- mice
CRP11	Inhibition of TrkB  bbbbb1 tyrosine eeeee1  kinase signaling with k252a, or with the selective  bbbbb2 BDNF eeeee2  scavenger TrkB-Fc, both inhibited MF-LTP to the same extent as observed in BDNF+/- mice
CRP11	Inhibition of TrkB  bbbbb1 tyrosine eeeee1  kinase signaling with k252a, or with the selective BDNF scavenger  bbbbb2 TrkB eeeee2 -Fc, both inhibited MF-LTP to the same extent as observed in BDNF+/- mice
CRP11	Inhibition of TrkB  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  signaling with k252a, or with the selective BDNF scavenger TrkB-Fc, both inhibited MF-LTP to the same extent as observed in BDNF+/- mice
CRP11	This mini-review evaluates the theoretical potential of a pharmacological enhancement strategy of cognitive remediation training with nicotinic  bbbbb1 acetylcholine eeeee1  bbbbb2 nicotinic acetylcholine receptor eeeee2  (nAChR) agonists. nAChR agonists can facilitate sensory processing, alertness, attention, learning and memory
CRP11	This mini-review evaluates the theoretical potential of a pharmacological enhancement strategy of cognitive remediation training with nicotinic  bbbbb1 acetylcholine eeeee1  receptor ( bbbbb2 nAChR eeeee2 ) agonists. nAChR agonists can facilitate sensory processing, alertness, attention, learning and memory
CRP11	This mini-review evaluates the theoretical potential of a pharmacological enhancement strategy of cognitive remediation training with nicotinic  bbbbb1 acetylcholine eeeee1  receptor (nAChR) agonists.  bbbbb2 nAChR eeeee2  agonists can facilitate sensory processing, alertness, attention, learning and memory
CRP11	From this unexpected result, we propose a new binding scheme bbbbb1  between the b eeeee1 oronate and a sulfated ethylene glycol or aminoethanol unit bbbbb2  eeeee2 
CRP11	There is only partial overlap, however, between Top1-dependent deletion hotspots identified in highly transcribed DNA and those associated with rNMPs, suggesting the existence of both rNMP-dependent and  bbbbb1 rNMP eeeee1  bbbbb2 Top1 eeeee2 -dependent deletion hotspots identified in highly transcribed DNA and those associated with rNMPs, suggesting the existence of both rNMP-dependent and rNMP-independent events
CRP11	There is only partial overlap, however, between Top1-dependent deletion hotspots identified in highly transcribed DNA and those associated with rNMPs, suggesting the existence of both  bbbbb1 rNMP eeeee1  bbbbb2 Top1 eeeee2 -dependent deletion hotspots identified in highly transcribed DNA and those associated with rNMPs, suggesting the existence of both rNMP-dependent and rNMP-independent events
CRP11	There is only partial overlap, however, between Top1-dependent deletion hotspots identified in highly transcribed DNA and those associated with  bbbbb1 rNMPs eeeee1  bbbbb2 Top1 eeeee2 -dependent deletion hotspots identified in highly transcribed DNA and those associated with rNMPs, suggesting the existence of both rNMP-dependent and rNMP-independent events
CRP11	Here, we present genetic studies confirming that there are two distinct types of hotspots bbbbb1  eeeee1  bbbbb2 s eeeee2 
CRP11	Here, we present genetic studies confirming that there are two distinct types of hotspots bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Here, we present genetic studies con bbbbb1 firm eeeee1 ing that there are two distinct types of hotspot bbbbb2 s eeeee2 
CRP11	Here, we present genetic studies con bbbbb1 firm eeeee1 ing that there are two distinct types of hotspots bbbbb2  eeeee2 
CRP11	A similar signature is associated with the persistence of ribonucleoside monophosphates ( bbbbb1 rNMPs eeeee1 ) in DNA, and it also depends on  bbbbb2 Top1 eeeee2  activity
CRP11	A similar signature is associated with the persistence of  bbbbb1 ribonucleoside monophosphates eeeee1  (rNMPs) in DNA, and it also depends on  bbbbb2 Top1 eeeee2  activity
CRP11	Furthermore, the expression of these  bbbbb1 GnRHs eeeee1  bbbbb2 GnRHs eeeee2  was correlated with the expression of dlGnRH-R-2A
CRP11	Furthermore, the expression of these  bbbbb1 GnRHs eeeee1  was correlated with the expression of  bbbbb2 dlGnRH-R-2A eeeee2 
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma  bbbbb2 LH eeeee2  levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  receptor ( bbbbb2 dlGnRH-R-2A eeeee2 ) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  bbbbb2 gonadotropin-releasing hormone eeeee2  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha ( bbbbb2 GPalpha eeeee2 ), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  receptor (dlGnRH-R-2A) and the three gonadotropin ( bbbbb2 GtH eeeee2 ) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely  bbbbb2 glycoprotein alpha eeeee2  (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta ( bbbbb2 LHbeta eeeee2 ), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and  bbbbb2 luteinizing hormone beta eeeee2  (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  bbbbb2 sGnRH eeeee2 ), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  receptor (dlGnRH-R-2A) and the three  bbbbb2 gonadotropin eeeee2  (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  bbbbb2 sbGnRH eeeee2 ) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha),  bbbbb2 follicle-stimulating hormone beta eeeee2  (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  bbbbb2 GnRH receptor eeeee2  (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb1 GnRH eeeee1  receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta ( bbbbb2 FSHbeta eeeee2 ) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma  bbbbb2 LH eeeee2  levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor ( bbbbb2 dlGnRH-R-2A eeeee2 ) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  bbbbb2 gonadotropin-releasing hormone eeeee2  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha ( bbbbb2 GPalpha eeeee2 ), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin ( bbbbb2 GtH eeeee2 ) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely  bbbbb2 glycoprotein alpha eeeee2  (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta ( bbbbb2 LHbeta eeeee2 ), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and  bbbbb2 luteinizing hormone beta eeeee2  (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon ( bbbbb2 sGnRH eeeee2 ), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three  bbbbb2 gonadotropin eeeee2  (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  ( bbbbb2 GnRH eeeee2 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream ( bbbbb2 sbGnRH eeeee2 ) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha),  bbbbb2 follicle-stimulating hormone beta eeeee2  (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb2 GnRH receptor eeeee2  (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of  bbbbb1 gonadotropin-releasing hormone eeeee1  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta ( bbbbb2 FSHbeta eeeee2 ) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma  bbbbb2 LH eeeee2  levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor ( bbbbb2 dlGnRH-R-2A eeeee2 ) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1  bbbbb2 gonadotropin-releasing hormone eeeee2  (GnRH), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha ( bbbbb2 GPalpha eeeee2 ), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin ( bbbbb2 GtH eeeee2 ) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely  bbbbb2 glycoprotein alpha eeeee2  (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta ( bbbbb2 LHbeta eeeee2 ), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and  bbbbb2 luteinizing hormone beta eeeee2  (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon ( bbbbb2 sGnRH eeeee2 ), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three  bbbbb2 gonadotropin eeeee2  (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream ( bbbbb2 sbGnRH eeeee2 ) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha),  bbbbb2 follicle-stimulating hormone beta eeeee2  (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of  bbbbb2 GnRH receptor eeeee2  (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta (FSHbeta) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	A likely endocrine control mechanism for sexual differentiation in size-graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of gonadotropin-releasing hormone ( bbbbb1 GnRH eeeee1 ), namely sea bream (sbGnRH) and salmon (sGnRH), the pituitary expression of one subtype of GnRH receptor (dlGnRH-R-2A) and the three gonadotropin (GtH) subunits, namely glycoprotein alpha (GPalpha), follicle-stimulating hormone beta ( bbbbb2 FSHbeta eeeee2 ) and luteinizing hormone beta (LHbeta), as well as the pituitary and plasma LH levels between 50 and 300 days post-hatching (dph)
CRP11	Moreover, the observed sexual dimorphism at the transcriptional or synthesis level of these  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  forms suggests that a different neuro-hormonal regulation is operating according to sex
CRP11	A critical role in organismal homeostatic functions is played by the  bbbbb1 aryl hydrocarbon eeeee1  receptor ( bbbbb2 AHR eeeee2 ) complex, which senses environmental and endogenous compounds, influences metabolic responses controlling phase I/II gene expression, and modulates vital phenomena such as development, inflammation and adaptive immunity
CRP11	A critical role in organismal homeostatic functions is played by the  bbbbb1 aryl hydrocarbon eeeee1  bbbbb2 aryl hydrocarbon receptor eeeee2  (AHR) complex, which senses environmental and endogenous compounds, influences metabolic responses controlling phase I/II gene expression, and modulates vital phenomena such as development, inflammation and adaptive immunity
CRP11	The anti-UC activity of these compounds may be explained by reducing the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), in addition to reduction of colonic  bbbbb1 malondialdehyde eeeee1  bbbbb2 tumor necrosis factor-alpha eeeee2  (TNF-α), in addition to reduction of colonic malondialdehyde (MDA) contents
CRP11	The anti-UC activity of these compounds may be explained by reducing the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), in addition to reduction of colonic  bbbbb1 malondialdehyde eeeee1  bbbbb2 TNF-α eeeee2 ), in addition to reduction of colonic malondialdehyde (MDA) contents
CRP11	The anti-UC activity of these compounds may be explained by reducing the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), in addition to reduction of colonic  bbbbb1 malondialdehyde eeeee1  bbbbb2 cytokine eeeee2  tumor necrosis factor-alpha (TNF-α), in addition to reduction of colonic malondialdehyde (MDA) contents
CRP11	The anti-UC activity of these compounds may be explained by reducing the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), in addition to reduction of colonic malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 tumor necrosis factor-alpha eeeee2  (TNF-α), in addition to reduction of colonic malondialdehyde (MDA) contents
CRP11	The anti-UC activity of these compounds may be explained by reducing the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), in addition to reduction of colonic malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 TNF-α eeeee2 ), in addition to reduction of colonic malondialdehyde (MDA) contents
CRP11	The anti-UC activity of these compounds may be explained by reducing the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), in addition to reduction of colonic malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 cytokine eeeee2  tumor necrosis factor-alpha (TNF-α), in addition to reduction of colonic malondialdehyde (MDA) contents
CRP11	Functional analyses of  bbbbb1 glycyl eeeee1  bbbbb2 glycyl-tRNA synthetase eeeee2  mutations suggest a key role for tRNA-charging enzymes in peripheral axons
CRP11	Functional analyses of  bbbbb1 glycyl eeeee1 -tRNA synthetase mutations suggest a key role for  bbbbb2 tRNA-charging enzymes eeeee2  in peripheral axons
CRP11	S is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates  bbbbb1 glycine eeeee1  bbbbb2 GARS eeeee2  ligates glycine to tRNA(Gly)
CRP11	S is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates  bbbbb1 glycine eeeee1  bbbbb2 aminoacyl-tRNA synthetases eeeee2  responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly)
CRP11	S is a member of the family of  bbbbb1 aminoacyl eeeee1 -tRNA synthetases responsible for charging tRNA with cognate amino acids;  bbbbb2 GARS eeeee2  ligates glycine to tRNA(Gly)
CRP11	S is a member of the family of  bbbbb1 aminoacyl eeeee1  bbbbb2 aminoacyl-tRNA synthetases eeeee2  responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly)
CRP11	S is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate  bbbbb1 amino acids eeeee1 ;  bbbbb2 GARS eeeee2  ligates glycine to tRNA(Gly)
CRP11	S is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate  bbbbb1 amino acids eeeee1  bbbbb2 aminoacyl-tRNA synthetases eeeee2  responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly)
CRP11	The sustained model raised the average plasma  bbbbb1 glucose eeeee1  concentration from 70 mg/dL to 180 mg/dL and led to decreased gene expression of  bbbbb2 glucose transporter eeeee2  GLUT1
CRP11	The sustained model raised the average plasma  bbbbb1 glucose eeeee1  concentration from 70 mg/dL to 180 mg/dL and led to decreased gene expression of glucose transporter  bbbbb2 GLUT1 eeeee2 
CRP11	The sustained model raised the average plasma glucose concentration from 70 mg/dL to 180 mg/dL and led to decreased gene expression of  bbbbb1 glucose eeeee1  bbbbb2 glucose transporter eeeee2  GLUT1
CRP11	The sustained model raised the average plasma glucose concentration from 70 mg/dL to 180 mg/dL and led to decreased gene expression of  bbbbb1 glucose eeeee1  transporter  bbbbb2 GLUT1 eeeee2 
CRP11	Toxicity of the flame-retardant  bbbbb1 BDE-49 eeeee1  on brain mitochondria and neuronal progenitor striatal cells enhanced by a  bbbbb2 PTEN eeeee2 -deficient background
CRP11	Blood samples were taken 5 min before the start of  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  infusion, at full cervical dilatation, and within 5 min after delivery of the placenta
CRP11	Matriptase-2, a recently identified cell surface protease, is the key enzyme of  bbbbb1 iron eeeee1  homoeostasis modulating the expression of the liver peptide hormone  bbbbb2 hepcidin eeeee2 
CRP11	Matriptase-2, a recently identified cell surface protease, is the key enzyme of  bbbbb1 iron eeeee1  bbbbb2 protease eeeee2 , is the key enzyme of iron homoeostasis modulating the expression of the liver peptide hormone hepcidin
CRP11	Matriptase-2, a recently identified cell surface protease, is the key enzyme of  bbbbb1 iron eeeee1  bbbbb2 Matriptase-2 eeeee2 , a recently identified cell surface protease, is the key enzyme of iron homoeostasis modulating the expression of the liver peptide hormone hepcidin
CRP11	The inhibitor abrogates the matriptase-2-mediated suppression of HAMP expression, presumably by inhibiting the supposed potential of matriptase-2 to cleave membrane-bound HJV (haemojuvelin) bbbbb1  eeeee1  bbbbb2 P exp eeeee2 ression, presumably by inhibiting the supposed potential of matriptase-2 to cleave membrane-bound HJV (haemojuvelin)
CRP11	The inhibitor abrogates the matriptase-2-mediated suppression of HAMP expression, presumably by inhibiting the supposed potential of matriptase-2 to cleave membrane-bound HJV (haemojuvelin) bbbbb1  eeeee1  bbbbb2 ptase-2  eeeee2 to cleave membrane-bound HJV (haemojuvelin)
CRP11	The inhibitor abrogates the matriptase-2-mediated suppression of HAMP expression, presumably by inhibiting the supposed potential of matriptase-2 to cleave membrane-bound HJV (haemojuvelin) bbbbb1  eeeee1  bbbbb2 by inhibitin eeeee2 g the supposed potential of matriptase-2 to cleave membrane-bound HJV (haemojuvelin)
CRP11	The inhibitor abrogates the matriptase-2-mediated suppression of HAMP expression, presumably by inhibiting the supposed potential of matriptase-2 to cleave membrane-bound HJV (haemojuvelin) bbbbb1  eeeee1  bbbbb2 P exp eeeee2 ression, presumably by inhibiting the supposed potential of matriptase-2 to cleave membrane-bound HJV (haemojuvelin)
CRP11	The inhibitor abrogates the matriptase-2-mediated suppression of HAMP expression, presumably by inhibiting the supposed potential of matriptase-2 to cleave membrane-bound HJV (haemojuvelin) bbbbb1  eeeee1  bbbbb2 ptase-2  eeeee2 to cleave membrane-bound HJV (haemojuvelin)
CRP11	The inhibitor abrogates the matriptase-2-mediated suppression of HAMP expression, presumably by inhibiting the supposed potential of matriptase-2 to cleave membrane-bound HJV (haemojuvelin) bbbbb1  eeeee1  bbbbb2 by inhibitin eeeee2 g the supposed potential of matriptase-2 to cleave membrane-bound HJV (haemojuvelin)
CRP11	Hydroxy-terminated conjugated polymer nanoparticles have near-unity bright fraction and reveal  bbbbb1 cholesterol eeeee1 -dependence of  bbbbb2 IGF1R nanodomains eeeee2 
CRP11	 bbbbb1 Hydroxy eeeee1 -terminated conjugated polymer nanoparticles have near-unity bright fraction and reveal cholesterol-dependence of  bbbbb2 IGF1R nanodomains eeeee2 
CRP11	Much is still bein bbbbb1 g learned about the fu eeeee1 nction and specificity  bbbbb2 of muscarinic receptor eeeee2 s, which will support the development of agents with sustained efficacy and enhanced tolerability compared with the available formulations to date
CRP11	We have identified a novel C/T polymorphism in the 3'UTR of the principal arginine transporter, solute carrier family 7 ( bbbbb1 cationic amino acid eeeee1  transporter, y+ system), member 1 gene ( bbbbb2 SLC7A1 eeeee2 )
CRP11	We have identified a novel C/T polymorphism in the 3'UTR of the principal arginine transporter, solute carrier family 7 ( bbbbb1 cationic amino acid eeeee1  bbbbb2 arginine transporter, solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 gene eeeee2  (SLC7A1)
CRP11	We have identified a novel C/T polymorphism in the 3'UTR of the principal  bbbbb1 arginine eeeee1  transporter, solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 gene ( bbbbb2 SLC7A1 eeeee2 )
CRP11	We have identified a novel C/T polymorphism in the 3'UTR of the principal  bbbbb1 arginine eeeee1  bbbbb2 arginine transporter, solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 gene eeeee2  (SLC7A1)
CRP11	The Slc7A1 transgenic mice exhibited significantly enhanced responses to the endothelium-dependent vasodilator  bbbbb1 acetylcholine eeeee1  bbbbb2 Slc7A1 eeeee2  transgenic mice exhibited significantly enhanced responses to the endothelium-dependent vasodilator acetylcholine (-log EC50 for wild-type versus Slc7A1 transgenic: 6.87+/-0.10 versus 7.56+/-0.13; P<0.001)
CRP11	The Slc7A1 transgenic mice exhibited significantly enhanced responses to the endothelium-dependent vasodilator  bbbbb1 acetylcholine eeeee1  (-log EC50 for wild-type versus  bbbbb2 Slc7A1 eeeee2  transgenic: 6.87+/-0.10 versus 7.56+/-0.13; P<0.001)
CRP11	To complement these studies, we generated an endothelial-specific transgenic mouse overexpressing  bbbbb1 L-arginine eeeee1  transporter  bbbbb2 SLC7A1 eeeee2 
CRP11	To complement these studies, we generated an endothelial-specific transgenic mouse overexpressing  bbbbb1 L-arginine eeeee1  bbbbb2 L-arginine transporter eeeee2  SLC7A1
CRP11	The performance of the model-based approach was assessed by comparing the predicted to the actual outcome of the Phase 2 study bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The performance of the model-based approach was assessed by comparing the predicted to the actual outcome of the Phase 2 study bbbbb1  eeeee1  bbbbb2 aring eeeee2  the predicted to the actual outcome of the Phase 2 study
CRP11	Two previously published models were used; an integrated glucose and insulin (IGI) model for meal tolerance tests and an integrated glucose-red blood cell-HbA1c (IGRH) model predicting the formation of HbA1c from the average  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  (IGI) model for meal tolerance tests and an integrated glucose-red blood cell-HbA1c (IGRH) model predicting the formation of HbA1c from the average glucose concentration (Cg,av )
CRP11	Two previously published models were used; an integrated glucose and insulin (IGI) model for meal tolerance tests and an integrated glucose-red blood cell-HbA1c (IGRH) model predicting the formation of HbA1c from the average  bbbbb1 glucose eeeee1  bbbbb2 HbA1c eeeee2  (IGRH) model predicting the formation of HbA1c from the average glucose concentration (Cg,av )
CRP11	Two previously published models were used; an integrated glucose and insulin (IGI) model for meal tolerance tests and an integrated glucose-red blood cell-HbA1c (IGRH) model predicting the formation of HbA1c from the average  bbbbb1 glucose eeeee1  bbbbb2 HbA1c eeeee2  from the average glucose concentration (Cg,av )
CRP11	Two previously published models were used; an integrated glucose and insulin (IGI) model for meal tolerance tests and an integrated  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  (IGI) model for meal tolerance tests and an integrated glucose-red blood cell-HbA1c (IGRH) model predicting the formation of HbA1c from the average glucose concentration (Cg,av )
CRP11	Two previously published models were used; an integrated glucose and insulin (IGI) model for meal tolerance tests and an integrated  bbbbb1 glucose eeeee1 -red blood cell- bbbbb2 HbA1c eeeee2  (IGRH) model predicting the formation of HbA1c from the average glucose concentration (Cg,av )
CRP11	Two previously published models were used; an integrated glucose and insulin (IGI) model for meal tolerance tests and an integrated  bbbbb1 glucose eeeee1 -red blood cell-HbA1c (IGRH) model predicting the formation of  bbbbb2 HbA1c eeeee2  from the average glucose concentration (Cg,av )
CRP11	Two previously published models were used; an integrated  bbbbb1 glucose eeeee1  and  bbbbb2 insulin eeeee2  (IGI) model for meal tolerance tests and an integrated glucose-red blood cell-HbA1c (IGRH) model predicting the formation of HbA1c from the average glucose concentration (Cg,av )
CRP11	Two previously published models were used; an integrated  bbbbb1 glucose eeeee1  and insulin (IGI) model for meal tolerance tests and an integrated glucose-red blood cell- bbbbb2 HbA1c eeeee2  (IGRH) model predicting the formation of HbA1c from the average glucose concentration (Cg,av )
CRP11	Two previously published models were used; an integrated  bbbbb1 glucose eeeee1  and insulin (IGI) model for meal tolerance tests and an integrated glucose-red blood cell-HbA1c (IGRH) model predicting the formation of  bbbbb2 HbA1c eeeee2  from the average glucose concentration (Cg,av )
CRP11	Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase  bbbbb1 Glucose eeeee1  bbbbb2 HbA1c eeeee2 , Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment
CRP11	In this paper, we present a model-based approach for predicting glycosylated hemoglobin (HbA1c) in late phase using  bbbbb1 glucose eeeee1  and  bbbbb2 insulin eeeee2  concentrations from an early-phase study, investigating an anti-diabetic treatment
CRP11	In this paper, we present a model-based approach for predicting glycosylated hemoglobin (HbA1c) in late phase using  bbbbb1 glucose eeeee1  bbbbb2 HbA1c eeeee2 ) in late phase using glucose and insulin concentrations from an early-phase study, investigating an anti-diabetic treatment
CRP11	In this paper, we present a model-based approach for predicting glycosylated hemoglobin (HbA1c) in late phase using  bbbbb1 glucose eeeee1  bbbbb2 glycosylated hemoglobin eeeee2  (HbA1c) in late phase using glucose and insulin concentrations from an early-phase study, investigating an anti-diabetic treatment